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Abstract 
Patients with diabetes exhibit hyperglucagonemia, or excess glucagon secretion. The 
glucagonocentric hypothesis of diabetes states that hyperglucagonemia, rather than 
hypoinsulinemia, may be the underlying mechanism of hyperglycemia of diabetes. Thus, 
uncovering mechanisms that regulate glucagon secretion from pancreatic α-cells is 
crucial for developing treatments for hyperglycemia.  One clue to the regulation of 
glucagon secretion may lie in the proteins that interact with glucagon in α-cell’s secretory 
pathway, primarily within the secretory granule. The purpose of my work was to identify 
proteins that interact with glucagon within the secretory granule and characterize a 
candidate protein within this network that regulates the intracellular trafficking of 
glucagon to control its secretion.   
To identify secretory granule proteins that interact with glucagon, I purified secretory 
granules from α-TC1-6 cells. I then used affinity purification using tagged glucagon to 
isolate protein complexes that interact with glucagon, and identified these proteins 
through liquid chromatography/mass spectrometry. In this way, I identified a glucagon 
“interactome” within the α-cell secretory granule. I found that components of the 
interactome changed in response to different glucose concentrations, and to treatment 
with the paracrine inhibitors insulin and GABA.  
Next, I characterized the function of one interactome protein, the neuronal cytoskeletal 
protein stathmin-2, in glucagon secretion. Through overexpression and siRNA-mediated 
silencing of stathmin-2 in α-TC1-6 cells, I showed that stathmin-2 is a tonic inhibitor of 
glucagon secretion. Using confocal high-resolution immunofluorescence microscopy, I 
found that stathmin-2 exerts its regulatory role by trafficking of glucagon to the 
endolysosomal system. 
Finally, I examined how the trafficking role of stathmin-2 is altered in the 
hyperglucagonemia of diabetes. Using isolated islets from a mouse model of diabetes, I 
showed that the increase in cellular glucagon was accompanied by a reduction in 
stathmin-2 levels. Confocal microscopy analysis indicated that, in diabetes, there is a 
switch from the anterograde trafficking of glucagon towards the lysosome to retrograde 
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trafficking towards secretory granules, possibility mediated by the endosomal protein 
Rab7.   
In summary, my thesis describes the discovery of a regulatory mechanism for glucagon 
secretion from α-cells that may operate in hyperglucagonemia. These findings have 
clinical application for treatment of hyperglycemia of diabetes. 
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Summary for Lay Audience 
People with diabetes have an abnormal amount of a hormone called “glucagon” in their 
blood, which seriously increases blood sugar. Glucagon is released from a cell called 
“alpha cell”, which is in the gland of the pancreas. My research was to discover some 
proteins within a special structure in alpha cells called “secretory granule” that control 
the release of glucagon. I found that the type and numbers of proteins within the secretory 
granule changed when I exposed alpha cells to suppressors of glucagon secretion (insulin 
or GABA). This would mean that those proteins are candidates for decreasing glucagon 
secretion (stathmin-2 being one of the proteins). I found that both glucagon and stathmin-
2 are located within the secretory granule of a mouse’s pancreas in a close distance from 
each other. By using a genetic technique, I removed stathmin-2 from the alpha cell and 
found that cells released a lot of glucagon. On the other hand, when alpha cells produced 
a lot of stathmin-2, they did not secrete glucagon. There is a structure within alpha cells 
called “endolysosome”. I found that when there is a lot of stathmin-2 within the alpha 
cell, it directs glucagon into the endolysosome, where it is destroyed. However, when 
there is a lack of stathmin-2 in alpha cells, glucagon is not destroyed in the 
endolysosome. These mean that stathmin-2 controls glucagon secretion through 
endolysosome. I then proposed that, in diabetes, glucagon is not destroyed in the 
endolysosome. This is the reason for high glucagon secretion from the pancreas. To test 
this idea, I found that, in diabetic mice, there was very little stathmin-2 versus lots of 
glucagon in its pancreas. Then, by using advanced microscopic studies, I found that both 
glucagon and stathmin-2 were not destroyed in the endolysosome of alpha cells in the 
diabetic mouse. I found that stathmin-2 collected into a structure called “late endosome”, 
and at the same time, alpha cells showed an increase in glucagon secretion. Therefore, 
stathmin-2 is a novel molecule that can control glucagon secretion. In future studies, it 
could be used to decrease high blood sugar in people with diabetes.  
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Chapter 1 
1.1 Introduction 
Diabetes as a widespread disease affects around half a billion people worldwide and is 
mainly categorized to type 1 and type 2 diabetes (1). Based on World Health 
Organization projections, diabetes will be affecting around 2 billion people by 2040, 
which would have a severe impact on global health. According to the Public Health 
Agency of Canada (www.canada.ca/en/public-health), diabetes affected 3.4 million 
Canadians in 2015 (9.3% of the population). Based on this report, the prevalence was 1 in 
300 for younger people (≤ 19 years old) and 1 in 10 for those over 20 years of age. The 
prevalence of diabetes in Canada is predicted to grow to  5 million (12.1% of the 
population) by 2025, a 44% increase compared to 2015 (2).   
The β-cell of pancreatic islet secretes insulin, which reduces high blood glucose levels 
and the α-cell secretes glucagon that counteracts insulin actions and increases blood 
glucose levels. Thus, euglycemia is achieved when there is a fine balance between 
functions of these two hormones. However, diabetes disrupts this balance, resulting in 
fasting hyperglycemia that is characteristic of diabetes (3–5). Preclinical and clinical 
findings in all diabetic models and clinical cases of diabetes also show a level of 
hyperglucagonemia, even in well-controlled diabetes (6). In particular, people with type 2 
diabetes have fasting hyperglucagonemia and defects in postprandial glucagon 
suppression (4). This hyperglucagonemia exacerbates the pathological consequences of 
diabetes such as hyperglycemia, hyperaminoacidemia, obesity, and cardiovascular 
diseases. Therefore, the impact of consistent hyperglucagonemia in diabetes has brought 
up questions up on how hyperglucagonemia exacerbates the pathophysiology of diabetes, 
and the development of potential pharmacological interventions targeting 
hyperglucagonemia for the treatment of diabetes (4,7). Uncovering the molecular 
mechanisms of glucagon secretion and action as the key to understanding the 
pathogenesis of hyperglucagonemia has been a relatively recent focus in diabetes 
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research. In fact, some recent findings have suggested that glucagon secretion should also 
be a main target for the treatment of diabetes(4,8).  
In this Introduction, I have first described the physiological actions of glucagon. I then 
discuss the role of glucagon in the development and pathophysiology of diabetes. I have 
specifically focused on hyperglucagonemia as the underlying mechanism of 
hyperglycemia in diabetes. I have reviewed the current literature on the cellular pathways 
governing normal and abnormal glucagon secretion, and emphasized what the latest 
proteomic studies have revealed on the alterations in the α-cell secretory pathway in 
relation to diabetes. This provided a rationale for my study to interrogate a protein within 
the secretory granule, which regulate glucagon secretion.   
1.2 Glucagon and its general function in metabolism 
Glucagon, a 29 amino acid peptide, is a product of the post-translational processing of 
proglucagon by the enzyme prohormone convertase 2 (PC2) within the secretory pathway 
of  pancreatic α-cells(9–11). Glucagon is then stored within secretory granules and 
secreted in response to nutritional, hormonal and neural factors. It is the major glucose 
counter-regulatory hormone, and also functions in lipid and protein metabolism and 
energy expenditure. In a general view, glucagon increases hepatic gluconeogenesis and 
glycogenolysis and by this means regulates glycemia. In terms of lipid metabolism, it 
increases lipolysis and ketogenesis. Regarding protein metabolism, it increases both 
ureagenesis and uptake of amino acids by the liver. In addition, by reducing the level of 
food intake and increasing energy expenditure it participates in energy metabolism (12).   
1.2.1 Glucagon and glucose metabolism  
Glucagon is the major glucose counter-regulatory hormone. In healthy individuals, 
following an overnight fast, blood glucose levels fall to 3.8 mmol/L, which potently 
stimulates glucagon secretion to increase blood glucose level towards its normal range (4-
5.4 mol/L). Then, when blood glucose levels reach above the normal level, glucagon 
secretion will be suppressed (13–15). Glucagon exerts it actions by binding to the 
glucagon receptor, a class B seven- transmembrane G-protein coupled receptor that is 
highly expressed in the liver. It is also present in the central nervous system, kidney, 
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gastrointestinal tract and pancreas. Following the binding of glucagon with its receptor, it 
triggers Gαs-coupled proteins, which activates downstream adenylate cyclase, and 
production of cAMP. The increased level of cAMP activates both protein kinase A 
(PKA) and cAMP response element-binding (CREB) protein. CREB enhances 
gluconeogenesis through increasing transcription of both glucose 6-phosphatase and 
phosphoenolpyruvate carboxykinase (PEPCK). At the same time, PKA activates fructose 
2, 6-bisphosphatease and inactivates phospho-fructokinase 2, increasing levels of fructose 
6-phosphate and potentiation of gluconeogenesis and suppression of glycolysis. PKA also 
increases fructose 1,6-bisphosphate and decreases pyruvate levels, which consequently 
suppresses glycolysis. In addition, PKA activates phosphorylase kinase that results in 
glycogenolysis and improved levels of glucose 1-phosphate and simultaneously 
suppression of glycogen synthase (16).  
However, in the absence of glucagon action, the counter-regulation of glucose 
metabolism still occurs.  Inducing glucagon deficiency by either blocking glucagon 
action through anti-glucagon antibodies or deleting the glucagon receptor in mice did not 
result in hypoglycemia. In the absence of glucagon, glucose counter-regulation can occur 
through the glucocorticoid hormone cortisol, (17), and through the actions of  the 
catecholamines, norepinephrine and epinephrine (18,19).Taken together, all of these 
hormones target the liver to release glucose, with catecholamines, especially epinephrine, 
playing a redundant role in glucose counter-regulation(19).   
1.2.2 Glucagon and lipid metabolism 
In hepatocytes, glucagon reduces hepatic fatty acid biosynthesis and simultaneously 
increases fatty acid oxidation. Glucagon receptor signaling through cAMP results in 
inhibition of acetyl-CoA carboxylase (ACC), prevention of malonyl-CoA formation and 
suppression of fatty acid biosynthesis; 2) increases the AMP/ATP ratio, which activates 
5' AMP-activated protein kinase (AMPK), inhibits ACC and suppresses fatty acid 
biosynthesis and enhancing β-oxidation of fatty acids; and 3) activates CREB, 
peroxisome proliferator-activated receptor-α  (PPAR-α) and forkhead transcription factor 
A2 (FoxA2), which enhance transcription of target genes controlling β-oxidation (20).  
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Triggering fatty acid oxidation is a protective mechanism that provides energy for the 
fight-or-flight response. However, whether glucagon exerts its lipolytic actions directly 
on human adipose tissue is a matter of some debate. Even though glucagon induces 
lipolysis in rodent adipose tissue, there are ambiguities about its role in human adipose 
tissue (20). In vitro experiments show that glucagon increases lipolysis in human 
adipocytes at both physiological (3 ng/kg) and pharmacological (0.5 – 1 mg) doses 
(21,22).  However, physiological concentrations of glucagon did not affect lipolysis in 
both healthy people and people with type 1 diabetes (23).   In a recently published review 
article, it was extensively discussed that pharmacological levels of glucagon (in the range 
of 6×10-11 – 10-8 M) has lipolytic effects on rat, bird, rabbit and human adipocytes in 
vitro, but that physiological concentrations of glucagon (1-40 pM) did not increase 
lipolysis in human adipocytes (20). These controversies about a direct effect of glucagon 
on adipocytes also extend to detection of the glucagon receptor on adipocytes. While 
following treatment of rat adipocytes with glucagon there was an increased level of Gcgr 
mRNA, alteration at the protein level was not shown for the receptor (24). In fact, 
determination of glucagon receptor in adipocytes is severely hampered by a lack of a 
specific antibody (25). Thus, further molecular research on glucagon action in adipocytes 
awaits another technique for detecting the glucagon receptor. 
1.2.3 Glucagon and metabolism of protein and amino acids 
Glucagon plays crucial roles in amino acids and protein metabolism. In neuroendocrine 
of glucagonoma, all affected people show hypoaminoacidemia (26). In contrast, there is a 
marked hyperaminoacidemia following total pancreatectomy (27). These effects are 
mirrored in experimental animal models, as direct administration of glucagon decreased 
blood amino acid levels and increased hepatic ureagenesis (26,28,29), and blocking 
glucagon action with anti-glucagon receptor antibodies or silencing of the Gcgr gene 
increased amino acid levels. Blocking the hepatic glucagon receptor also brought about 
α-cell proliferation (30–32), prompting the description of a hepatic-α-cell axis (32).  
Mechanistically, glucagon receptor signaling through cAMP in hepatocytes increases the 
transcription of genes encoding amino acid transporters and enzymes involved in 
ureagenesis (16), thereby promoting amino acid clearance and metabolism. 
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Interestingly, blocking the hepatic glucagon receptor results not only in 
hyperaminoacidemia, but also α-cell hyperplasia. Kim et al (2017) showed that after 
blocking glucagon action on mouse hepatocytes, there was an increase in expression of 
slc38a5, which encodes the neutral amino acid transporter in α-cells. When slc38a5 was 
depleted, blocking glucagon action on liver had a very mild effect on α-cell proliferation 
(33), indicating that specific amino acids that were transported by SLC38A5, such as 
glutamine, functioned in α-cell hyperplasia.  Glutamine may promote α-cell hyperplasia 
through activation of the nutrient sensor mammalian target of rapamycin complex 1 
(mTORC1), since blocking mTORC1 by rapamycin suppresses both induction of slc38a5 
and α-cell proliferation (34). Other signaling processes may also mediate the effects of 
glutamine on α-cell proliferation (35). Additionally, Dean et al (2017) showed that serum 
of the Gcgr-/- mouse enhanced expression of a proliferation marker, Ki67, in α-cells. 
They treated intact mouse islets with the serum of Gcgr-/- or Gcgr+/+ mouse, and then 
dispersed the islets and prepared primary cell culture. Further analysis showed that serum 
fraction of <10 KDa had proliferative effect on α-cells, which contained amino acids, in 
particular glutamine (32). 
Altogether, these findings suggest a crucial role for glucagon in amino acids and protein 
homeostasis. 
1.2.4 Glucagon and energy metabolism 
 In healthy individuals, it was shown that glucagon administration brings about an 
increase oxygen consumption and weight loss; however, there are controversies about its 
effect in non-diabetic animal models(36,37). Mechanistically, it is proposed that 
glucagon increases energy expenditure through its receptor on brown adipose tissue 
(BAT). Glucagon’s acute effect on energy expenditure through BAT immediately 
appears following its administration, with a rapid up-regulation of FGF21 in BAT of 
mice and humans (38), increases in oxygen consumption and changes in the expression of 
genes linked to thermogenesis and mitochondrial function in ex vivo BAT of mice (39). 
However, depletion of GCGR in BAT does not affect whole body energy expenditure, 
suggesting a BAT-independent pathway for glucagon’s effect on energy expenditure. In 
humans, glucagon can also mediate its effects on energy expenditure by increasing blood 
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cortisol levels (40), which results in higher energy expenditure through increasing the 
levels of BAT UCP1 at both the gene and protein levels (41,42). 
1.3 The glucagonocentric hypothesis of diabetes 
The increased blood glucose levels in diabetes is attributed to β-cell dysfunction 
(defective insulin secretion) and insulin resistance in peripheral tissues. The pathogenesis 
of diabetes, which includes decreased glucose utilization, increased lipolysis, increased 
proteolysis, increased hepatic glycogenolysis, increased ketogenesis and decreased 
glycogen synthesis, has historically been attributed to a lack of insulin (43). In the 1970s, 
new findings about role of glucagon in metabolism and energy homeostasis led to the 
discovery of other mechanisms based on the action of glucagon that could be responsible 
for the pathogenesis of diabetes. These findings that led an α-cell research team to 
propose a novel theory on pathogenesis of diabetes. 
In 1975, Roger Unger and Lelio Orci proposed the “bi-hormonal theory of abnormalities 
in diabetes”, which profoundly changed views on pathophysiology of diabetes (41). 
Based on this theory, people with diabetes suffer from both a lack of insulin and 
excessive glucagon. They described that some diabetes abnormalities are due to lack of 
insulin, such as decreased glucose utilization, increased lipolysis and increased 
proteolysis, while some other abnormalities such as increased hepatic glycogenolysis, 
increased hepatic gluconeogenesis, increased ketogenesis and decreased glycogen 
synthesis are caused by excess glucagon levels (44).  
Over the next several decades, further research by Unger’s group and other researchers 
revealed more biological effects of glucagon on the pathogenesis of diabetes. In 2012, 
Unger and Cherrington proposed a “glucagonocentric hypothesis of abnormalities in 
diabetes” to describe the pathogenesis of diabetes (3). This hypothesis states that 
blockade of glucagon action will reduce hyperglycemia even in case of insulin 
deficiency. It was shown that glucagon receptor knockout mice (Gcgr -/- ) were resistant 
to STZ-induced diabetes (45) and normalization of hyperglucagonemia in rodent models 
of uncontrolled diabetes reversed  ketosis (3,44,46), decreased hepatic glucose production 
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and mitigated  hyperglycemia (3). Thus, hyperglucagonemia plays a crucial, and perhaps 
the primary, role in the development of diabetic hyperglycemia (47).  
There is a range of relative to absolute hyperglucagonemia in diabetes, which contributes 
to both fasting and postprandial hyperglycemia. People with diabetes always have at least 
a relative hyperglucagonemia; however, in patients with type 2 diabetes often there is an 
absolute hyperglucagonemia. In this state, a carbohydrate meal or glucose load does not 
suppress glucagon secretion; instead it paradoxically increases glucagon secretion, thus 
reflecting a degree of α-cell dysfunction. Furthermore, in the presence of 
hyperglucagonemia, a protein meal often exacerbates glucagon secretion regardless of 
blood glucose concentrations. Malfunctioning of α-cells can be due to resistance of α-
cells to insulin, postprandial disturbance in interaction between glucagon and insulin, 
defect in glucose-induced suppression of glucagon secretion, malfunctioning β-cells or 
reduced numbers of β-cells, and lack of GLP-1(48,49), all of which lead to exacerbation 
of hyperglycemia.   Therefore, combating hyperglucagonemia has been spotlighted in 
diabetes research over the past few years.  
There are two strategies to combat hyperglucagonemia: 1) blocking glucagon action at 
target organs; or 2) inhibition of glucagon secretion from α-cells.  Blocking glucagon 
action can be achieved through: i) glucagon receptor antagonists, in particular small 
molecule antagonists, which can allosterically or competitively inhibit glucagon action 
(50); ii) Glucagon receptor neutralizing antibody (51); and iii) Antisense oligonucleotides 
against the glucagon receptor (52). However, many of the compounds that target the 
glucagon receptor have been discontinued at different phases of clinical trials, since they 
only have short-term beneficial effects towards reducing blood glucose levels. Their 
long-term administration can be accompanied by the following consequences :  i) severe 
α-cell hyperplasia (20,30,53,54); ii) elevation of hepatic and serum transaminases 
(20,29,55); iii) increased risk of hypoglycemia (55–57);  iv) increased hepatic glycogen 
storage (16); v) increased risk of hyperlipidemia; (58); and vi) increased body weight 
(54,57,59).  
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1.4 Understanding the mechanisms and 
consequences of hyperglucagonemia 
In order to understand the mechanisms that underlie hyperglucagonemia, we should know 
about the cellular and molecular mechanisms thar regulate glucagon secretion. These 
mechanisms have not been as widely studied as insulin secretion from β-cells, as a result, 
there are conflicting hypotheses. 
Inhibition of glucagon secretion from α-cells is a long-standing puzzle in islet biology. In 
fact, there is no single factor to govern glucagon secretion or alter its secretion rate. 
Glucagon secretion is simultaneously under the control of nutritional, neural and 
hormonal factors, which interact with each other to making a complex set of pathways for 
governing glucagon secretion (60). The following three theories have been proposed as 
governing mechanisms for glucagon secretion from α-cells; i) Intrinsic mechanism, ii) 
Paracrine mechanisms and iii) Extrinsic mechanism (which is not going to be discussed 
here). 
1.4.1 Intrinsic mechanism of glucagon secretion  
This hypothesis states that glucose is the key regulator of glucagon secretion from the α-
cell. One argument in favour of this hypothesis is that glucagon secretion from isolated 
non-diabetic α-cells can respond directly to glucose in the absence of paracrine inputs.  
A) Pattern of glucagon secretion from dispersed α-cells and intact islets 
1) Glucagon secretion from dispersed α-cells: Isolated non-diabetic mouse pancreatic 
α-cells, clonal hamster In-R1-G9 cells(14,61), and non-diabetic human dispersed α-
cells(62) show a bimodal V-shaped curve in response to increasing glucose 
concentrations. Increasing glucose concentrations from 1 to ~7 mM suppresses glucagon 
secretion in a dose-dependent manner. On the other hand, increasing glucose 
concentrations from 7-20 mM increases glucagon secretion dose-dependently (Figure 1-
1). This profile of secretion suggests that α-cells are equipped with intrinsic mechanism 
for regulating glucagon secretion which are effective in the range of 1-7 mM of glucose, 
and these mechanisms are ineffective at higher glucose concentrations. It is noteworthy to 
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mention that in this context, there is an argument as to whether if glucose- regulated 
glucagon secretion in isolated α-cells follow a V shape curve or a dose pattern. A dose 
dependent increase in glucagon secretion was shown in FACS sorted rat α-cells(63).  
 
 
 
 
 
                                                                                                      Glucose (mM) 
                                                                                                                   
 
 
 
 
 
2) Glucagon secretion from α-cells within intact islets: It was shown that increasing 
glucose concentration from 1 to 7 mM dose dependently decreases glucagon secretion 
from mouse α-cells within intact islets (64) and human intact islets (62). However, by 
increasing glucose concentration from 7 mM to 20 mM glucagon secretion remains low 
(Figure 1- 2). A U shape curve was shown for glucagon secretion when glucose 
concentration gradually increased up to 30 mM (61). In other words, 7-20 mM glucose 
suppresses glucagon secretion when α-cells are located in their normal anatomical 
positions within the islet and subject to paracrine regulation from other islet cells.  
Figure 1-1. V-shape curve of glucagon secretion in response to glucose in 
dispersed human non-diabetic α-cells (black line). Red line denotes 
response of islets from patients with T2D, which is discussed in the 
related section in 1.6.3.  The Figure was extracted from reference 62 
under the Creative Commons Attribution License 
(http://creativecommons.org/Licenses/by/4.0/). 
 
Figure 1-2. Cross-talk among α, β, and δ-cells towards inhibition of 
glucagon secretion. The Figure was extracted from reference 113 under 
the Creative Commons Attribution License 
(http://creativecommons.org/Licenses/by/4.0/).Figure 1-3. V-shape curve 
of glucagon secretion in response to glucose in dispersed human non-
diabetic α-cells (black line). Red line denotes response of islets from 
patients with T2D, which is discussed in the related section in 1.6.3.  The 
Figure was extracted from reference 62 under the Creative Commons 
Attribution License (http://creativecommons.org/Licenses/by/4.0/). 
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B) Mechanisms of glucose-regulated glucagon secretion: Human α-cells transport 
glucose into the cell via the glucose transporter GLUT1 and sodium-dependent glucose 
transporters SGLT1 and SGLT2. Glucose then has direct effects on glucagon secretion 
via the following mechanisms: 
1) Effect of glucose on KATP channel conductance: Glucose is subsequently metabolized 
to generate ATP which binds to and closes KATP channels at the plasma membrane. (65) 
As a result, voltage-dependent Ca2+ channels close, which decreases Ca2+ influx into the 
cytosol, thus reducing SNARE protein-mediated docking and fusion of secretory granules 
to the plasma membrane (66). 
 2) Effect of glucose on store-operated current (SOC): While α-cells have potent voltage-
dependent Ca2+ channels, SOC through Orai1 Ca2+-release-activated channel (CRAC)  
also plays an important role in regulation of glucagon secretion from α-cells(67). Under 
low glucose conditions, the Ca2+ depletion of the ER causes the translocation of stromal 
interaction molecule 1 (STIM1) from the ER to the subplasmalemmal junctions leading 
to clustering with Orai1, resulting in SOC activation.  It is believed that SOC plays a 
central role in glucose inhibition of glucagon secretion and epinephrine-stimulated 
Figure 1-2. Glucagon secretion from intact mouse islets. The 
Figure was extracted from reference 64 under the license of 
https://www.asbmb.org/journals-news/editorial-policies. 
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glucagon secretion(68). It is mentioned that α-cells have a low membrane conductance, 
which confers high sensitivity to SOC-induced current(14).  In contrast, exposure of α-
cells to high glucose conditions and subsequent high ATP levels activate the 
sarcoendoplasmic reticulum calcium transport ATPase (SERCA) pump, which results in 
Ca2+ sequestration from the cytoplasm into the ER. Filling the store with Ca2+ inhibits the 
translocation of STIM1, turns off CRAC channel subunit, reduces VDCC activity and 
suppresses glucagon secretion (68,69). 
3) Effect of glucose on cytosolic levels of cAMP: When high glucose levels strongly 
suppress glucagon secretion, there is only a moderate (or temporary) reduction in the 
cytoplasmic Ca2+ levels, suggesting the presence of an alternate regulator for glucagon 
secretion. Low glucose levels regulate glucagon secretion through increasing cytoplasmic 
levels of cAMP, which activates the Epac signaling pathway, stimulating L-type Ca2+ 
channels and increasing glucagon secretion. Furthermore, it was emphasized that 
increased cAMP is accompanied by mobilization of secretory granules into the “readily 
releasable pool”, which potentiates glucagon secretion. High glucose levels lower 
cytoplasmic levels of cAMP, resulting in PKA-mediated inhibition of N-type or P/Q type 
Ca2+ channel and suppression of glucagon secretion (66,70). 
1.5 Paracrine and autocrine regulation of glucagon 
secretion  
1.5.1 Released factors from β-cells 
1) Insulin: Insulin plays a key role in the paracrine regulation of glucagon secretion. 
Insulin binds to its receptor on the α-cell and suppresses glucagon secretion through 
several mechanisms. Insulin receptor signaling through PI3 kinase reduces KATP-channel 
activity, causing plasma membrane hyperpolarization and reduced activity of the P/Q 
type Ca2+ channel which results in reduced glucagon secretion (71). Insulin receptor 
activation also results in the translocation of GABAA receptors from the cytoplasm to the 
plasma membrane which activates GABA signaling pathway towards suppression of 
glucagon secretion(72). In fact, all of these findings demonstrate that insulin directly 
suppresses glucagon secretion from α-cells (73).   
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 In addition to direct effects on the α-cell, insulin can also inhibit glucagon secretion 
through promoting the secretion of somatostatin from δ-cells. Although initial work 
failed to find the insulin receptor on δ-cells (74), it has recently been shown that insulin 
binds to its receptor on δ-cells and stimulates somatostatin secretion. Then somatostatin 
binds to its receptor on α-cells and potently inhibits glucagon secretion (75) (discussed 
below). 
2) Gamma amino butyric acid (GABA):  GABA is a potent suppressor of glucagon 
secretion from α-cells (76,77). Activating the GABAA receptor in α-cells results in Cl
- 
influx into the cells which hyperpolarizes the membrane and reduces glucagon secretion 
(78). As well, there is coordination between insulin and GABAA receptor activity, as 
insulin action leads to the translocation of GABAA receptor to the cell membrane(79). In 
addition, GABA also inhibits mTOR activity to suppress α-cell proliferation. In type 1 
diabetes, due to destruction of β-cells, the amount of secreted GABA is also reduced, 
resulting in the activation of mTOR and cell proliferation(80).  It has been shown that 
activation of GABAA receptor may trans-differentiate adult α- cells to β-like cells(81–
83), in a way that cell secretory granules will pack insulin and respond to glucose. 
3) Serotonin: In human islets, serotonin can suppress glucagon secretion in two ways: 
through a stimulatory autocrine effect on β-cells to increase insulin secretion and by this 
way indirectly suppress glucagon secretion, or by a direct paracrine effect on α-cells 
(84,85). Direct effects are mediated by activation of the serotonin receptor, 5-HT1FR, on 
α-cells, which reduces intracellular cAMP to suppress glucagon secretion.  In patients 
with long-standing T2D, the proportion of α-cells expressing 5-HT1FR is decreased, 
suggesting that reduced serotonin action on α-cells may play a role in hyperglucagonemia 
of diabetes. In STZ-treated mice, administration of the 5-HT1FR agonist LY344864 
alleviated hyperglucagonemia and hyperglycemia. However, insulin-induced 
hypoglycemia was worsened, suggesting that the effects of serotonin are glucose-
independent. (84). Therefore, while α-cell HT1FR may be a potential target for the 
treatment of hyperglucagonemia, it may not be an ideal target.  
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4) Amylin: Amylin, a 39 amino acid peptide, is a major component of the islet amyloid 
deposit in patients with type 2 diabetes. It is co-released with insulin in response to 
nutritional stimuli (86) and is an inhibitor of glucagon secretion. Exogenous 
administration of amylin and its agonists potently and profoundly suppresses glucagon 
secretion in intact animals or subjects (87). However, there are controversies about 
underlying mechanism of Amylin’s effect on glucagon secretion. Some researchers 
proposed that Amylin just suppresses glucagon secretion in vivo, and does not have effect 
on glucagon secretion in isolated islets and perfused pancreas (88). On the other hand, 
some other researchers oppose this idea and believe that Amylin binds to its receptor on 
α-cells and its action suppresses glucagon secretion in both in vitro and in vivo conditions 
(89). As another proposed mechanism, amylin modulates vagus nerve signals in pancreas, 
which inhibits post-meal glucagon secretion (90). 
5) Adenosine: There are some controversies about the source of adenosine. One 
hypothesis states that the ATP that is co-secreted with insulin is converted to adenosine in 
the interstitial matrix of islet (91). However, there are species-related variations in 
expression of 5'-ectonucleotidase (92). Adenosine may also be secreted directly with 
insulin. Pharmacological concentrations of adenosine may stimulate glucagon secretion 
(92), but physiologically, adenosine secreted from β-cells has an  inhibitory effect on 
glucagon secretion (93). The effects of adenosine are mediated by the adenosine A1 
receptor (Adora1), in which activation is coupled to opening of KATP channels, 
hyperpolarization of the cell membrane and prevention of granule exocytosis. In NOD 
mice, human autoantibody-positive and people with long-term T1D, α-cells gradually 
lose Adora1 expression, suggesting that the hyperglucagonemia of diabetes is associated 
with a loss of adenosine action (93). 
6) Zn2+: The Zn2+ transporter, Slc30A/ZnT8, is a causative gene for T2D, and ZnT8 is 
located in the secretory granule membrane of both α-and β-cells. There is a direct 
relationship between expression of the proglucagon gene and  Slc30A in α-cells (94). 
However, there are conflicting findings about the effects of Zn2+ on glucagon secretion 
(94). There are reports that, in isolated mouse islets and α-cells,  Zn2+ administration 
decreases glucagon secretion (95), or has no effect (96). In contrast, treatment of isolated 
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human islets with similar concentrations of Zn2+ enhanced glucagon secretion (97). The 
reason for these discordant results is not clear; it may be that exogenously administered 
Zn2+ or Zn2+ secreted from the β-cell does not have a direct role in glucagon secretion in 
normal physiology. Interestingly, in mice lacking  Slc30A/ZnT8 specifically in α-cells, 
there is a heightened secretory response to 1 mM glucose (98), and overexpression of 
ZnT8 specifically in α-cells restricted glucagon secretion in response to  1 mM glucose 
(99), suggesting paracrine regulation by Zn2+. 
1.5.2 Released factors from α-cells  
1) Acetylcholine: In addition to cholinergic innervation of islets from parasympathetic 
nerve endings, a cholinergic system is also contained within α-cells: the vesicular 
acetylcholine transporter  is present on α-cells, and choline acetyltransferase  co-localizes 
with glucagon in human pancreatic islets (131). Acetylcholine is secreted upon low 
glucose stimulation, whereby it acts on M3 muscarinic receptors on β-cells and  sensitizes 
β-cells for insulin secretion (100).  Acetylcholine has an important role in minimizing 
blood glucose volatility and potentially aids in survival of β-cells (100,101). Therefore, α-
cells are equipped with a unique cholinergic-based system that responds to daily 
variations in blood glucose.  
2) Glutamate: The α-cell contains its own glutaminergic system that regulates glucagon 
secretion in an autocrine manner. α-cells express the vesicular glutamate transporter, 
VGLUT2, on secretory granules, enabling the transport and storage of glutamate within 
the α-cell secretory granules.  Both metabotropic and ionotropic glutamate receptors are 
present on α-cells, but only ionotropic AMPA/kainite receptor activation was coupled to 
glucagon secretion (102,103). Following α-cell exposure to low glucose, a glutamate 
feedback loop is activated, which further increases the glucagon secretory response to 
low glucose. In this way, the α-cell glutaminergic system guarantees that enough 
glucagon is secreted in case of need, which prevents blood glucose 
volatility(34,102,104). As well, the secreted glutamate may also activate α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on β and δ-cells , thus 
participating in an intra-islet glutaminergic system that finely controls glucose 
homeostasis(105). In both patients with diabetes and diabetic mice, glutamate levels are 
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significantly increased. It was proposed that glutamate takes a role in development of 
diabetes through exaggerated activation of N-methyl-D-aspartate (NMDA) receptors in 
β-cells that may result in dysfunction and apoptosis of β-cells(106).  
3) Glucagon: Secreted glucagon from α-cells can stimulate its secretion through an 
autocrine effect. It has been shown that glucagon stimulates glucagon secretion from the 
rat and mouse isolated α-cells in an autocrine manner through glucagon receptor-
stimulated cAMP signaling (107). Both biosynthesis and secretion of glucagon in human 
and mouse α-cells is augmented due to the autocrine effect of glucagon. Thus, targeting 
autocrine and paracrine effectors of glucagon secretion, including glucagon, has been 
proposed as therapeutic strategies in patients with diabetes(108). 
4) Other α-cell proteins: The role of proteins, in particular proteins of secretory granule, 
may be new factors that regulate the secretion of glucagon from α-cells. It was shown 
that brefeldin A-inhibited guanine nucleotide exchange protein 3 (BIG3) is a conserved 
secretory granule protein in α-cells, and negatively regulates glucagon secretion (109). Li 
et al (2015) showed that levels of glucagon within the secretory granule were increased in 
different animal models of diabetes, in pancreatic islets and isolated α-cells, which may 
contribute to higher glucagon secretion in diabetes. Therefore, the α-cell secretory 
granule itself may contain other proteins that play a role in the regulation of glucagon 
secretion.  
1.5.3 Released factors from δ-cells 
Somatostatin is a well-known inhibitor of glucagon secretion. Somatostatin binds to its 
receptor, SSTR2, on α-cells, activates adenylate cyclase and generates cAMP. In the 
downstream process, cAMP activates the serine/threonine protein phosphatase 
calcineurin, which results in de-priming of the secretory granule (14). Notably, secretion 
of somatostatin and inhibition of glucagon secretion potently occurs at 3mM glucose, 
while this level of glucose does not have stimulatory effect on insulin secretion, 
indicating that the α-cell response to low glucose may be mediated by somatostatin (110). 
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Circulating and pancreatic somatostatin, together with SST mRNA, are elevated in 
diabetes. However, expression of SSTR2 on α-cells is decreased in T2D, which makes α-
cells resistant to somatostatin; together with α-cell insulin resistance, this could be a 
reason for paradoxical high glucagon secretion in hyperglycemic condition of 
diabetes(62). 
1.5.4 Cross-talk among β and δ and α-cells and glucagon 
secretion 
In gross histology, rodents’ islets are composed of β-cells in the core and non-β-cells in 
the periphery. However, in human islets, non-β-cells are intermingled within β-cells(111) 
and appear to be organized as “superclusters” of islets(112). Recently, Briant et al (2018) 
applied optogenetic techniques to study temporal and spatial cross-talk among mouse 
islet cells (Figure 1-3). By this approach, they demonstrated that, under high glucose 
conditions, insulin secreted from β-cells suppresses glucagon secretion through insulin 
receptor signaling , and through actions on δ-cells mediated by gap junctions (113). As 
shown in Figure 1-3,  high glucose levels stimulate glycolysis in β-cells to generate ATP, 
which closes KATP channels, causing membrane depolarization, Ca
2+ influx through the 
voltage-dependent Ca2+ channels (VDCC), and insulin secretion (113). Additionally, 
following Ca2+ influx into the β-cells, this Ca2+ is transported via gap junction proteins 
into δ-cells, causing depolarization of the δ-cell membrane and initiating Ca2+ influx into 
the cell through the VDCCs, which results in somatostatin secretion (113). At the same 
time, entrance of glucose into the δ-cell and generation of ATP could activate δ-cells 
through the KATP channels to release somatostatin (as mentioned in section 1.3.1)(114). 
Somatostatin then binds to SSTR2 on α-cells, triggering Gαi and activating G-protein 
coupled inwardly rectifying K+ (GIRK) channels, hyperpolarizing the α-cell membrane 
and suppressing glucagon secretion(113). 
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It has been shown that eliminating insulin receptor on δ-cells completely abolishes the 
glucagonostatic effect of insulin, which proposes an indirect glucagonostatic effect for 
insulin through cell-cell junction. Additionally, the ability of insulin to inhibit glucagon 
secretion was lost when either SSTR2 or the sodium-glucose co-transporter 2 (SGLT2) 
were blocked. (75).Thus these findings highlight a central role for δ-cells in the context 
of intra-islet regulation of glucagon secretion, and may have implications for designing 
drugs for the treatment of hyperglucagonemia of diabetes. Glucagon may also play a role 
in the intra-islet regulation of insulin secretion. In a mouse specifically engineered to 
investigate intra-islet regulation, selectively shutting off glucagon secretion resulted in 
impairment of the insulin secretory response to glucose, resulting in hyperglycemia and 
glucose intolerance. Furthermore, it was demonstrated that these actions of glucagon 
were mediated through the GLP-1 receptor on β-cells (115). Further studies confirmed 
Figure 1-3. Cross-talk among α, β, and δ-cells towards inhibition of glucagon 
secretion. The Figure was extracted from reference 113 under the Creative 
Commons Attribution License (http://creativecommons.org/Licenses/by/4.0/). 
 
Figure 1-4. Kinetic model for trafficking of secretory granules in α-cells.  
R(reserve pool); P0(primed pool); F (fused pool); r1(forward resupply rate); r-
1(backward resupply rate); Kon(binding rate); Koff (unbinding rate); γ (fusion 
rate); r0(granule formation); rF( granule release). The Figure was extracted from 
reference 157 according to the Creative Commons Attribution License 
(http://creativecommons.org/Licenses/by/4.0/).Figure 1-5. Cross-talk among α, β, 
and δ-cells towards inhibition of glucagon secretion. The Figure was extracted 
from reference 113 under the Creative Commons Attribution License 
(http://creativecommons.org/Licenses/by/4.0/). 
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insulinotropic role of glucagon through the β-cell GLP-1 receptor, in a way that in the fed 
state, glucagon cooperates with insulin towards glucose homeostasis instead of 
counteracting insulin’s action (116).  
In case of diabetes, α-cells do not respond to elevated levels of glucose in a physiological 
way, instead paradoxically secreting higher amounts of glucagon. The loss of response to 
hyperglycemia may be due to either β-cell secretory defects or α-cell insulin or 
somatostatin resistance (117,118). In spite of these proposed mechanisms, the underlying 
events of paradoxical glucagon hypersecretion in hyperglycemic condition has not been 
fully uncovered. 
1.6 Chronic inflammation and diabetes 
In the pancreatic islet of people with diabetes, in particular type 2 diabetes, there is a 
remarkable reduction in the beta cell population due to the presence of a chronic 
inflammation. This chronic inflammation is due to an increased levels of cytokines and 
chemokines that affect whole islets (119). In fact, activation of immune system in islets, 
triggers proinflammatory response and release of cytokines. Cytokines will be secreted 
by both innate immune cells and all parenchymal cells of islets(120). It was shown that in 
both human and rodent animal models there is an increase in macrophage infiltration in 
islets, which produces and secretes Interleukin-1 (IL-1). To this end, IL-1β plays a master 
role in development of  inflammation within islets in a way that in the downstream 
induces expression of some proinflammatory factors ( such as IL-6, IL-8, IL-1β, CXCL1, 
CCL2, and TNF-α)(119). These inflammatory factors bring about ER stress, oxidative 
stress, dysfunction of mitochondria, and apoptosis, which result in cell dysfunction. 
Furthermore, these adverse effects trigger up-regulation of more inflammatory mediators 
(such as  CCL2, CXCL1, iNOS and Fas), which amplify inflammatory response, and 
exacerbate loss of β-cells (121). In addition, long-term exposure of islets to glucose 
induces Fas expression and increases secretion of IL-1β from resident immune cells 
within islets. This phenomenon activates amyloid system in islets, which results in 
initiation of inflammation. Thus, inflammation, brings about dysfunction in the cell-cell 
interaction within islets through inducing malfunction in β-cells, which will be resulted in 
dysfunction of δ and α-cells. 
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1.7 GLP-1: Intra-islet or intestinal?  
In addition to the pancreatic α-cell, proglucagon is also expressed in the intestinal L cell, 
where it is post-translationally processed to glucagon-like peptide (GLP)-1 and GLP-2. 
GLP-1 is an incretin hormone, secreted following meal ingestion and stimulates insulin 
secretion in a glucose-dependent manner. GLP-1 also suppresses glucagon secretion in 
both healthy people and people with type 2 diabetes (122), leading to the development of 
GLP-1 receptor agonists for the treatment of T2D. The glucagonostatic actions of GLP-1, 
the glucagonotropic actions of GLP-2 (123,124) and another incretin, glucose-dependent 
insulinotropic polypeptide (GIP) (125,126) all regulate post-prandial blood glucose 
levels.  This balance is disrupted in diabetes, in particular type 2 diabetes, which results 
in dysregulated glucagon secretion and hyperglucagonemia (126).  
It has been believed that proglucagon processing to GLP-1 does not occur in pancreatic 
α-cells under normal circumstances, due to the relative lack of the processing enzyme 
PC1/3 (127). However, this hypothesis has been very recently overturned by a study 
showing that there is a substantial subpopulation of α-cells (40%) within the non-diabetic 
human pancreatic islets that potently secretes GLP-1(128), and that this subpopulation 
increases in T2D. It has previously been shown that, when α-cells encounter metabolic 
stress, such as in both T1D and T2D and hyperplasia, the abundance and activity of 
PC1/3 increases, cleaving proglucagon to generate GLP-1 (129,130). Therefore, the  α-
cell has a degree of plasticity which allows it to respond to sustained metabolic stress 
(131). 
It has been postulated that islet-derived GLP-1 may act on β-cells to promote β- cell 
regeneration and thus ameliorate hyperglycemia and loss of β-cell mass  By considering 
generation of GLP-1 in both gut and islet, there is a debate on which source of GLP-1 
suppresses glucagon secretion from pancreatic α-cells. Chambers et al (2017)  generated 
a Gcg knockout mouse and then by reactivation of Gcg in L-cells or α-cells, showed that 
islet-generated GLP-1 was primarily responsible for glucose homeostasis by promoting 
glucose-stimulated insulin secretion and suppressing glucagon secretion (118). The gut-
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derived GLP-1 binds to its receptor on local afferent vagal nerve terminals, which 
ultimately signals for satiety, delaying gastric emptying and suppression of hepatic 
glucose release (129,132).  
 How GLP-1 exerts its actions on α-cells is a matter of debate. The search for a GLP-1 
receptor on α-cells has been hampered by a lack of a reliable GLP-1 receptor antibody 
(127,133). However, GLP-1 appears to mildly reduce action potentials in the α-cell 
membrane at 1 mM glucose in isolated mouse α-cells, and this effect is blocked by the 
GLP-1R antagonist exendin (9-39), therefore suggesting the presence of GLP-1R, 
perhaps at a very low density, on a small proportion of α-cells (122). 
It is known that GLP-1 acts on α-cells to trigger signaling through cAMP, which 
stimulates PKA-dependent activation of N-type Ca2+ channels, blocking Ca2+ influx and 
suppressing glucagon secretion. Notably, GLP-1 inhibits glucagon secretion in both basal 
status and in case of diabetes. It is noteworthy to mention that the low level of GLP-1R 
expression is crucial for GLP-1 inhibitory effect on glucagon secretion (134). It has also 
been shown that GLP-1R may be expressed on rat δ-cells, which, when activated, 
stimulates somatostatin secretion, which results in suppression of glucagon secretion 
from α-cells (127,135). However, this area needs further future research through 
designing a δ-cell-specific GLP-1R knockout. 
As I have discussed so far, glucagon secretion from the pancreatic α-cell is regulated by 
multiple inputs from outside and within the α-cell.  However, the entire picture of how 
glucagon secretion is regulated is far from clear (71). All of the factors I have thus far 
discussed ultimately converge on components of the regulated secretory pathway in the 
α-cell. In particular, the secretory granule, which stores mature glucagon, is the 
compartment that responds to factors that either stimulate or inhibit glucagon secretion. 
In the next section, I will outline the regulated secretory pathway of the α-cell, and 
propose that proteins contained within the secretory granule can regulate glucagon 
secretion. 
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1.8 Biogenesis of the regulated secretory pathway  
The α-cell secretory pathway begins with the synthesis of proglucagon in the 
endoplasmic reticulum. It is then transported through the Golgi to the trans-Golgi 
network (TGN). Budding immature secretory granules from the TGN contain 
proglucagon, its processing enzymes and many other proteins (136). Two models have 
been proposed as underlying mechanisms for secretory granule biogenesis: “sorting for 
entry” and  “sorting by retention”(137). 
1.8.1 Molecular mechanisms of sorting glucagon into secretory 
granule  
Based on the sorting for entry model, nascent granule budding occurs in a specific site on 
TGN, which contains sorting receptors and allows proteins with specific sorting signals 
to be directed into secretory granules. The sorting by retention model suggests that all 
protein components of the TGN are contained within the nascent secretory granule, 
which then matures by budding off constitutively-secreted proteins. Currently, it is not 
clear which of these models operate in α-cells, but it is generally believed that granule 
biogenesis is governed by the natural entity of the prohormone and its synthesis 
rate(136). Storage and concentration of proteins within secretory granule take place 
within the dense core portion of secretory granules (137). 
Advocators of the TGN-based sorting model have been striving to find a governor sorting 
receptor in the TGN, and sorting signals within prohormones that interact with sorting 
receptors. It has been proposed that membrane-bound form of the processing enzyme 
carboxypeptidase E (CPE) can be a prohormone sorting receptor (138–141). It was 
shown that ablation of CPE disturbed regulated secretion of proopiomelanocortin 
(POMC), proenkephalin and proinsulin in related cell lines and the CPE fat mouse model, 
in which CPE is degraded within the pituitary (140,141). Sorting signals can take the 
form of amphipathic loops, such as for POMC (142) or proinsulin (140), or amphipathic 
alpha helices, as is the case for the N-terminal region of prosomatostatin, and in the C-
terminal regions of PC1/3, PC2, PC5/6a, and CPE (143). These signals may also interact 
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directly with membrane lipids, in particular with lipid raft regions, to be sorted into 
secretory granules  (143).  
In pancreatic β-cells, there is evidence to support the “sorting-by-retention” theory of 
secretory granule biogenesis,, as the protein composition of immature secretory granules 
is altered during the process of granule maturation (144). In this context, proinsulin and 
the enzymes involved in the post-translational processing to mature insulin are retained 
within the secretory granule, while other proteins designated for constitutive secretion are 
removed (144).  
By considering all of these findings, it is more likely that both “sorting for entry” and 
“sorting by retention” mechanisms operate in the sorting of prohormones into secretory 
granules. In this scenario, prohormones could be sorted into secretory granules by means 
of sorting signals, followed by retention within the granule as maturation of secretory 
granules takes place. The maturation process involves alterations in the components and 
composition of the secretory granule, by removal of constitutively-secreted proteins, 
acidification of the granule milieu, and exclusion of water to condense the intragranular 
environment.  
The cellular events underlying the sorting of proglucagon to secretory granules have not 
been fully elucidated, and studying this mechanism is complicated by the multi-step 
processing of proglucagon. The processing of proglucagon in the α-cell is largely 
governed by the prohormone convertase (PC) family of enzymes. Proglucagon 
processing begins with cleavage of proglucagon at K70R71, which yields glicentin and 
major proglucagon fragment (MPGF) (Figure 1- 4)(145). This site is accessible to a 
number of processing enzymes and is likely cleaved by furin or PC1/3 in the absence of 
PC2 (148). This event occurs early in the secretory pathway, either in the TGN or 
immature secretory granule.  Subsequent cleavage of glicentin by PC2 at K31R32 results 
in the production of mature glucagon. This cleavage event likely occurs within the mature 
secretory granule since the acidic pH and millimolar calcium level of secretory granules 
is optimal for PC2 activity (9,10,146,147).  Thus, the sorting of proglucagon into the 
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secretory granule is vital for the generation of active glucagon, and storage within 
granules assures a robust secretory response in case of physiological need. 
Previous work from the Dhanvantari lab has investigated some mechanisms of 
proglucagon sorting into the secretory granule by searching for sorting receptors and 
sorting signals.  Using the α-cell line −TC1-6, it was shown that siRNA-mediated 
knockdown of CPE increased constitutive secretion of glucagon (141), thereby 
suggesting that CPE may play a role in directing proglucagon to secretory granules(141). 
However, the processing of proglucagon to glucagon remained unchanged, and therefore 
these results are not clear. The search for sorting signals provided more clarity on the 
mechanisms of proglucagon sorting. Using Fc-tagged proglucagon-derived peptides that 
could be detected by immunoprecipitation and immunofluorescence microscopy, two 
dipolar α-helices containing hydrophobic patches with three charged residues within the 
sequences play roles as sorting signals. One amphipathic α-helix was located within the 
amino acid sequence of glucagon (SDYSKYLDSRRAQDFVQWLMN), and one within 
GLP-1(SDVSSYLEGQAAKEFLAWLVK) (145). Interestingly, Fc-glicentin could be 
sorted to secretory granules, but Fc-MPGF was not, indicating that proglucagon 
processing occurs after sorting to secretory granules. 
 
 
 
 
 
 
As discussed above, this proglucagon processing profile changes in diabetes. In human α-
cells co-presence of GLP-1 and PC1/3 was shown in both healthy individuals and 
patients with type 2 diabetes (148). As well, it was shown that high glucose condition 
Figure 1-4. Cleavage processing of proglucagon in α-cells. Arrows depict 
sorting signals. The Figure was extracted from reference 145 under the 
license of https://www.asbmb.org/journals-news/editorial-policies. 
 
Figu e 0-6. Glucagon secretion and cell content are regulate  by a subset 
of interactome proteins. (A  Glucagon secretion and (B) cell content i  
the context of 25 mM glucose, and (C) glucagon secretion and (D) cell 
content in the context of 5.5 mM glucose were assessed after siRNA-
mediated gene silencing of the following proteins: Alpha-tubulin 2 (AT2), 
ATP synthase F1 subunit alpha (ATP5F1A) , Malate dehydrogenase 1 
(MDH1), Protein disulfide-isomerase (PDI), ELKS/Rab6-
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induced expression of PC1/3  and GLP-1 in primary culture of rat islets and also α-cell 
line models (149). In addition, it was shown that the diabetes-related pro-inflammatory 
cytokine, IL-6, caused an increase in the production of both GLP-1 and glucagon as well 
as expression of PC1/3 in primary culture of both human and mouse islets (150). Also, 
db/db (151), and ob/ob (152) showed the same expression pattern for PC1/3 , GLP-1 and 
glucagon. However, the NOD type 1 diabetic mouse did not show expression of GLP-1 
and PC1/3 in α-cells(151). Thus, the presence of PC1/3 and GLP-1 and other processed 
fragments of MPGF (GLP-2 and IP-2) within the secretory granules of diabetic α-cells is 
a subject of ongoing research. 
1.8.2 Secretory granule exocytosis 
After proglucagon processing and granule maturation, glucagon is stored in the granule 
until a stimulus triggers exocytosis. Releasing stored glucagon from the large dense-core 
secretory granules in α-cells needs coupling of stimulus and secretion. The electrically 
excitable membrane of the α-cell is active with action potentials below the range of 4-5 
mM glucose (153). Glucagon secretion could be in a Ca2+ dependent or independent 
manner. 
 A) Ca2+ dependent pathway of glucagon secretion: it was shown that a set of channels 
were clustered within the membrane of α-cells, which generate action potentials in the 
absence or low levels of glucose. Activation of KATP channels in low glucose condition 
brings about a level of membrane voltage that opens T-type Ca2+ channels. Influx of Ca2+ 
depolarizes the membrane to a level that opens Na+ channels and then N-type Ca2+ 
channels (non L-type, presumably P/Q type), which bring about glucagon secretion. At 
this step, L-type Ca2+ channels are also opened, but do not play a role in glucagon 
secretion (maybe due to spatial isolation). On the other hand, in high glucose condition, 
generation of ATP increases ATP/ADP ratio, which inhibits KATP channels and 
depolarizes the cell membrane (through L-type Ca2+ channels) at a level that it inactivates 
those mentioned channels in generation of action potentials, and consequently, suppresses 
electrical activity, Ca2+ influx and glucagon secretion. As it was discussed in 1.3.1, there 
is also a KATP -independent mechanism for inhibition of glucagon secretion from α-cells. 
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Based on this mechanism, high glucose condition inhibits glucagon secretion through 
suppression of SOC and preventing Ca2+ entry(153,154). 
B) Ca2+-independent pathway of glucagon secretion: This alternative theory expresses 
that in the context of high glucose concentration (e.g. 12 mM), KATP channels do not play 
a role in suppression of glucagon secretion. Accordingly, high glucose condition 
suppresses secretory granule trafficking or inhibits glucagon exocytosis in non-diabetic 
α-cells, which results in suppression of glucagon secretion. (155,156).  
Based on experimental evidence from isolated mouse islets, a kinetic model of the 
exocytotic behaviour of secretory granules in α-cells under low glucose conditions has 
been derived (140). This model predicts the relationship between intracellular Ca2+ levels 
and granule dynamics and mobilization (Figure 1- 5). A reserve pool of secretory 
granules within the cytoplasm resupplies the primed pool in a reversible equilibrium rate. 
Priming occurs as a result of sequential Ca2+ binding events. Following binding with  
three Ca2+, granules fuse with the plasma membrane in a non-reversible manner, which 
forms the fused pool and results in glucagon exocytosis (157). 
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It was quantitatively shown that in the presence of 1mM glucose, the mouse α-cell 
contains ~4400 secretory granules, of which ~140 are docked. This means that the 
reserve pool is large, and can resupply the primed pool to maintain euglycemia over 
extended periods of time. On the other hand, in the presence of 16.7 mM glucose 
numbers of the docked secretory granules increase to ~310 (157). By increasing exposure 
of α-cells to glucose from 1 to 16.7 mM, the levels of secreted glucagon will be reduced 
from ~40 to ~20 pg/islet/h (158). 
It is believed that α-cells are highly sensitive to small changes in Ca2+ (159). The Ca2+ 
dependence of glucagon granule exocytosis is due to the actions of  synaptotagmin VII 
(160), a major Ca2+-responsive component  of the SNARE complex of exocytotic 
proteins (62,161). This complex contains two subsets of proteins; i) the t-SNAREs 
syntaxin 1A and SNAP-25, located in the plasma membrane; and ii) the v-SNAREs 
VAMP2 and synaptotagmin VII, which are located in the granule membrane. Under low 
glucose conditions, SNAP-25 and syntaxin 1A are translocated to the plasma membrane. 
SNAP-25 itself may play a role in the transportation of granules from the RP to the RRP, 
and then mediates their fusion with plasma membrane via interaction with syntaxin 
1A(157,159). Then, C2 domain of synaptotagmin VII binds to syntaxin 1A and forms the 
SNARE complex to prime the secretory granules for exocytosis (159) in a mechanism 
similar to that in β-cells (162,163). .  
Figure 1-5. Kinetic model for trafficking of secretory granules in α-cells.  
R(reserve pool); P0(primed pool); F (fused pool); r1(forward resupply 
rate); r-1(backward resupply rate); Kon(binding rate); Koff (unbinding 
rate); γ (fusion rate); r0(granule formation); rF( granule release). The 
Figure was extracted from reference 157 according to the Creative 
Commons Attribution License 
(http://creativecommons.org/Licenses/by/4.0/). 
 
Figure 1-8. Cleavage processing of proglucagon in α-cells. Arrows depict 
sorting signals. The Figure was extracted from reference 145 under the 
license of https://www.asbmb.org/journals-news/editorial-policies.Figure 
1-9. Kinetic model for trafficking of secretory granules in α-cells.  
R(reserve pool); P0(primed pool); F (fused pool); r1(forward resupply 
rate); r-1(backward resupply rate); Kon(binding rate); Koff (unbinding 
rate); γ (fusion rate); r0(granule formation); rF( granule release). The 
Figure was extracted from reference 157 according to the reative 
Commons Attribution License 
(http://creativecommons.org/Licenses/by/4.0/). 
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1.8.3 Diabetes and alterations in dynamics of secretory granules   
It was shown that α-cells of patients with T2D show normal action potentials and Ca2+ 
entry into the cell; nonetheless, secretory granules remained close to the plasma 
membrane for a longer period of time compared to non-diabetic α-cells, and exocytosis is 
impaired (62). As mentioned above in section 1.3.1, the secretory behavior of dispersed 
α-cells from patients with T2D  is similar to that of non-diabetic dispersed α-cells, which 
implies that paracrine effectors are determinants for the normal dynamics of glucagon 
secretory granules (108).  
One very recent study has  shown that α-cells in intact islets from patients with T2D were 
resistant to the effects of somatostatin due to a  reduction in the expression of SSTR2.  
(62). SSTR2 is associated with L-type Ca2+ channels, and is linked with Gi2 proteins; the 
binding of somatostatin  activates the serine/threonine protein phosphatase calcineurin 
and prevents exocytosis through depriming secretory granules (164). Accordingly, it was 
mentioned that all paracrine effectors (insulin, somatostatin and GABA) suppress 
glucagon secretion through reducing priming, but not docking of secretory granules (62). 
These results suggest that reductions in paracrine regulation disrupt the depriming of 
secretory granules in diabetic α-cells, thus increasing secretory granule exocytosis, 
leading to glucagon hypersecretion.  
Therefore, in this section I have outlined how properties of the α-cell secretory granule 
may be determinants of glucagon secretion, and how their alterations are linked to 
hyperglucagonemia of diabetes. While it is known that granule contents and composition 
are modified during normal granule maturation, a more complete picture of granule 
remodeling and heterogeneity in normal islet cell physiology and in diabetes is required, 
and can be provided by islet proteomics and single cell transcriptomics. 
1.9 Pancreatic islet protein reference map 
Development of proteomic techniques coupled with bioinformatic analysis has provided a 
means to discover a wide range of low expression proteins within the pancreatic islet that 
may provide a greater understanding of the mechanisms of glucagon secretion. 
Specifically, this strategy has enabled the discovery of protein networks in organelles that 
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may regulate islet hormone secretion, such as the rough endoplasmic reticulum (RER), 
Golgi, mitochondria and secretory granules. In particular, secretory granule proteomics 
has revealed some novel protein networks involved in proinsulin processing, insulin 
secretory granule maturation, secretory granule trafficking and exocytosis and 
degradation of proteins in the β-cell. Such an approach may also reveal new networks 
that govern glucagon secretion and their dysregulation in diabetes.   
1.9.1 Islet proteomics and glucagon secretion 
In a proteomics study on normal human islets,  it was proposed that there is correlation 
between changes in islet protein profile and functional performance of islets, in particular 
insulin secretion (165,166). Importantly, islet proteomics shows dynamic alterations in 
secretory protein networks in response to changes in microenvironmental conditions, in 
particular those networks governing granule trafficking and exocytosis. After incubation 
of mouse islets for 24h in medium containing 5.6 mM versus 16.7 mM glucose, 
comparative analysis showed an increase in proteins related to glucose catabolism, 
cellular stress and cytoskeletal proteins, and a concomitant reduction in proteins related 
to vesicle trafficking (e.g. VAMP2, SERCA complex, synaptotagmin-like protein 4, 
Rab3b) under high glucose conditions. Accordingly, these alterations were accompanied 
by reduction in insulin secretion(167), thus identifying metabolic and structural changes 
that impact the β-cell secretory pathway in response to changes in prevailing glucose 
concentrations in a long-term cumulative incubation. 
In rodent models of diabetes, islet proteome studies have revealed interactions between 
metabolic, structural and secretory protein networks. Proteomic analysis of islets from the 
MKR mouse (insulin resistance), Zucker diabetic fatty rat (leptin receptor mutation), 
HFD diabetic mouse (diet-induced obesity and diabetes) and STZ-treated mice 
(chemically-induced T1D) all showed differential regulation for expression of proteins 
involved in the redox system, chaperone activity, cytoskeleton, and vesicle trafficking 
(166,168). Furthermore, there is downregulation of proteins involved in insulin 
exocytosis in insulin-resistant pre-diabetes (169), demonstrating substantial alterations in 
islet secretory protein networks prior to the onset of diabetes.  
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Importantly, islet proteomics of diabetic db/db mice revealed potentially new proteins in 
β-cells that may have  roles in ER-Golgi vesicle transport, granule trafficking, and 
signaling through PI3K-AKT and ERK1/2 pathways, such as: CD63 antigen (CD63), 
Neudesin (NENF), Glycerol-3-phosphate phosphatase (PGP), Minor histocompatibility 
antigen H13(HM13), Polyadenylate-binding protein-interacting protein 2B (PAIP2B), 
Pyruvate kinase PKM  (PKM; isotopes M1 and M2), Prominin-1 (PROM1), 
Mitochondrial import receptor subunit TOM22 homolog (TOMM22), Protein SET 
(SET), Apoptosis-stimulating of p53 protein 1 (PPP1R13B), and Methionine 
aminopeptidase 2 (METAP2).  The METAP2 has been introduced as a therapeutic target 
for the treatment of diabetes and obesity(170).  
Islet proteomics can also show how diabetes-induced derangements in β-cell secretory 
networks can be restored by normalizing glucose conditions. Adaptation of islets from 
diabetic db/db mice to euglycemic conditions brought about a non-diabetic mouse islet 
proteomics profile in terms of both expression and phosphorylation of proteins involved 
in ER-Golgi vesicular transport (Transport and Golgi organization protein 1 homolog, 
MIA3;  Coatomer subunit alpha, α-COP;  GTP-binding protein SAR1b ;SAR1B),  post-
Golgi vesicular transport (Vesicle-associated membrane protein 4, VAMP4;  ADP-
ribosylation factor-related protein 1, ARFRP1; Vesicle transport through interaction with 
t-SNAREs homolog 1B , VTI1B;  Brefeldin A-inhibited guanine nucleotide-exchange 
protein 2, ARFGEF2), secretory granule trafficking (Ras-related protein Rab-3B ,Rab3b; 
Ras-related protein Rab-27A,  Rab27a;  Rabphilin-3A, RPH3a1;  Microtubule-associated 
protein 2, MAP2;  Polycomb protein Pcl, PCL0; Myosin-9, MYH9; Vesicle-trafficking 
protein SEC22b, Sec22b), and exocytosis (Synaptotagmin-like protein 5, SYTL5; 
Synaptotagmin-7, SYT7; Synaptotagmin-10, SYT10; Exonuclease 1, EXO1; Syntaxin-4 , 
STX4a; Syntaxin-18, STX18; Regulating synaptic membrane exocytosis protein 2, 
RIMS2) (171). In this context, post-translational alterations such as phosphorylation and 
sialylation were particularly important (170) and revealed a role for the Golgi protein 
kinase FAM20C, which targets secretory proteins (e.g. BIG3), in trafficking and 
secretory granule biogenesis (171). Meanwhile, such alterations could be restored 
following treatment (for example in rat diabetic islets) with EPS (a hypoglycemic fungal 
extracellular polysaccharides) or Imidazoline (cationic surfactant with an insulinotropic 
30 
 
effect) (166). These types of experiments have revealed some new proteins involved in 
insulin secretion that could be novel targets for pharmaceutical treatment of diabetes.    
1.9.2 The state-of-the-art secretory granule proteomics 
Recent advances in the isolation and purification of secretory granules have enabled 
accurate coverage in the proteomic analysis of the granule compartment. Secretory 
granule proteomics complement islet proteomics through; 1) uncovering genuine protein 
components of secretory granules (172), and 2) unveiling alterations in protein 
components of secretory granules in diabetes. Diabetes alters the protein components of 
the secretory granule responsible for secretory granule trafficking, docking and 
exocytosis. For instance, in islets from patients with T2D, islet proteomics revealed 
down-regulation in a network of proteins that function in granule docking, fusion and 
exocytosis, such as the SNARE proteins SNAP25, Syntaxin-1A, Syntaxin-binding 
protein 1(STXBP1), Synaptotagmin-1(SYT1), Synaptotagmin-7 (SYT7) and the Rab 
family of GTPases, Rab-3A, Rab-3B and Rab-3C, and new proteins that may function in 
this network, such as Regulating synaptic membrane exocytosis protein 1 (RIMS1) and 
RIMS2 and the presynaptic scaffold proteins Piccolo (PCLO) and Bassoon (BSN) (173). 
Uncovered proteins in proteomic analysis of secretory granules can be categorized into 
three groups; 1) Proteins annotated as secretory granule proteins, 2) proteins annotated to 
have multiple localizations, and 3) proteins annotated as immature secretory granules or 
contaminants.  
Annotated secretory granule proteins can be subcategorized as a) secretory granule 
proteins (e.g. INS-1E cell proteins of CPE, PC2,VAPM2, VAMP3, chromogranins) , b) 
islet cell protein, but not related to any organelle (e.g. INS-1E cell proteins of  tubulin 
beta-2A chain, Annexin A11 , Kinesin-1 heavy chain) and c) non-islet cell proteins (e.g. 
INS-1E cell proteins of neuronal differentiation-related gene protein, and Proprotein 
convertase subtilisin/kexin type 1 inhibitor, proSAAS ) (172). Importantly, this 
subcategorization could have clinical application in terms of introducing novel targets for 
the treatment of diabetes. Proteomics of  INS-1E secretory granules revealed the presence 
of some membrane proteins within the granules (such as ARFRP1, ADP-ribosylation 
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factor-related protein 1;SCFD1, Sec1 family domain-containing protein 1; syntaxin12, 
STX12, syntaxin5, STX5; VPS45, Vacuolar protein sorting-associated protein 45, and 
ATP6V0C, V-type proton ATPase 16 kDa proteolipid subunit ) that could play a role in 
the secretory granule biogenesis, maturation, trafficking and exocytosis (174). For 
instance, ATP6V0C is a subunit of vacuolar ATPase and regulates the acidification of the 
secretory granule over the maturation process. The presence of SNARE proteins within 
the secretory granule proposes their roles in the fusion step of exocytosis. The presence 
of related proteins to immature secretory granules (such as STX12, VTI1A, STX6 and 
VAMP4) within the secretory granule proposes homotypic fusion of immature secretory 
granule, which is an important step in the maturation process (174). In this context, the 
presence of transmembrane protein (such as Transmembrane 9 superfamily member 3, 
TM9SF3, a nine-transmembrane protein) implies a role for transmembrane proteins in 
secretory granule biogenesis, and their potential involvement in maturation, trafficking, 
and exocytosis. 
Annotated proteins with multiple localizations imply that other intracellular 
compartments may interact with secretory granules and therefore have inputs into the 
secretory pathway. For instance, proteomic analysis of granules isolated from INS-1E 
cells revealed the presence of the endosomal proteins syntaxin 7 and VAMP 8 (172). In 
islets from diabetic mice, a lysosomal protein, Rab7 interacting lysosomal protein (RILP) 
is overexpressed, and plays a role in the maturation of secretory granules through cross-
talk with lysosomes (175).  As well, the presence of endosomal and lysosomal proteins in 
secretory granules indicates cross-talk between these two subcellular compartments, and 
may reveal new mechanisms of regulation of islet hormone secretion, and ultimately  
novel therapeutic candidates for treatment of diabetes (176,177).  
1.10 Endolysosomal system of islet cells in diabetic 
condition 
There is relationship between diabetes and lysosomal functions, in a way that alterations 
in lysosomal activities take part in physiopathology of diabetes. 
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1.10.1 Alterations in endolysosmal enzyme activities in islet cells 
Alterations in the lysosomal enzyme activities have been reported in the liver, kidney, 
heart, saliva, brain and plasma of people with diabetes. While there is no published 
document to show activities of lysosomal system in α-cells, relationship between normal 
activities of lysosomes and insulin secretion from β-cells has been documented (178). In 
the β-cell, lysosomal enzyme of glucan-1,4-α-glucosidase has a direct relationship with 
glucose-stimulated insulin secretion from β-cells. Importantly, significant levels of 
abnormalities were shown in activities of lysosomal enzymes in islets of diabetic GK rats. 
While glucan-1,4-α-glucosidase and acid α –glucosidase showed higher activities, acid 
phosphatase, N-acetyl-β-D-glucosaminidase, cathepsin D, and β-glucuronidase showed 
diminished activities (178). Further to aberrant enzyme activities of lysosomal system in 
diabetes, there is uncontrolled lysosomal degradation of proinsulin/insulin in diabetic 
condition (179).While uncontrolled degradation of insulin in endolysosomal system 
participates in pathogenesis of type 2 diabetes, there is a question about implication of 
this aberrant system for diabetic α-cells and its potential role in glucagon hypersecretion 
and the hyperglucagonemia of diabetes. 
1.10.2 Degradation of glucagon in endolysosomal system 
In terms of glucagon degradation in α-cells, it has been shown that glucagon is taken up 
by α-cells after secretion and then directed into the lysosome. Within the lysosome, 
glucagon is dissociated from its receptor and then undergoes degradation (180). 
illustrating the capability of the α-cell to degrade glucagon through the endolysosomal 
system. Degradation of the endocytosed glucagon is governed by the rate of fusion 
between endocytic vesicles and lysosomes. This fusion event is a rate limiting step for the 
degradation of endocytic vesicle contents in the lysosome and could be altered in 
response to changes in microenvironmental conditions. For instance, α-cells 
simultaneously internalize several receptor-bound islet hormones, which may saturate the 
endolysosomal system and consequently inhibit glucagon degradation (180).  
In a parallel finding on β-cells, it was proposed that insulin also will be taken up after 
secretion by β-cells and then undergo degradation in the lysosomal system (181). In 
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diabetes, aberrant insulin degradation in β-cells has been proposed as underlying 
mechanism for β-cell failure in type 2 diabetes (179). Importantly, in the context of 
diabetes, there is no published document to show status of glucagon degradation within 
endosomal/lysosomal system of α-cells. 
1.11 Aims and rationale of the study 
 
Based on the glucagoncentric hypothesis of diabetes, hyperglycemia of diabetes would be 
due to hyperglucagonemia instead of hypoinsulinemia. Several theories have been 
proposed to address underlying mechanisms of glucagon hypersecretion from α-cells. 
While some researchers have focused on glucose-regulated glucagon secretion from α-
cells and alterations in its signaling processes in diabetes, some other researchers targeted 
paracrine effectors as major determinants in glucagon secretion and their disturbances in 
diabetes. Additionally, protein components of the regulated secretory pathway also 
regulate glucagon secretion from α-cells. In this context, our laboratory has already 
shown that alterations in ambient glucose levels alters levels of proteins in the regulated 
secretory pathway in α-cells. The prevailing hypothesis is that dissecting the cellular 
mechanisms of glucagon trafficking in the α-cell may reveal novel proteins, or networks 
of proteins, that function in glucagon secretion, and provide explanations for the 
hyperglucagonemia of diabetes.  
Mapping of the α-cell secretory granule proteome under different microenvironmental 
inputs, such as glucose or insulin, would likely provide answers to our questions 
regarding the regulation of glucagon secretion in normal physiology, and in the 
pathobiology of diabetes. It may also reveal novel inputs to secretory granules, new 
cellular pathways by which glucagon secretion is regulated, and new insights into the 
development of hyperglucagonemia.  
 
The specific aims of my thesis are: 
1) To determine the glucagon interactome in the secretory granules of α-cells and its 
potential plasticity in response to microenvironmental conditions. 
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2) To identify and characterize a protein within the interactome that modulates glucagon 
secretion in normal α-cells by regulating its intracellular trafficking.  
3) To determine how the interactome protein-mediated trafficking of glucagon is altered 
in the hyperglucagonemia of diabetes. 
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2.1 Abstract 
Glucagon is stored within the secretory granules of pancreatic α-cells until stimuli trigger 
its release.  The α-cell secretory responses to the stimuli vary widely, possibly due to 
differences in experimental models or microenvironmental conditions. We hypothesized 
that the response of the α-cell to various stimuli could be due to plasticity in the network 
of proteins that interact with glucagon within α-cell secretory granules. We used tagged 
glucagon with Fc to pull out glucagon from the enriched preparation of secretory 
granules in α-TC1-6 cells. Isolation of secretory granules was validated by 
immunoisolation with Fc-glucagon and immunoblotting for organelle-specific proteins. 
Then, enriched secretory granules were used for affinity purification with Fc-glucagon 
followed by liquid chromatography/tandem mass spectrometry to identify secretory 
granule proteins that interact with glucagon. Proteomic analyses revealed a network of 
proteins containing glucose regulated protein 78 KDa, GRP78, and histone H4. The 
interaction between glucagon and the ER stress protein GRP78 and histone H4 was 
confirmed through co-immunoprecipitation of secretory granule lysates, and 
colocalization immunofluorescence confocal microscopy. Composition of the protein 
networks was altered at different glucose levels (25 mM vs 5.5 mM) and in response to 
the paracrine inhibitors of glucagon secretion, GABA and insulin. siRNA-mediated 
silencing of a subset of these proteins revealed their involvement in glucagon secretion in 
α-TC1-6 cells. Therefore, results indicate a novel and dynamic glucagon interactome 
within α-TC1-6 cell secretory granules. We suggest that variations in the α-cell secretory 
response to stimuli may be governed by plasticity in the glucagon “interactome”. 
 
Keywords: glucagon, α-cell, proteomics, co-immunoprecipitation, confocal microscopy, 
glucagon interactome, glucagon secretion 
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2.2 Introduction 
Glucagon is the major glucose counter-regulatory hormone, and maintains euglycemia by 
enhancing hepatic gluconeogenesis and glycogenolysis (1). However, both type 1 and 
type 2 diabetes are characterized by varying levels of hyperglucagonemia (2), which 
paradoxically exacerbates the hyperglycemia of diabetes (3, 4). More recently, it has been 
shown that glucagon may be an amino acid regulatory hormone, suggesting a link 
between hepatic amino acid metabolism and hyperglucagonemia (5). In pancreatic α- 
cells, glucagon secretion is tightly regulated by nutritional, hormonal, and neural 
effectors to maintain normal glucose homeostasis. However, in diabetes, this tight 
coupling is disrupted (6), resulting in dysfunctional glucagon secretion, which may be a 
factor in the development of type 2 diabetes (7). This abnormal glucagon secretion has 
led to strategies (8) to control glucagon action to ameliorate the hyperglycemia of 
diabetes, such as administering glucagon receptor antagonists or neutralizing antibodies 
against the glucagon receptor (9, 10). Although effective in the short term, this strategy 
tends to increase α-cell mass and worsen α-cell dysfunction over the long term (6). 
Therefore, a preferable strategy may be to control the secretion, rather than the action, of 
glucagon for improved glycemic control in diabetes. 
In the context of the pancreatic islet, there is some debate as to whether glucagon 
secretion is primarily regulated by the paracrine influence of the β-cell, or through 
intrinsic factors (11, 12). Both insulin and GABA secreted from the β-cell strongly inhibit 
glucagon secretion, as does somatostatin (13, 14). However, these actions are dependent 
on prevailing glucose concentrations; at 5 mM glucose, both glucagon and insulin 
secretion are maximally suppressed (11), suggesting that intrinsic factors may exert an 
equally prominent influence on glucagon secretion. Some proposed mechanisms of 
intrinsic regulation of glucagon secretion include glucose metabolic-induced changes in 
Ca2+ and K+ membrane conductances or intracellular Ca2+ oscillations (15, 16). Intrinsic 
factors can also include proteins involved in the intracellular trafficking of glucagon. We 
have previously shown that prolonged culture of α-TC1-6 cells in medium containing 25 
mM glucose resulted in the up-regulation of components of the regulated secretory 
pathway (17), notably proteins associated with secretory granules, such as SNARE 
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exocytotic proteins and granins. There may be direct interactions between granule 
proteins, such as chromogranin A and carboxypeptidase E, to ensure proper trafficking of 
glucagon into secretory granules (18), and distinct sorting signals within glucagon may 
mediate these interactions (19). Therefore, proteins within the α-cell secretory granules 
that directly interact with glucagon may provide additional clues for the regulation of 
glucagon secretion. 
In order to identify networks of secretory granule proteins that interact with glucagon, we 
have continued to use the α-TC1-6 cell line, as this is a well-established cell line in which 
to study the intrinsic regulation of glucagon secretion (20). This cell line has been 
extensively used to study glucagon secretory pathway (17, 21) due to its resemblance to 
the normal pancreatic α-cell in terms of proglucagon processing (22) and response to 
insulin and somatostatin and nutritional effectors (12, 17). Our work has revealed a novel 
glucagon “interactome” that exhibits plasticity in response to glucose, insulin and GABA, 
and contains some novel glucagon-interacting proteins that may regulate glucagon 
secretion in α-TC1-6 cells. 
2.3 Materials and methods 
Sources for all reagents, assays, and software packages are listed in Supplementary Table 
2-1. 
2.3.1 Gene construct and plasmid preparation 
We designed a glucagon fusion construct [Fc-glucagon –pcDNA3.1(+)] as follows: the 
amino acid sequence of glucagon derived from human proglucagon (GenScript, USA; 
http://www.genscript.com) was fused to the 3′ end of cDNA encoding the CH2/CH3 
domain of mouse IgG-2b (Fc), preceded by a 28 amino acid signal peptide as described 
previously (19). As a negative control for all transfections, proteomics, 
immunofluorescence microscopy, and co-immunoprecipitation experiments, we also 
designed a Fc-pcDNA3.1(+) construct. DNA sequences were confirmed at the London 
Regional Genomics Facility, Western University. 
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2.3.2 Extraction and enrichment of secretory granules 
Wild type α-TC1-6 cells (a kind gift from C. Bruce Verchere, Vancouver, BC) were 
cultured in DMEM containing 25 mM glucose, L-glutamine, 15% horse serum, and 2.5% 
fetal bovine serum, as described previously (17, 23). Based on the ATCC product sheet, 
the base cell culture medium for α-TC1-6 cells is low glucose (5.5 mM) Dulbecco's 
Modified Eagle's Medium (DMEM); however, for glucagon secretion (glucagon 
hypersecretion) studies, high glucose DMEM (16.7 or 25 mM) has been traditionally 
used to prepare α-TC-6 cells for downstream experiments (17, 24). Cells were grown to 
90% confluency and transfected with Fc alone or Fc-glucagon using Lipofectamine 2000. 
To determine changes in granule size, mass, and proteome, cells were transiently 
transfected with Fc-glucagon or Fc-alone and then incubated with or without GABA (25 
μM), insulin (100 pM), or GABA (25 μM) plus insulin (100 pM) in either 25 or 5.5 mM 
glucose prior to the granule enrichment procedure. To account for all potential 
modulators of glucagon secretion, including the possibility of autocrine regulation of 
glucagon secretion (25, 26) we chose long-term cumulative incubation that has 
previously been used by our team (17) and other investigators (23) for secretion studies in 
α-TC1-6 cells.  
At the end of the incubation period, granules were extracted as previously published (27) 
with some modifications. Briefly, cells were detached using 5 mM EDTA in PBS (pH 
7.4) containing cOmplete Mini Protease Inhibitor Cocktail (Supplementary Table 1) on 
ice, centrifuged and resuspended in ice-cold homogenization buffer (20 mM Tris-HCl 
pH7.4, 0.5 mM EDTA, 0.5 mM EGTA, 250 mM sucrose, 1 mM DTT, cOmplete Mini 
Protease Inhibitor Cocktail, and 5 μg/mL Aprotinin). The cells were passed 10 times 
through a 21G needle and again 10 times through a 25G needle. The resulting lysates 
were centrifuged to obtain a post-nuclear supernatant (PNS). The nuclear fraction was 
washed seven times in ice-cold homogenization buffer and stored at −80°C. The PNS 
was centrifuged at 5,400 × g for 15 min at 4°C to obtain a post-mitochondrial 
supernatant, which then was spun at 25,000 × g for 20 min, and the resultant pellet was 
washed five times at 4°C. Enrichment was confirmed through immunoblotting for 
organelle-specific markers as described below. 
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2.3.3 Immunoblotting for organelle-specific markers 
The enriched preparations of secretory granules from α-TC1-6 cells were lysed using 
non-ionic lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100 plus 
cOmplete Mini Protease Inhibitor Cocktail, and 5 μg/mL Aprotinin). Proteins were 
resolved by 4–12% NuPAGE, transferred to a PVDF membrane and probed with the 
following antibodies (Supplementary Table 1): vesicle-associated membrane protein 2 
(VAMP2) for mature secretory granules; calreticulin for the endoplasmic reticulum; 
TGN46 for the trans-Golgi network; and Lamin B1 for the nuclear envelope. 
Immunoreactive bands were visualized using HRP-conjugated goat anti-rabbit secondary 
antibody and Clarity Western ECL substrate. Images were acquired on a BioRad 
ChemiDoc Imaging System. Total cell extracts were used as positive controls. 
2.3.4 Nanoscale flow cytometry 
Secretory granule preparation 
We used nano-scale flow cytometry (A50-Micro nanoscale flow cytometer; Apogee 
FlowSystems Inc.) to confirm enrichment of the secretory granules and to determine the 
size distribution of the granules. α-TC1-6 cells were transfected with Fc-glucagon or Fc 
alone, and secretory granules were extracted as described above. Granules were fixed in 
freshly prepared 2% PFA (pH 7.4), permeabilized with 0.5% saponin at room 
temperature, centrifuged at 25,000 × g for 20 min at 4°C and washed three times in 0.1% 
saponin in PBS. Fc-containing granules were labeled with FITC-IgG (1:250 dilution in 
0.1% saponin in 1% BSA/PBS) in the dark for 1 h, and diluted 200X in 0.1% saponin. 
Size calibration  
Secretory granules of non-transfected cells were used for size calibration. ApogeeMix 
beads were used to establish sizing gates along the Y axis—large angle light scattering 
(LALS) vs. X-axis- small angle light scattering (SALS) plot. The microparticle mixture 
contained plastic spheres with diameters of 180, 240, 300, 590, 880, and 1,300 nm with 
refractive indexes of 1.43 and 110 nm, and 500 nm green fluorescent beads with 
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refractive index of 1.59. Based on the manufacturer's default settings, the calibrated gates 
of the size distribution were 110, 179, 235, 304, 585, and 880 nm, which were used to 
categorize subpopulations of the enriched secretory granules. 
Nano-flow analysis 
To count the numbers of Fc-glucagon+ granules, fluorescence of FITC excitation (L488) 
was gated and the numbers of Fc-glucagon+ granules were counted at 110, 179, 235, 304, 
585, and 880 nm within the LALS vs. L488 plot. To get the LALS vs. L488 plot, its gate 
was normalized for the following isotypes: secretory granules of non-transfected cells, 
secretory granules of Fc-transfected cells, FITC-IgG and diluent. This method resulted in 
size distributions of the granules that were positive for Fc-glucagon, specifically. All 
experiments were done in three biological samples and values were expressed as percent 
distribution of gated granules. 
2.3.5 Proteomic analysis of secretory granule proteins associated 
with glucagon 
Granule lysate preparation 
α-TC1-6 cells were transfected by Fc-glucagon and treated with effectors (GABA, insulin 
and GABA plus insulin) in media containing 25 or 5.5 mM glucose as described above. 
To identify non-specific interactors, we used the Fc construct in untreated conditions. 
Secretory granules were extracted as described above, and lysed in a non-ionic lysis 
buffer.  
Affinity purification 
Fc or Fc-glucagon was purified from the granule lysate by immunoprecipitation as we 
have done previously (19). Briefly, a slurry of Protein A-Sepharose beads 
(Supplementary Table 1) was mixed 1:1 with the granule lysate and rotated overnight at 
4°C. The mixture was then centrifuged at 500 × g for 2 min at 4°C and the pellet was 
washed twice with 50 mM Tris (pH 7.5) and once with pre-urea wash buffer (50 mM Tris 
pH 8.5, 1 mM EGTA, 75 mM KCl). Fc or Fc-glucagon was eluted with two volumes of 
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urea elution buffer (7 M urea in 20 mM Tris buffer pH 7.5 plus 100 mM NaCl). This step 
was repeated twice more and the supernatants were collected and pooled. The pooled 
supernatant was mixed with acetone in a 1:4 ratio and kept at −20°C overnight, then 
centrifuged at 16,000 × g for 15 min at 4°C. The pellet was air-dried for proteomic 
analysis. 
Proteomic analysis 
Protein identification was conducted using LC-MS/MS according to the protocols of the 
Western University Mass Spectrometry Laboratory 
(https://www.schulich.uwo.ca/lrpc/bmsl/protocols/index.html). Briefly, the air-dried 
pellet was reconstituted in 50 mM NH4CO3, and proteins were reduced in 200 mM 
dithiothreitol (DTT), alkylated in freshly prepared 1M iodoacetamide and digested with 
trypsin for 18 h at 37°C with occasional shaking. Tryptic peptides were acidified using 
formic acid (0.25; v/v), loaded onto a Hypersep C18 column, washed, and eluted in 50% 
acetonitrile. The eluent was dried down in a speed vacuum and reconstituted in 
acetonitrile. Each experimental condition was done in three biological replicates. Peptide 
sequences were identified using the mouse database and further analyzed for protein 
categorization through PANTHER GO (http://www.Pantherdb.org), determination of 
subcellular locations and activity using http://www.uniport.org, and functional protein-
protein interaction clustering through http://string-db.org. To predict protein-protein 
interactions using string, clustering of proteins was done based on strength of data 
support in the context of all active interaction sources. The minimum interaction score 
was set at median of 0.4 and maximum at 5 for the first shell and no limitation for the 
second shell. 
Proteins that were pulled down using Fc alone were subtracted from proteins pulled down 
by Fc-glucagon to obtain the profile of proteins that specifically interact with glucagon. 
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2.3.6 Immunoprecipitation-immunoblotting of proteins associated 
with glucagon 
To validate the interaction of glucagon with either GRP78 or histone H4 within secretory 
granules we first purified Fc-glucagon or Fc (as control) from the secretory granule 
preparation by incubating the secretory granule lysate with Protein A-Sepharose beads 
overnight at 4°C with rotation. The Fc or Fc-glucagon complex was eluted from the 
beads with 0.1 M glycine buffer (pH 2.8). The eluate was concentrated 50 times using a 
speed vac, run on a 10% Bis-Tris NuPAGE gel (Supplementary Table 1) and proteins 
were transferred onto a PVDF membrane. After an overnight incubation with primary 
antibodies against GRP78 or histone H4, bands were visualized with HRP-conjugated 
goat anti-rabbit secondary antibody and Clarity Western ECL substrate (Supplementary 
Table 1). Images were acquired on a BioRad ChemiDoc Imaging System. 
2.3.7 Histone H4 assay 
Enriched secretory granule fractions were prepared, resuspended in 0.2 N HCl, passed 10 
times through a 30G needle, and kept at 4°C overnight. The reaction was stopped by 
addition of 0.2 volumes of 1N NaOH. The supernatant was collected after centrifugation 
at 6,500 × g at 4°C for 10 min. Protein levels were determined by BCA assay, and 100 ng 
of protein was used for measuring total histone H4 (Histone H4 Modification Multiplex 
ELISA-like format Kit, Supplementary Table 1), as per the manufacturer's instructions. 
The nuclear fraction was also assayed for histone H4 as a positive control. 
2.3.8 Immunofluorescence microscopy 
To validate the presence of GRP78 and histone H4 in glucagon-positive secretory 
granules, α-TC1-6 cells were cultured on collagen1-coated coverslips (three per 
experiment), and processed for immunofluorescence microscopy as described previously 
(18). Briefly, cells were fixed in 4% paraformaldehyde and permeabilized in 0.1% 
saponin in 0.5% BSA for 1 h. After blocking in 10% goat serum, cells were incubated 
with primary antibodies (mouse anti-glucagon and rabbit anti-GRP78 or rabbit anti-
histone H4) overnight. Coverslips were washed in PBS and incubated with goat anti-
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mouse Alexa Fluor IgG 488 and goat anti-rabbit Alexa Fluor 594 (Supplementary Table 
1) for 3 h in the dark at room temperature, then mounted using ProLong Gold Antifade 
Mountant. Images were acquired on a Nikon A1R Confocal microscope with a 60x Nikon 
Plan-Apochromat oil differential interference contrast objective lens using NIS-Elements, 
software. To show secretory granule co-localization, images were post-processed by 2D 
deconvolution. To measure the degree of co-localization, regions of interest were 
manually drawn around distinct single or multicell bodies, positive for Fc-glucagon and 
either GRP78 or histone H4 and cropped for analysis. Co-localization of the pixels from 
each pseudo-colored image were used to calculate Pearson's correlation coefficient 
(PCC), as we described previously (19). 
2.3.9 siRNA-mediated depletion of targeted proteins 
After treatment of α-TC1-6 cells with GABA and/or insulin in media containing 25 mM 
glucose as described above, the proteomes were tabulated, and Venn diagram analysis 
revealed 27 metabolic/regulatory/secretory proteins and 36 
histone/cytoskeletal/ribosomal proteins that were common between the groups treated 
with GABA and insulin. We selected 11 of these proteins (based on availability of the 
pre-designed siRNA) for siRNA-mediated depletion: Peroxiredoxin-2 (PRDX2), Malate 
dehydrogenase 1 (MDH1), Aconitate hydratase, mitochondrial (ACO2), 14-3-3 protein 
zeta/delta (KCIP-1), ELKS/Rab6-interacting/CAST family member 1 (ERC1), Alpha-
tubulin 2 (AT2), ATP synthase F1 subunit alpha (ATP5F1A), Histone H4, GRP78, 
FXYD domain-containing ion transport regulator 2 (FXYD2), and Protein disulfide-
isomerase (PDI), (Silencer siRNA, Thermo Fisher Scientific Inc. MA, USA). 
Gene silencing was based on a published protocol (28). Briefly, α-TC1-6 cells were 
cultured to 60% confluency and transfected with final concentrations of 50 nM of pooled 
siRNAs (three siRNAs for each target) or control scrambled siRNA using 
Lipofectamine2000. Cells were incubated for 48 h, after which media were removed and 
replaced. After 24 h, expression levels of the targeted proteins were evaluated by 
immunoblotting using primary antibodies against each protein (Supplementary Table 1). 
Meanwhile, siRNA mediated knockdown of the proglucagon gene was shown as a 
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positive control using real-time PCR (Quant Studio Design and Analysis Real-Time PCR 
Detection System) (Supplementary Figure 2-1). 
2.3.10 Glucagon measurement 
To measure cellular and secreted glucagon levels after siRNA-mediated gene silencing, 
cell lysates or media were acidified in HCl-ethanol (92:2 v/v) in a 1:3 ratio, kept at −20°C 
overnight, then centrifuged at 13,000 × g for 15 min at 4°C. The supernatant was then 
mixed 1:1 with 20 mM Tris, pH 7.5 26 and glucagon levels were measured by ELISA 
(Thermo Fisher Scientific, Supplementary Table 1) according to the manufacturer's 
instructions. To measure Fc-glucagon, samples were diluted to reach an OD at the linear 
part of the standard curve. 
2.3.11 Glucagon secretion and cell glucagon content in response to 
nutritional and paracrine effectors 
α-TC1-6 cells cultured and kept under chronic exposure to 25 mM glucose and at 
confluency rate of ~70% were plated out into six-well plates. After 24 h, two sets of 
experiments were designed. In one set, medium was replaced by fresh 25 mM glucose-
containing medium and in the other set medium was replaced by fresh medium 
containing 5.5 mM glucose. In both sets, cells were treated by GABA (25 μM), insulin 
(100 pM), or GABA (25 μM) + insulin (100 pM), and incubated for 24 h in serum free 
medium containing 0.5% BSA. At the end of incubation, plates were placed on ice and 
media were collected, centrifuged at 16,000 × g for 5 min, and supernatant was removed 
for glucagon measurement. The cells were washed three times with ice-cold PBS and 
scraped in Glycine-BSA buffer (100 mM glycine, 0.25% BSA, cOmplete Mini Protease 
Inhibitor Cocktail, 5 μg/mL Aprotinin, pH 8.8). The scraped cells were lysed by 
sonication (12 s at 30% amplitude on ice), and centrifuged at 16,000 × g for 45 min, from 
which the supernatant was collected for analysis. The protein concentration of the cell 
lysate was measured using BCA assay. To measure glucagon levels, the cell lysate or 
medium was mixed in an ethanol-acid solution (96% ethanol containing 0.18 M HCl) in a 
1:3 ratio, kept at −20°C overnight, then centrifuged at 16,000 × g for 15 min at 4°C. The 
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supernatant was then mixed with 20 mM Tris buffer, pH 7.5, and glucagon measurements 
were conducted by ELISA. 
2.3.12 Statistical analysis 
Experiments were done in three biological replicates (three batches of newly thawed α-
cells), each of which had two technical replicates (on passaged cells following three 
weeks adaptation to high glucose condition). Values were compared among treatment 
groups by one-way ANOVA (Bonferroni post-hoc test) using Sigma Stat 3.5 software (α 
= 0.05). For image analysis, co-localization of channels in the merged images was 
calculated by PCC using NIS-Elements software (Nikon, Canada). 
2.4 Results 
Our method for purification of proteins that associate with glucagon within the α cell 
secretory granules consisted of two sequential steps. First, we modified and used a 
previously published method (27) for enrichment of the secretory granule fraction. 
Second, we used Fc-glucagon for affinity purification to pull down proteins associated 
with glucagon within the secretory granules.  
2.4.1 Secretory granule enrichment  
Immunoblotting for organelle-specific markers confirmed enrichment of secretory 
granules (Supplementary Figures 2- 2A–D). The final granule fraction was positive for 
the secretory granule marker, VAMP2. In contrast, the granule fraction did not contain 
the trans-Golgi marker TGN46, the nuclear envelope marker LaminB1, or the 
endoplasmic reticulum marker Calreticulin. As a positive control, the general cell lysate 
contained all four markers. 
2.4.2 Confirmation of the enriched secretory granules  
Secretory granules in α-cells have been previously studied using transmission electron 
microscopy and their average sizes have been reported to be in the range of 180–240 nm 
(29–31). Accordingly, we confirmed the presence of secretory granules using nano-scale 
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flow cytometry with Fc-glucagon as an exclusive marker for α-cell secretory granules 
(32, 33). We used beads in the range of 110–880 nm for calibration in the range of the 
reported sizes for secretory granules (Supplementary Figure 2- 3A). Fc-glucagon+ 
secretory granules distributed mostly to the gated regions of 179 and 235 nm 
(Supplementary Figures 2- 3B, C), confirming enrichment of secretory granules from α-
TC1-6 cells. 
2.4.3 Proteomic analysis of proteins that are associated with 
glucagon within α-cell secretory granules 
Fc or Fc-glucagon was purified from the granule lysate by affinity purification, and 
proteins that interact with either Fc alone or Fc-glucagon were identified with LC-
MS/MS. Proteins that were pulled down by Fc alone in both 25 mM glucose 
(Supplementary Table 2) and 5.5 mM glucose (Supplementary Table 3) conditions were 
subtracted from the list of proteins identified using Fc-glucagon, thus identifying proteins 
that specifically interact with glucagon, which we term the glucagon interactome. 
Proteins were assigned the following categories: metabolic-secretory-regulatory, 
histones, cytoskeletal, and ribosomal. 
We identified 42 and 96 glucagon-interacting proteins within the category of metabolic-
regulatory-secretory proteins when the cells were cultured in media containing 25 mM 
(Figure 2- 1A) and 5.5 mM glucose (Figure 2- 1B), respectively. 
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In media containing 25 mM glucose, there was a predicted direct interaction of glucagon 
with glucose regulated protein 78 kDa (GRP78 or Hspa5), and ATPase copper 
transporting alpha polypeptide (Atp7a) (Figure 2- 1A), while in media containing 5.5 mM 
glucose, GRP78, Stathmin1 (Stmn1), and Heat shock protein 90- alpha (Hsp90aa1) were 
predicted to directly interact with glucagon (Figure 2- 1B). Under conditions of either 25 
or 5.5 mM glucose, one common predicted interaction was that between glucagon and 
GRP78. 
2.4.4 GRP78 interacts with glucagon and co-localizes to glucagon-
positive secretory granules 
Affinity purification of Fc-glucagon or Fc alone from the secretory granule lysate was 
followed by immunoblotting for GRP78. The presence of GRP78 immunoreactivity with 
Fc-glucagon, and not Fc alone, demonstrates a direct interaction with glucagon in the 
Figure 2-1. The glucagon interactome in secretory granules of α-TC1-6 cells. 
Cells were transfected with Fc-glucagon or Fc alone, and cultured in 
DMEM containing 25 mM or 5.5 mM glucose for 24h. Fc-glucagon was 
purified from enriched secretory granules and associated proteins were 
identified by LC-MS/MS. (A) Proteomic map of the metabolic-regulatory-
secretory proteins that are predicted to associate with glucagon in the 
context of 25 mM glucose. Network clustering predicts direct interactions 
between glucagon and glucose regulated protein 78 KDa (Hspa5, also 
known as GRP78), and ATPase copper transporting alpha polypeptide 
(Atp7). (B) Proteomic map of the metabolic-regulatory-secretory proteins 
that are predicted to associate with glucagon in the context of 5.5 mM 
glucose. Network clustering predicts direct interactions between glucagon 
and GRP78, stathmin1 (Stmn1), and heat shock protein 90-alpha 
(Hsp90aa1). The thickness of the lines indicates the strength of the predicted 
protein-protein interaction. 
 
Figure 2-2. The glucagon interactome in secretory granules of α-TC1-6 cells. 
Cells were transfected with Fc-glucagon or Fc alone, and cultured in 
DMEM containing 25 mM or 5.5 mM glucose for 24h. Fc-glucagon was 
purified from enriched secretory granules and associated proteins were 
identified by LC-MS/MS. (A) Proteomic map of the metabolic-regulatory-
secretory proteins that are predicted to associate with glucagon in the 
context of 25 mM glucose. Network clustering predicts direct interactions 
between glucagon and glucose regulated protein 78 KDa (Hspa5, also 
known as GRP78), and ATPase copper transporting alpha polypeptide 
(Atp7). (B) Proteomic map of the metabolic-regulatory-secretory proteins 
that are predicted to associate with glucagon in the context of 5.5 mM 
glucose. Network clustering predicts direct interactions between glucagon 
and GRP78, stathmin1 (Stmn1), and heat shock protein 90-alpha 
(Hsp90aa1). The thickness of the lines indicates the strength of the predicted 
protein-protein interaction. 
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enriched secretory granules (Figure 2- 2A). Immunofluorescence microscopy showed co-
localization of GRP78 and endogenous glucagon within the secretory granules in α-TC1-
6 cells (Figure 2- 2B). There was a strong positive correlation between glucagon and 
GRP78 immunoreactivities (PCC = 0.85 ± 0.08), indicating significant co-localization of 
GRP78 and glucagon. 
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2.4.5 GABA induces histone H4 interaction and co-localization 
with glucagon  
Interestingly, proteomic analysis also revealed the presence of histone proteins, along 
with structural proteins and ribosomal proteins, within the secretory granules in α-TC1-6 
cells (Supplementary Table 4). Histone H4 was predicted to interact with glucagon in 
cells incubated in medium containing 5.5 mM glucose. Therefore, we reasoned that this 
interaction was responsive to external effectors. We treated α-TC1-6 cells with GABA, a 
well-known modulator of glucagon secretion (21) and examined the interaction between 
histone and glucagon. Co-immunoprecipitation of granule lysates, histone H4 ELISA of 
granule lysates, and immunofluorescence microscopy all validated the interaction of 
histone H4 with glucagon and presence of histone H4 in secretory granules of α-TC1-6 
cells after treatment with GABA (Figure 2- 3). Affinity purification of Fc-glucagon or Fc 
alone from the secretory granule lysate was followed by immunoblotting for histone H4 
Figure 2-3. Glucagon and GRP78 directly interact and are localized within 
secretory granules in α-TC1-6 cells. (A) Western blot showing GRP78 
immunoreactivity in: total cell extracts from untransfected (lane 2) and 
transfected (lane 3) cells; affinity-purified Fc-glucagon from isolated 
secretory granules (lane 4); and affinity-purified Fc alone from isolated 
secretory granules (lane 5). GRP78 binds to Fc-glucagon, but not Fc alone. 
(B) Immunofluorescence microscopy of glucagon (green), GRP78 (red) and 
both images merged. Cells were cultured on collagen-coated coverslips for 
24h in DMEM containing 25 mM glucose. Images were acquired, 2D 
deconvoluted and analyzed with NIS software (Nikon, Canada). Pearson 
correlation coefficient (PCC) indicates strong correlation between GRP78 
and glucagon (PCC = 0.85 ± 0.08). ROI shows areas of colocalization of 
GRP78 and glucagon within secretory granules. 
 
Figure 2-4. The glucagon interactome in secretory granules of α-TC1-6 cells. 
Cells were transfected with Fc-glucagon or Fc alone, and cultured in DMEM 
containing 25 mM or 5.5 mM glucose for 24h. Fc-glucagon was purified from 
enriched secretory granules and associated proteins were identified by LC-
MS/MS. (A) Proteomic map of the metabolic-regulatory-secretory proteins 
that are predicted to associate with glucagon in the context of 25 mM glucose. 
Network clustering predicts direct interactions between glucagon and glucose 
regulated protein 78 KDa (Hspa5, also known as GRP78), and ATPase 
copper transporting alpha polypeptide (Atp7). (B) Proteomic map of the 
metabolic-regulatory-secretory proteins that are predicted to associate with 
glucagon in the context of 5.5 mM glucose. Network clustering predicts direct 
interactions between glucagon and GRP78, stathmin1 (Stmn1), and heat 
shock protein 90-alpha (Hsp90aa1). The thickness of the lines indicates the 
strength of the predicted protein-protein interaction.Figure 2-5. Glucagon 
and GRP78 directly interact and are localized within secretory granules in α-
TC1-6 cells. (A) Western blot showing GRP78 immunoreactivity in: total cell 
extracts from untransfected (lane 2) and transfected (lane 3) cells; affinity-
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(Figure 2- 3A). The presence of histone H4 immunoreactivity with Fc-glucagon, and not 
Fc alone, demonstrates a direct interaction with glucagon in the enriched secretory 
granules (Figure 2- 3A). We then confirmed the presence of histone H4 in the enriched 
secretory granules of α-TC1-6 cells by ELISA (Figure 2- 3B). In cells treated with 
GABA in 25 mM glucose, there was a detectable amount of histone H4 in the granules. 
That this result was not due to contamination from the nuclear fraction was shown by the 
finding that histone H4 levels were undetectable in the secretory granules of cells not 
treated with GABA. As a positive control, the nuclear fraction showed high levels of 
histone H4. Finally, immunofluorescence microscopy showed the presence of histone H4 
in glucagon-containing secretory granules (Figure 2- 3C), and there was significant co-
localization with glucagon as assessed by Pearson's correlation coefficient (PCC = 0.78 ± 
0.08). 
 
 
 
 
 
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.6 The glucagon interactome changes in response to glucose, 
GABA and insulin 
Since the interaction between histone H4 and glucagon was dependent on glucose levels 
and GABA, we determined the effects of the major α-cell paracrine effectors, GABA and 
insulin, on the glucagon interactome. The profiles of the metabolic-regulatory-secretory 
proteins that associate with glucagon within secretory granules were altered upon 
treatment with GABA, insulin or GABA + insulin, respectively, when α-TC1-6 cells 
Figure 2-6. GABA induces direct interaction between glucagon and histone 
H4 within secretory granules in α-TC1-6 cells. (A) Western blot shows 
histone H4 immunoreactivity in: total cell extracts from untransfected (lane 
2) and transfected (lane 3) cells; affinity-purified Fc-glucagon from isolated 
secretory granules (lane 4); and affinity-purified Fc alone from isolated 
secretory granules (lane 5). Histone H4 binds to Fc-glucagon, but not Fc 
alone.  (B) Quantitative ELISA measurement of histone H4 (left Y axis) and 
glucagon (right Y axis) within the secretory granules (control GABA, 
insulin) and the nuclear fraction of α-TC1-6 cells. Values are expressed as 
mean ± SD and compared with 1-way ANOVA (α=0.05).*p<0.05; **p<0.001. 
(C) Immunofluorescence microscopy of glucagon (green), histone H4 (red) 
and both images merged. Cells were cultured on collagen-coated coverslips 
for 24h in DMEM containing 25 mM glucose. Images were acquired, 2D 
deconvoluted and analyzed with NIS software (Nikon, Canada). Pearson 
correlation coefficient (PCC) indicates strong correlation between histone 
H4 and glucagon (PCC = 0.78 ± 0.08). ROI shows areas of colocalization of 
histone H4 and glucagon within secretory granules. 
 
Figure 2-7. Glucagon and GRP78 directly interact and are localized within 
secretory granules in α-TC1-6 cells. (A) Western blot showing GRP78 
immu oreactivity in: total cell extr cts from u transf cted (lane 2) and 
transfected (lane 3) cells; a inity-purified Fc-glucagon f om isolated 
secretory ranules (lane 4); and affinity-puri ied Fc alone from isolated 
secretory granules (lane 5). GRP78 binds to Fc-glucagon, but not Fc al e. 
(B) Immunofluorescence microscopy of glucagon (gr en), GRP78 (red) and 
both images merged. Cells were cultured on collagen-coated coverslips for 
24h in DMEM containing 25 mM glucose. Images were acquired, 2D 
deconvoluted and analyzed with NIS software (Nikon, Canada). Pearson 
correlation coefficient (PCC) indicates strong correlation between GRP78 
and glucagon (PCC = 0.85 ± 0.08). ROI shows areas of colocalization of 
GRP78 and glucagon within secretory granules.Figure 2-8. GABA induces 
direct interaction between glucagon and histone H4 within secretory 
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were cultured in medium containing 25 mM glucose (Figure 2- 4) and in 5.5 mM glucose 
(Figure 2- 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-9. The glucagon interactome is altered in response to paracrine 
effectors in 25 mM glucose. α-TC1-6 cells were transfected with Fc-glucagon 
or Fc alone, and treated with GABA (25 µM), insulin (100 pM) or GABA 
(25 µM) plus insulin (100 pM) for 24h in DMEM containing 25 mM glucose. 
Fc-glucagon was purified from isolated secretory granules and associated 
proteins were identified by LC-MS/MS. (A) Proteomic map of metabolic-
regulatory-secretory proteins that are associated with glucagon after 
treatment of α-TC1-6 cells with GABA shows direct interactions with 4 
proteins: GRP78, Heat shock 70 kDa protein 1B (Hspa1b) Heat shock 
protein 90- alpha (Hsp90aa1), and Vimentin (Vim). (B) After treatment with 
insulin or (C) GABA+Insulin, glucagon is predicted to interact only with 
GRP78. Line thickness indicates the strength of data support. 
 
Figure 2-10. GABA induces direct interaction between glucagon and histone 
H4 within secretory granules in α-TC1-6 cells. (A) Western blot shows 
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Additionally, we tabulated the profiles of histone, cytoskeletal, and ribosomal proteins in 
response to GABA, insulin and GABA + insulin in 25 mM glucose (Supplementary 
Tables 5A–C) or 5.5 mM glucose (Supplementary Tables 6A–C). 
The glucagon interactomes were functionally classified into the following groups: 
Binding, Structural molecule, Catalytic, Receptor, Translation regulator, Transporter, 
Signal transducer, Antioxidant. The proportion of proteins in each category is shown in 
the context of 25 mM glucose (Supplementary Table 7) and 5.5 mM glucose 
(Supplementary Table 8). 
The protein networks that are predicted to interact with glucagon within the secretory 
granules under conditions of 25 mM glucose are illustrated in Figure 2- 4. In cells treated 
with GABA, glucagon is predicted to directly interact with GRP78, HSP1B, HSP90, and 
Figure 2-12. The glucagon interactome is altered in response to paracrine 
effectors in 5.5 mM glucose.  α-TC1-6 cells were transfected with Fc-
glucagon or Fc alone, and treated with GABA (25 µM), insulin (100 pM) or 
GABA (25 µM) plus insulin (100 pM) for 24h in DMEM containing 5.5 mM 
glucose. Fc-glucagon was purified from isolated secretory granules and 
associated proteins were identified by LC-MS/MS. (A) Proteomic map of 
metabolic-regulatory-secretory proteins that are associated with glucagon 
after treatment of α-TC1-6 cells with GABA shows direct interactions with 6 
proteins:  GRP78, Heat shock protein 90- alpha (Hsp90aa1), Protein 
convertase subtilisin/kexin type2 (PCSK2), Heat shock 70 kDa protein 1B 
(Hspa1b), Calmodulin 1 (Calm1), Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-7 (Gng7). (B) After treatment with insulin, 
glucagon is predicted to directly interact with 7 proteins: GRP78, Heat shock 
protein 90-alpha, Annexin A5 (Anxa5), Stathmin1 (Stmn1), PCSK2, Fatty 
acid synthase (Fasn), and Chromogranin A (ChgA). (C) After treatment with 
GABA+Insulin, glucagon is predicted to directly interact with GRP78 and 
PCSK2. Line thickness indicates the strength of data support. 
 
Figure 2-13. The glucagon interactome is altered in response to paracrine 
effectors in 25 mM glucose. α-TC1-6 cells were transfected with Fc-glucagon 
or Fc alone, and treated with GABA (25 µM), insulin (100 pM) or GABA (25 
µM) plus insulin (100 pM) for 24h in DMEM containing 25 mM glucose. Fc-
glucagon was purified from isolated secretory granules and associated 
proteins were identified by LC-MS/MS. (A) Proteomic map of metabolic-
regulatory-secretory proteins that are associated with glucagon after 
treatment of α-TC1-6 cells with GABA shows direct interactions with 4 
roteins: GRP78, Heat shock 70 kDa p otein 1B (Hspa1b) Heat shock 
protein 90- alpha (Hsp90aa1), and Vimentin (Vim). (B) Aft r treatment with 
insulin or (C) GABA+Insulin, glucagon is predicted to interact only with 
GRP78. Line thickness indicates the strength of data support.Figure 2-14. 
The glucagon interactome is altered in response to paracrine effectors in 5.5 
mM glucose.  α-TC1-6 cells were transfected with Fc-glucagon or Fc alone, 
and treated with GABA (25 µM), insulin (100 pM) or GABA (25 µM) plus 
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vimentin (Figure 2- 4A); however, in cells treated with insulin and GABA + insulin, 
glucagon interacts directly with only GRP78 (Figures 2- 4B,C). The clusters of 
metabolic-secretory-regulatory proteins that make up the rest of the glucagon 
interactomes change in composition in response to the different treatments. The numbers 
of proteins categorized as “structural molecule activities” decreased in response to 
GABA (~45%) or insulin (~38%) and increased in the GABA + insulin group (~16%) 
compared to the control (Supplementary Table 7). The numbers of cytoskeletal proteins 
increased in the GABA (29%), insulin (12%), and GABA + insulin (35%) groups, while 
the numbers of ribosomal proteins decreased in those groups by 51, 14, and 66%, 
respectively (Table 2-1. A). 
Table 2-1. A- Sub-groups of proteins categorized as “structural molecules” in the 
glucagon interactome under conditions of 25 mM glucose. Panther GO-Slim 
Molecular Function analysis resulted in 3 sub-categories. The values represent 
protein hits as a percentage of the total number of hits within each sub-category 
when α-TC1-6 cells were cultured in media containing 25 mM glucose. 
 Structural constituent 
of cytoskeleton 
Structural 
constituent of 
ribosome 
Extracellular 
matrix structural 
constituent 
Control 66.7 29.2 4.2 
GABA 85.7 14.3 - 
Insulin 75 25 - 
GABA+Insulin 90 10 - 
Compared to cells incubated in medium containing 25 mM glucose, there were dramatic 
increases in the numbers of metabolic-regulatory-secretory proteins associated with 
glucagon after treatment with GABA, insulin or GABA + insulin in cells incubated in 
media containing 5.5 mM glucose (Figure 2- 5). In cells treated with GABA, glucagon is 
predicted to directly interact with the following proteins: GRP78 (Hspa5), HSP 90alpha 
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(Hsp90aa1), proprotein convertase subtilisin/kexin type 2 (PCSK2), heat shock 70 kDa 
protein 1B (Hsp1b), calmodulin 1(Calm1), and guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-7 (Gng7) (Figure 2- 5A). Under insulin treatment, the 
following proteins were predicted to directly interact with glucagon: GRP78, HSP 90-
alpha, annexin A5 (Anxa5), stathmin1 (Stmn1), fatty acid synthase (Fasn), and 
chromogranin A (ChgA) (Figure 2- 5B); and only two proteins, GRP78 and PCSK2, were 
predicted to directly interact with glucagon after treatment with GABA + insulin (Figure 
2- 5C). 
In the context of 5.5 mM glucose, the number of cytoskeletal proteins decreased, and the 
number of ribosomal proteins increased compared to cells treated with GABA, insulin 
and GABA + insulin in 25 mM glucose (Table 2-1. B). Interestingly, the total numbers of 
proteins classified as “structural molecule activities” did not change appreciably across 
treatments (Supplementary Table 8). However, differences became apparent when 
cytoskeletal and ribosomal proteins were compared separately. When compared to 5.5 
mM glucose alone, there were decreases of ~24 and ~35%, respectively, in the numbers 
of cytoskeletal proteins when cells were treated with GABA or insulin alone, but a ~71% 
increase in response to GABA + Insulin. Conversely, the numbers of ribosomal proteins 
increased by ~26 and ~43% in response to GABA and insulin, respectively, and 
decreased by ~69% in response to GABA + Insulin (Table 2-1. B). 
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Table 2-1. B - Sub-groups of proteins categorized as “structural molecules” in the 
glucagon interactome under conditions of 5.5 mM glucose. Panther GO-Slim 
Molecular Function analysis resulted in 3 sub-categories. The values represent 
protein hits as a percentage of the total number of hits within each sub-category 
when α-TC1-6 cells were cultured in media containing 5.5 mM glucose. 
 Structural constituent 
of cytoskeleton 
Structural 
constituent of 
ribosome 
Extracellular 
matrix structural 
constituent 
Control 50 45.5 4.5 
GABA 38.1 57.1 4.8 
Insulin 32.4 64.9 2.7 
GABA+Insulin 85.7 14.3 - 
 
2.4.7 The dynamic glucagon interactome reveals novel proteins 
that regulate glucagon secretion 
From our glucagon interactomes, we identified 11 proteins that interact with glucagon 
after treatment of α-TC1-6 cells with either GABA or insulin in media containing 25 mM 
glucose. To determine their effects on glucagon secretion, these proteins were depleted 
with siRNAs (Supplementary Figure 2-4) and glucagon secretion and cell content were 
measured.   
Of these 11 proteins, knockdown of ELKS/Rab6-interacting/CAST family member 1 
(ERC1) increased glucagon secretion (p < 0.001), while gene silencing of 14-3-3 
zeta/delta (KCIP-1), cytosolic malate dehydrogenase (MDH1), FXYD domain-containing 
ion transport regulator 2 (FXYD2) and protein disulfide-isomerase (PDI) reduced 
glucagon secretion to the same statistically significant level (p < 0.001). As well, 
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knockdown of peroxiredoxin-2 (PRDX2), ATP synthase F1 subunit alpha (ATP5F1A), 
histone H4, and aconitate hydratase mitochondrial (ACO2) reduced glucagon secretion (p 
< 0.01), as did knockdown of alpha-tubulin 2 (AT2) (p < 0.05) (Figure 2- 6A). Gene 
silencing of MDH1, PRDX2, ATP5F1A, and FXYD2 reduced cellular glucagon content 
to a significance level of p < 0.001. Gene silencing of KCIP-1, ACO2, Histone H4 and 
PDI all reduced the levels of cellular glucagon content to a significance level of p < 0.01 
and that for ERC1 at p < 0.05 (Figure 2- 6B). Gene silencing of GRP78 had no effect on 
glucagon secretion, and reduced cellular glucagon content (p < 0.05). 
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In the context of 5.5 mM glucose, significant reduction of glucagon secretion occurred by 
depletion of MDH1 (p < 0.05), PDI(p < 0.05), ERC1(p < 0.01), and ACO2 (p < 0.01). 
However, silencing of the other abovementioned genes did not significantly alter 
glucagon secretion (Figure 2- 6C). Cellular glucagon content was significantly decreased 
by silencing of ATP5F1A (p < 0.05), AT2, PDI, ERC1, FXYD2, KCIP-1, histone H4, 
GRP78 (p < 0.01), ACO2, and PRDX2 (p < 0.001) (Figure 2- 6D). 
2.4.8 Alterations in glucagon secretion and cell glucagon content 
in response to nutritional and paracrine effectors 
α-TC1-6 cells were cultured under high glucose conditions (25 mM) and then treated 
with paracrine effectors (GABA, insulin or GABA + insulin). The profiles of cumulative 
glucagon secretion and cellular glucagon content in 25 mM glucose was different from 
Figure 2-15. Glucagon secretion and cell content are regulated by a subset of 
interactome proteins. (A) Glucagon secretion and (B) cell content in the 
context of 25 mM glucose, and (C) glucagon secretion and (D) cell content in 
the context of 5.5 mM glucose were assessed after siRNA-mediated gene 
silencing of the following proteins: Alpha-tubulin 2 (AT2), ATP synthase F1 
subunit alpha (ATP5F1A) , Malate dehydrogenase 1 (MDH1), Protein 
disulfide-isomerase (PDI), ELKS/Rab6-interacting/CAST family member 1 
(ERC1), Aconitate hydratase mitochondrial (ACO2), Peroxiredoxin-2 
(PRDX2), 14-3-3 protein zeta/delta (KCIP-1), FXYD domain-containing ion 
transport regulator 2 (FXYD2), histone H4, and GRP78 using  pre-designed 
siRNAs for the mouse genome. After siRNA transfection, α-TC1-6 cells were 
cultured in DMEM containing 25 mM or 5.5 mM glucose for 24h and glucagon 
levels were measured using ELISA. Values are expressed as mean ± SD 
(α=0.05; n=3-4). *p<0.05; **p<0.01; ***p<0.001. 
 
Figure 2-16. The glucagon interactome is altered in response to paracrine 
effectors in 5.5 mM glucose.  α-TC1-6 cells were transfected with Fc-glucagon 
or Fc alone, and treated with GABA (25 µM), insulin (100 pM) or GABA (25 
µM) plus insulin (100 pM) for 24h in DMEM containing 5.5 mM glucose. Fc-
glucagon was purified from isolated secretory granules and associated proteins 
were identified by LC-MS/MS. (A) Proteomic map of metabolic-regulatory-
secretory proteins that are associated with glucagon after treatment of α-TC1-
6 cells with GABA shows direct interactions with 6 proteins:  GRP78, Heat 
shock protein 90- alpha (Hsp90aa1), Protein convertase subtilisin/kexin type2 
(PCSK2), Heat shock 70 kDa protein 1B (Hspa1b), Calmodulin 1 (Calm1), 
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 (Gng7). 
(B) After treatment with insulin, glucagon is predicted to directly interact with 
7 proteins: GRP78, Heat shock protein 90-alpha, Annexin A5 (Anxa5), 
Stathmin1 (Stmn1), PCSK2, Fatty acid synthase (Fasn), and Chromogranin A 
(ChgA). (C) After treatment with GABA+Insulin, glucagon is predicted to 
directly interact with GRP78 and PCSK2. Line thickness indicates the strength 
of data support.Figure 2-17. Glucagon secretion and cell content are regulated 
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that in 5.5 mM glucose. While neither GABA nor insulin affected glucagon secretion in 
5.5 mM glucose, they suppressed glucagon secretion in 25 mM glucose (Supplementary 
Figure 2- 5A). In the context of 25 mM glucose, GABA reduced cellular glucagon 
content, while insulin increased cellular glucagon content (Supplementary Figure 2- 5B); 
in contrast, neither GABA nor insulin alone affected cellular glucagon content, but in 
combination, they decreased cellular glucagon content.  
2.5 Discussion 
We have identified a dynamic “glucagon interactome” within secretory granules of α- 
cells that is altered in response to glucose levels and the paracrine effectors GABA and 
insulin. We used a tagged glucagon construct, Fc-glucagon, to bring down proteins 
within secretory granules. We validated enrichment of the secretory granules by nano-
scale flow cytometry and immunoblotting with compartment-specific markers. We 
identified a network of 392 proteins within the secretory granules that interact with 
glucagon and showed a direct interaction with GRP78 and Histone H4. Components of 
the interactome played a role in glucagon secretion, thus revealing a role for the 
interactome in the regulation of glucagon secretion in α-TC1-6 cells. 
We have previously shown that α-TC1-6 cells have elevated levels of both proglucagon 
mRNA and glucagon secretion in response to 25 mM glucose (17), and other groups have 
shown the same effect in isolated mouse islets (3), clonal hamster InR1G9 glucagon-
releasing cells (3, 34), and perfused rat pancreas (35). We also showed that this 
paradoxical glucagon release is accompanied by an up-regulation of components of the 
regulated secretory pathway, particularly in the active forms of PC1/3 and PC2 that post-
translationally process proglucagon to glucagon, and in SNARE proteins that mediate 
vesicle exocytosis (17). Under conditions of 5.5 mM glucose, the up-regulation in RNA-
binding proteins that modulate biosynthesis of islet secretory granule proteins, along with 
chaperonins, may indicate an increase in protein synthesis (36, 37). Chaperonins, as key 
components of the cellular chaperone machinery, are involved in maturation of newly-
synthesized proteins in an ATP dependent manner (36). As ATP-generating proteins, 
such as ATP5F1A, MDH1, and glucose metabolic proteins, were also increased, we 
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speculate that 5.5 mM glucose induced a stress response that resulted in increased protein 
translation. This hypothesis is strengthened by the identification of cold shock protein, 
peroxiredoxin, thiol-disulfide isomerase and thioredoxin within the glucagon interactome 
at 5.5 mM glucose, all of which are up-regulated in pancreatic islets in response to stress 
(37). 
One protein that was consistently predicted as interacting directly with glucagon was the 
ER stress protein and molecular chaperone GRP78. Previous proteomic studies have 
identified GRP78 in islets and β-cells (38, 39). Its presence in α-cell secretory granules 
may not be surprising, as it has previously been found in non-ER compartments such as 
the nucleus and lysosomes. Our data suggest that GRP78 may be a novel sorting receptor 
for glucagon in the regulated secretory pathway of α-cells. We have previously shown a 
potential role of chromogranin A as a sorting receptor for glucagon in both α-TC1-6 cells 
and PC12 cells (19), but unlike GRP78, we did not demonstrate any direct interactions 
with glucagon. While knockdown of GRP78 did not reduce glucagon secretion, it did 
reduce cell content, indicating a potential role in intracellular trafficking, but not 
exocytosis, of glucagon. 
Interestingly, we identified histone proteins as a functional part of the glucagon 
interactome. The discovery of histone proteins within α-cell secretory granules is novel, 
and supported by the findings that the cytosolic fraction of pooled islets from multiple 
human donors had abundant amounts of the histone H2A (40). As well, quantitative 
proteomics of both α-TC1 and ßTC3 cells revealed the presence of histones H4, H3, 
H2A, H2B, and H1 (41). Our data indicate that one of these histones, H4, may directly 
bind to glucagon and regulate its basal level of secretion, perhaps under conditions of 
stress. Oxidative stress contributes to the pathogenesis of diabetes by disrupting the 
balance between reactive oxygen species and antioxidant proteins (42). Such an 
imbalance could target chromatin and globally alter profiles of gene expression, 
especially those encoding histone and DNA-binding proteins (42, 43). Thus, we speculate 
that the presence of histone H4 in the secretory granules could reflect a response to 
microenvironmental stress. Furthermore, it has been suggested that histones contained 
within secretory granules in neutrophils could function as a defense mechanism, 
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interacting with the plasma membrane to generate extracellular traps in response to 
bacterial infections (44). Thus, it is possible that histone proteins in the glucagon 
interactome take a role in the fusion step of granule exocytosis. Additionally, secretion of 
histones and other nuclear proteins has been associated with an inflammatory or 
senescent secretory phenotype (45, 46). 
The α-cell paracrine effectors, GABA and insulin, remodeled the glucagon interactome in 
α-TC1-6 cells in a manner that was dependent on glucose levels. Compared to the 
respective control groups, GABA altered >70 and >80% of the metabolic-regulatory-
secretory proteins within the glucagon interactome in the context of 25 and 5.5 mM 
glucose, respectively. One potentially novel GABA-regulated protein that may function 
in glucagon secretion in 25 mM glucose is ERC1, which has a role in the formation of the 
cytomatrix active zone and insulin exocytosis from β-cells (47), and we show for the first 
time a potential inhibitory effect of ERC1 on glucagon secretion that may be dependent 
on GABA. Ohara-Imaizumi et al. showed that ERC1 depletion in MIN6 cells and rat 
pancreatic β-cells suppressed glucose stimulated insulin secretion (47). When pancreatic 
β-cells were exposed to high glucose conditions, ERC1 takes a role in the process of 
granule docking and fusion toward insulin exocytosis. Here, by showing that depletion of 
ERC1 increased glucagon secretion at 25 mM glucose and reduced it at 5.5 mM glucose, 
it is tempting to speculate that ERC1 is a part of the granule exocytosis machinery in α-
cells and plays a potential role in controlling glucagon exocytosis under diabetic 
conditions. Another potentially novel player in GABA-regulated glucagon secretion is 
KCIP-1, associated with β-cell survival (48). Furthermore, our proteomics findings 
suggest that GABA may enhance glucose uptake and glucose tolerance through leucine-
rich repeat proteins. These proteins bind to the insulin receptor to promote glucose uptake 
in β-cells (49), and thus may be a new paracrine, or even autocrine, regulator of α-cell 
function. Interestingly, in the context of 5.5 mM glucose, GABA recruited PCSK2 and 
secretogranin 2, known α- cell granule proteins that function in proglucagon processing 
(19). Although our previous work showed no changes in PCSK2 in response to 5.5 mM 
glucose (17), we now show that plasticity in PCSK2 expression may be due to GABA 
under these glucose concentrations. 
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In the context of 25 mM glucose, insulin treatment increased the number of biosynthetic 
proteins, consistent with its role in cellular growth. Kinesin-like proteins also increased, 
suggesting a potential role in α-cell secretory granule synthesis and glucose homeostasis, 
as has been documented in β-cells (50). In the context of 5.5 mM glucose, insulin up-
regulated nucleoside diphosphate kinases A and B, proposed regulators of insulin 
secretion (51). We also identified the small G proteins SAR1, Rab2A, and RhoA, present 
in INS-1E cell secretory granules (52); however, their functions are not known. 
Interestingly, treatment of the α-TC1-6 cells with GABA + insulin in 25 mM glucose 
caused a dramatic decrease in the overall numbers of proteins within the glucagon 
interactome. Interaction with GRP78 remained preserved, while a new protein, 
microtubule-associated protein 2, appeared in the glucagon interactome. This protein may 
have a potential role in glucose homeostasis, as it is down-regulated in isolated diabetic 
rat islets exposed to low glucose conditions (53). In the context of 5.5 mM glucose, the 
combination of GABA and insulin again predicted the presence of PCSK2 in the 
glucagon interactome, as seen with GABA treatment alone and invites revisiting the 
question of PCSK2 acting as a sorting receptor for glucagon (19). 
The design of our experiments was to mimic blood glucose volatility in diabetes in 
particular, and not in normal physiology, to investigate potential dynamic alterations in 
the glucagon interactome (54). Here, we have identified the glucagon interactome in α-
TC1-6 cells after chronic exposure to extremely high glucose (25 mM), which, in 
diabetes, paradoxically increases glucagon secretion from pancreatic α-cells (3, 5). We 
further showed remodeling of this interactome by replacing that extremely high glucose 
condition (25 mM) with a relatively low glucose (5.5 mM) medium, which mimic 
conditions that represent glucose volatility in diabetes. However, we did not examine 
changes in the glucagon interactome throughout a range of high and low glucose 
conditions, which could be a limitation for the current study. Also, we used our negative 
control, Fc alone, only in the two glucose conditions and not in treatments with GABA 
and insulin, which may affect the interpretation of the interactome under these conditions. 
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It is well-established that, under normal physiological conditions, glucagon secretion is 
suppressed by high glucose (21). However, chronic hyperglycemia disrupts this fine 
regulation and results in elevated glucagon secretion (34, 55). It has been documented 
that chronic exposure to 25 mM glucose stimulates glucagon secretion in α-TC1-6 cells 
(17), thus mimicking the α-cell response to glucose in the diabetic, and not normal, 
condition. 
While we presented a novel glucagon interactome within enriched secretory granules of 
α-TC1-6 cells and its alterations due to nutritional or paracrine effectors, direct 
comparisons to primary α-cells may be limited. When we compared our described 
glucagon interactome with the transcriptomic profile of mouse α-cells (56), and human α-
cells (57), there were some differences in the protein profiles. Additionally, Lawlor et al. 
(58) compared gene expression profiles of α-TC1 cells with their primary mouse and 
human counterparts and showed a high level of discrepancy between them. One 
possibility for this discrepancy may be changes in gene expression in primary cells while 
cultured in vitro (17, 59). However, we feel that the findings we are reporting generally 
show that: (1) networks of proteins can interact with glucagon within the secretory 
granule compartment of the pancreatic α-cell; (2) this interactome is remodeled according 
to the micro-environmental milieu; and (3) some proteins within the interactome can 
regulate glucagon secretion. The next step will be to use our data to guide the 
identification of glucagon-interacting proteins that may regulate glucagon secretion 
within primary α-cells. 
Under normal physiological conditions, GABA and insulin suppress glucagon secretion 
in pancreatic α-cells (21, 60). This response to GABA and insulin may differ depending 
on the cell line and experimental conditions used. Piro et al. (61) showed that with short-
term treatment, insulin significantly suppressed glucagon secretion in α-TC1-6 cells 
without affecting cellular glucagon content. In INR1G cells, Kawamori et al. (62) showed 
that silencing of the insulin receptor significantly increased glucagon secretion, indicating 
that insulin receptor signaling is required for suppression of glucagon secretion. Here, we 
show that treatment with insulin suppresses the long-term cumulative secretion of 
glucagon when α-TC1-6 cells were cultured and chronically kept in 25 mM glucose. 
87 
 
Interestingly, under these conditions, cellular glucagon content increased, perhaps due to 
excess glucagon in the medium and its potential abolishing effect on insulin action (63). 
In addition, this increase could be due to an autocrine effect of glucagon on proglucagon 
gene expression, a notion that has been argued by Leibiger et al. for short-term effect of 
glucagon on proglucagon gene expression in non-cumulative culturing (26). As well, it is 
known that GABA inhibits glucagon secretion under high glucose conditions (64). 
Importantly, our findings show reductions in both glucagon secretion and content. 
Surprisingly, the combination of GABA and insulin did not suppress glucagon secretion, 
leading to questions on the mechanism of the interactions between these two signaling 
pathways. 
In conclusion, we have described a novel and dynamic glucagon interactome in α-TC1-6 
cells that is remodeled in response to glucose and the α-cell paracrine effectors, GABA 
and insulin. Our proteomics approach has revealed a number of novel secretory granule 
proteins that function in the regulation of glucagon secretion and illustrates the plasticity 
in the protein components of the α-cell secretory granules. These findings provide an 
important proteomics resource for further data mining of the α-cell secretory granules and 
targeting diabetes treatment. 
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2.7 Supplementary Figures 
 
 
 
 
 
 
                                                                                                   
                                                                                                                    
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2-1. Proglucagon gene knock down in α-TC1-6 cells. 
cDNA synthesis was performed using total extracted RNA. Quantitative PCR 
was achieved using Quant Studio Design and Analysis Real-Time PCR 
Detection System in conjunction with the Maxima SYBR Green qPCR 
Master Mix. The glucagon gene (Gcg) expression was determined in the 
transfected cells with scrambled siRNA (control) or Gcg-KD. Glucagon gene 
expression level was normalized to that of the internal control β-Actin. The 
normalized level of transcripts in protein depleted cells was shown relative to 
that of the negative control. Gene expression levels show >70% reduction in 
the glucagon depleted group compare to the control. 
 
Supplementary Figure 2-2. Proglucagon gene knock down in α-TC1-6 cells. 
cDNA synthesis was performed using total extracted RNA. Quantitative PCR 
was achieved using Quant Studio Design and Analysis Real-Time PCR 
Detection System in conjunction with the Maxima SYBR Green qPCR 
Master Mix. The glucagon gene (Gcg) expression was determined in the 
transfected cells with scrambled siRNA (control) or Gcg-KD. Glucagon gene 
expression level was normalized to that of the internal control β-Actin. The 
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Supplementary Figure 2-3. Immunoblotting assessment of enrichment in 
the extracted secretory granules. Western blot analyses of the cell extract 
(CE), extract of the secretory granules in media containing 25 mM  glucose 
(E-25) and 5.5 mM glucose (E-5.5). Proteins were resolved on  4-12% SDS-
PAGE gel (NuPAGE), transferred to  PVDF membrane and probed with  
antibodies  to identify  (A) vesicle-associated membrane protein 2 
(VAMP2) for mature secretory granules; (B) TGN46 for the trans-Golgi 
network; (C) Lamin B1 for the nuclear envelope; and (D) Calreticulin for 
the endoplasmic reticulum. The immunoreactive bands were visualized 
using HRP-conjugated goat anti-rabbit secondary antibody and Clarity 
Western ECL substrate. 
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Supplementary Figure 2-4. Nano-scale flow cytometry of the enriched 
secretory granules.  (A) Calibrating nano flow cytometer for size distribution 
of the enriched secretory granules using ApogeeMix beads. Circles indicate 
bead sizes of 110, 179, 235, 304, 585 and 880 nm. (B) Gating the glucagon+ 
secretory granules (L488) using FITC secondary antibody against the Fc 
segment of Fc-glucagon. (C) Size distribution of the secretory granules within 
the gate containing glucagon+ secretory granules. 
 
Supplementary Figure 2-5. Nano-scale flow cytometry of the enriched 
secretory granules.  (A) Calibrating nano flow cytometer for size distribution 
of the enriched secretory granules using ApogeeMix beads. Circles indicate 
bead sizes of 110, 179, 235, 304, 585 and 880 nm. (B) Gating the glucagon+ 
secretory granules (L488) using FITC secondary antibody against the Fc 
segment of Fc-glucagon. (C) Size distribution of the secretory granules within 
the gate containing glucagon+ secretory granules. 
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Supplementary Figure 2-6. siRNA mediated gene silencing of target proteins in 
the secretory granules. α-TC1-6 cells were transfected with 50 nM pooled of 3 
predesigned siRNAs. Cell extract subjected to Western blot to follow expression 
of the following target proteins. For each protein, band intensity of the expressed 
protein was determined using ImageJ software. Values of ≥ 70% reduction in 
protein expression levels were considered as successful protein depletion. Alpha-
tubulin 2 (AT2),  ATP synthase F1 subunit alpha (ATP5F1A),  cytosolic malate 
dehydrogenase (MDH1), Protein disulfide-isomerase (PDI), ELKS/Rab6-
interacting/CAST family member 1 (ERC1), Aconitate hydratase mitochondrial 
(ACO2), peroxiredoxin-2 (PRDX2), FXYD domain-containing ion transport 
regulator 2 (FXYD2), 14-3-3 zeta/delta (KCIP-1), Histone H4 and Glucose 
regulated protein 78 KDa (GRP78). 
 
Supplementary Figure 2-7. siRNA mediated gene silencing of target proteins in 
the secretory granules. α-TC1-6 cells were transfected with 50 nM pooled of 3 
predesigned siRNAs. Cell extract subjected to Western blot to follow expression 
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Supplementary Figure 2-8. Alterations in glucagon secretion and cell glucagon 
content of α-TC1-6 cells in response to nutritional and paracrine effectors. α-
TC1-6 cells were cultured and kept under high glucose (25 mM) condition for a 
long-term. These chronically exposed cells to high glucose condition were 
treated with GABA (25 µM), insulin (100 pM) or GABA (25 µM) + insulin (100 
pM) for 24h in 25 mM or 5.5 mM glucose containing media. At the end if 
incubation, glucagon levels were measured in the media and cell extract. Values 
were expressed as mean ± SD (n=4-5) and compared among groups using one-
Way ANOVA (α=0.05).*p<0.05, **p<0.01. ***p<0.001. 
 
Figure 2-18. Overexpression of Stathmin-2 increases the presence of glucagon in 
late endosomes. After transfection with either empty vector (A), vector encoding 
Stmn2 (B) or siRNAs against Stmn2 (C), α-TC1-6 cells were immunostained 
using primary antibodies against glucagon and the late endosome-lysosome 
marker LAMP2A. Images were acquired and analysed for co-localization as 
described in Figure 1. (A) In wt cells, glucagon and LAMP2 show some co-
localization at the plasma membrane (arrowheads). (B) In cells overexpressing 
Stmn2, there is colocalization of glucagon and LAMP2A in the cell body 
(arrowheads) and at the plasma membrane (arrows). (C) In cells in which 
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2.8 Supplementary Tables 
Supplementary Table 2-1. Reagents and resources. 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Research 
Resource 
Identification 
number 
GABA Sigma Cat # A2129 
 
Insulin Sigma Cat # 105-16 
 
ApogeeMix beads  Apogee 
FlowSystems Inc. 
Cat # 1493 
 
Lipofectamine 2000 Invitrogen Cat # 11668-027 
 
Acetonitrile BDH Cat # 83639.100E 
 
Formic acid Optima Cat # A117-50 
 
Dithiotreitol Fisher Scientific Cat # BP172-5 
 
Iodoacetamide Alfa Aesar Cat # A14715 
 
Protein A 
Sepharose CL-4B 
GE Healthcare Life 
Science 
Cat # 71-7090-00 
AF 
 
HYPERSEP C18 
column 
ThermoFisher 
Scientific 
Cat # 60108-303 
 
Mini Protease 
Inhibitor Cocktail 
Sigma-Aldrich Cat # 11836153001 
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Trypsin Promega Cat # V5111 
 
 
Supplementary Table 2-1 (Continued) 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Research Resource 
Identification 
number 
Collagen type 1 Sigma Cat # C3867 
 
NuPAGE Invitrogen Cat # NP0335Box 
 
iBlot Gel Transfer 
stacks, PVDF 
Invitrogen Cat # IB401001 
 
Anti-GRP78 Bip 
(HSPA5) antibody 
Abcam Cat # Ab21685 
 
Anti-VAMP2 
antibody 
Abcam Cat # ab181869 
AB_ 2721005 
Anti-TGN46 
antibody 
Abcam Cat # 1605 
AB_443307 
Anti-LaminB1 
antibody 
Abcam Cat # ab16048 
AB_ 443298 
Anti-Histone H4 
antibody (ChIP 
grade) 
Abcam Cat # ab10158 
AB_ 296888 
Anti-Glucagon 
antibody 
Abcam Cat # Ab10988 
AB_ 297642 
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ProLong Gold 
antifade reagent 
with DAPI 
Molecular Probes Cat # P36935 
 
 
Supplementary Table 2-1 (Continued) 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Research Resource 
Identification 
number 
AlexaFluor 488 
goat anti-mouse IgG 
Molecular Probes Cat # A-11001 
AB_ 2534069 
AlexaFluor 488 
goat anti-rabbit IgG 
Molecular Probes Cat # A-11012 
AB_ 2534079 
Fc-specific FITC 
antibody 
Sigma Cat # F4143 
AB_ 259587 
Anti-ERC1 
antibody 
Abcam Cat # ab 180507 
 
Anti- MDH1 
antibody 
Abcam Cat # ab 180152 
 
Anti-ATP5A 
antibody 
Abcam Cat # ab 176569 
 
Anti-Aconitase 2 
antibody 
Abcam Cat # ab 129105 
 
Anti-peroxiredoxin2 
antibody  
Abcam Cat # ab 109367 
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Anti-TUBA1B 
antibody 
Abcam Cat # ab 108629 
 
Anti-14-3-3zeta 
antibody 
Abcam Cat # ab 51129 
 
 
Supplementary Table 2-1 (Continued) 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Research 
Resource 
Identification 
number 
Anti Na/K ATPase 
antibody 
Thermo Fisher 
Scientific 
Cat# PA5-75640 
 
Anti-PDI antibody Abcam Cat # ab 3672 
 
Anti-Calreticulin 
antibody 
Abcam Cat # ab 2907 
 
Anti-Histone H4 
antibody 
Abcam Cat # ab 10158 
 
Software and Algorithms 
Panther 
Classification 
System 
 http://Pantherdb.org 
SCR_015893 
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ExPASY 
Bioinformatics 
Resource Portal 
 http://string-db.org 
SCR_015894 
UniportKB  http://uniport.org 
SCR_004426 
STRING  https://string-db.org 
SCR_005223 
Experimental model: cell line 
α-TC1-6 cell  mouse pancreatic α-
cell line 
 
 
Supplementary Table 2-1 (Continued) 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Research 
Resource 
Identification 
number 
Recombinant DNA 
FC_pcDNA3.1(+)  http://www.genscript.com 
 
FC-
glucagon_pcDNA3.1(+) 
 http://www.genscript.com 
 
Commercial assays 
Glucagon assay kit ThermoFisher 
Scientific 
Cat # EHGCG 
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BCA protein assay kit Biovision 
Incorporated 
Cat # K813-2500 
 
Histone H4 
Modification Multiplex 
Assay Kit 
Abcam Cat # Ab185914 
 
RNeasy extraction kit  Qiagen Cat # 74104 
 
SuperScript III First 
Strand Synthesis 
Supermix 
Thermo Fisher 
Scientific 
Cat # 11752050 
 
Maxima SYBR Green 
qPCR Master Mix  
 
Thermo Fisher 
Scientific 
Cat # K0221 
 
Maxima SYBR Green 
qPCR Master Mix  
 
Thermo Fisher 
Scientific 
Cat # K0221 
 
siRNA 
14-3-3 zeta/delta Thermo Fisher 
Scientific 
Cat # S76190 
Cat # S76191 
Cat # S76189 
 
Aconitase Thermo Fisher 
Scientific 
Cat # S61847 
Cat # S61845 
Cat # S61846 
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Supplementary Table 2-1 (Continued) 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Research 
Resource 
Identification 
number 
Sodium-Potassium 
transporting subunit 
gamma 
Thermo Fisher 
Scientific 
Cat # S62726 
Cat # S201066 
Cat # S62725 
 
Protein disulfide-
isomerase 
Thermo Fisher 
Scientific 
Cat # S71205 
Cat # S71206 
 
Peroxiredoxin-2 Thermo Fisher 
Scientific 
Cat # S204749 
Cat # S232273 
Cat # S232272 
 
Malate 
dehydrogenase 
cytoplasmic 
Thermo Fisher 
Scientific 
Cat # S69980 
Cat # S69981 
Cat # S69979 
 
Aconitate hydratase 
mitochondrial 
Thermo Fisher 
Scientific 
Cat # S61847 
Cat # S61845 
Cat # S61846 
 
ELKS/Rab6-
interacting/CAST 
family member 1 
Thermo Fisher 
Scientific 
Cat # S200972 
Cat # S99972 
Cat # S99973 
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Supplementary Table 2-1 (Continued) 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Research Resource 
Identification 
number 
Tubulin alpha-1B 
chain 
Thermo Fisher 
Scientific 
Cat # S202331 
Cat # S202330 
Cat # S75582 
 
ATP synthase 
subunit alpha 
mitochondrial 
Thermo Fisher 
Scientific 
Cat # S62742 
Cat # S62744 
Cat # S62743 
 
Histone H4 Thermo Fisher 
Scientific 
Cat # S234377 
Cat # S234480 
Cat # S234061 
 
GCG (PPG) Thermo Fisher 
Scientific 
Cat# s66523 
Cat# s66522 
Cat# s66524 
 
β-Actin Thermo Fisher 
Scientific 
Cat# s61899        
Cat# s200989      
Cat# s200988 
 
Mission siRNA 
Universal Negative 
Control #1 
Sigma SIC001 
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Supplementary Table 2-2. List of proteins that interact the with Fc segment alone 
under conditions of 25 mM glucose. 
Associated proteins with Fc segment in 25 mM glucose containing medium 
Endoplasmin, Protein disulfide-isomerase A6, Leucine zipper protein 1, Eukaryotic 
initiation factor 4A-II, DnaJ homolog subfamily C member 12, UPF0565 protein 
C2orf69 homolog, Obg-like ATPase 1, Catenin beta-1, Nascent polypeptide-associated 
complex subunit alpha, muscle-specific form, Protein scribble homolog, AP2-
associated protein kinase 1, Drebrin-like protein, Sorting nexin-2, Nucleoporin NUP53, 
Transient receptor potential cation channel subfamily M member 6, Transcription 
elongation factor A protein-like 3, Tyrosine-protein phosphatase non-receptor type 23, 
Protein phosphatase 1G, T-complex protein 1 subunit zeta, Malate dehydrogenase, 
mitochondrial, Protein CutA, Transaldolase, Dihydropyrimidinase-related protein 2, 
60S ribosomal protein L10-like, Probable cation-transporting ATPase 13A1, 40S 
ribosomal protein S30, Phosphatidylethanolamine-binding protein 1, RNA-binding 
protein 14, Synaptosomal-associated protein 25, 60S ribosomal protein L8, 
Phosphatidylinositol-binding clathrin assembly protein, Importin subunit beta-1, T-
complex protein 1 subunit delta, Proliferating cell nuclear antigen, Zyxin, Non-histone 
chromosomal protein HMG-17, Aldose reductase, T-complex protein 1 subunit eta, 
Sulfated glycoprotein 1, Stress-induced-phosphoprotein 1, Peroxiredoxin-1, 40S 
ribosomal protein S6, Ataxin-2-like protein, C-1-tetrahydrofolate synthase, 
cytoplasmic, Endophilin-B1, ProSAAS, Histidine triad nucleotide-binding protein 1, 
Transitional endoplasmic reticulum ATPase, Desmoplakin, Myosin-10, Clathrin light 
chain A, 26S protease regulatory subunit 6A, Rab GDP dissociation inhibitor alpha, 
Eukaryotic translation initiation factor 4 gamma 1, N-acetylglucosamine-6-sulfatase, 
Histone H3.3C, Eukaryotic initiation factor 4A-I, Transketolase, 60S ribosomal protein 
L22, Glucosidase 2 subunit beta, Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit, Nuclear transport factor 2, Golgin subfamily A 
member 4, Tryptophan--tRNA ligase, cytoplasmic, Eukaryotic translation initiation 
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factor 4B, Tripeptidyl-peptidase 2, Ubinuclein-2, V-type proton ATPase subunit G 1, 
Peroxiredoxin-4, Aminoacyl tRNA synthase complex-interacting multifunctional 
protein 1, Potassium voltage-gated channel subfamily C member 3, Afadin, Nuclear 
autoantigenic sperm protein, 60S ribosomal protein L19, Histone H3.1, Vacuolar 
protein sorting-associated protein VTA1 homolog, Coatomer subunit alpha, COP9 
signalosome complex subunit 3, Thioredoxin domain-containing protein 17, 
Serine/threonine-protein kinase PAK 2, Rho-associated protein kinase 2, G protein-
regulated inducer of neurite outgrowth 1, Pleckstrin homology domain-containing 
family G member 5, F-actin-capping protein subunit beta, Histone H1.3, Microtubule-
associated protein 4, Septin-9, Stromal membrane-associated protein 2, Trifunctional 
purine biosynthetic protein adenosine-3, Eukaryotic initiation factor 4A-III, Creatine 
kinase B-type, Chromatin target of PRMT1 protein, 
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Supplementary Table 2-3. List of proteins that interact the with Fc segment alone 
under conditions of 5.5 mM glucose. 
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial, Histone-lysine N-
methyltransferase SETD1B, Importin subunit beta-1, Aldose reductase, Tumor-
associated calcium signal transducer 2, Heterogeneous nuclear ribonucleoprotein A3, 
Elongation factor 1-gamma, 60S ribosomal protein L22, Calmodulin, Ubiquitin-
conjugating enzyme E2 N, Actin, alpha skeletal muscle, Peptidyl-prolyl cis-trans 
isomerase FKBP2, V-type proton ATPase catalytic subunit A, Ubiquitin-like modifier-
activating enzyme 1, Nascent polypeptide-associated complex subunit alpha, L-lactate 
dehydrogenase B chain, Farnesyl pyrophosphate synthase, Protein FAM171A2, Msx2-
interacting protein, T-complex protein 1 subunit gamma, Calreticulin, Electron transfer 
flavoprotein subunit alpha, mitochondrial, ER membrane protein complex subunit 2, 
40S ribosomal protein S2, L-lactate dehydrogenase A chain, Acyl-CoA-binding 
protein, Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha 
isoform, L-lactate dehydrogenase C chain, Alpha-actinin-4, Nuclease-sensitive 
element-binding protein 1, Chromogranin-A, Prefoldin subunit 2, Protein FAM117B, 
Stromal interaction molecule 2, ATP-dependent RNA helicase DDX3X, Nucleosome 
assembly protein 1-like 4, 60S ribosomal protein L5, Protein SET, Neurofilament light 
polypeptide, Transgelin-2 
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Supplementary Table 2-4. Profile of the histone, cytoskeletal and ribosomal proteins 
contained within the glucagon interactome when α-TC1-6 cells were incubated for 
24h in media containing 25 mM or 5.5 mM glucose. 
           25 mM glucose containing medium       5.5 mM glucose containing medium 
Histone H2A type 1, Histone H2A type 1-
F, Histone H2A type 1-F,  Histone H2A 
type 1-H,  Histone H2A type 1-K, Histone 
H2A type 2-A,  Histone H2A type 2-B,  
Histone H2A type 2-C,  Histone H2A type 
3, Histone H2A.J,  Histone H2AX,  
Histone H2B type 1-B,  Histone H2B type 
1-C/E/G, Histone H2B type 1-F/J/L, 
Histone H2B type 1-H, Histone H2B type 
1-K, Histone H2B type 1-M, Histone H2B 
type 1-P, Histone H2B type 2-B, Histone 
H2B type 2-E,  Histone H2B type 3-A, 
Histone H2B type 3-B 
 
 
Actin cytoplasmic 2, Actin cytoplasmic 1, 
Actin alpha skeletal muscle, Actin aortic 
smooth muscle, Actin alpha cardiac 
muscle 1, Actin gamma-enteric smooth 
muscle, Beta-actin-like protein 2, Tubulin 
beta-4B chain, Tubulin alpha-1C chain, 
Tubulin alpha-1A chain, Tubulin alpha-
1B chain, Tubulin beta-5 chain, Tubulin 
beta-2B chain, Tubulin beta-4A chain, 
Histone H2A type 3, Histone H2A type 1-
F, Histone H2B type 1-B, Histone H1.3, 
Histone H2A type 2-A, Histone H2B type 
1-H, Histone H2B type 3-A, Histone H4, 
Histone H3.3, Histone H3.3C, Histone 
H2A.J, Histone H2A type 1-K, Histone 
H3.1, Histone H2A type 2-C, Histone 
H2A type 1, Histone H2B type 1-K, 
Histone H3.2, Histone H2B type 1-M, 
Histone H1.2, Histone H2B type 3-B, 
Histone H2B type 2-B, Histone H2B type 
2-E, Histone H2B type 1-C/E/G, Histone 
H2A type 1-H, Histone H1.5, Histone 
H2B type 1-P, Histone H1.1, Histone 
H2A type 2-B, Histone H2A type 1-F, 
Histone H2B type 1-B, Histone H2AX, 
Histone H2B type 1-F/J/L 
 
Actin, cytoplasmic 1, Actin, cytoplasmic 
2, Tubulin beta-4B chain, Tubulin beta-
4A chain, Tubulin beta-5 chain, Tubulin 
alpha-1C chain, Tubulin beta-3 chain, 
Tubulin alpha-1A chain, Tubulin alpha-
1B chain 
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Tubulin beta-3 chain, Tubulin beta-2A 
chain 
 
60S ribosomal protein L13, 40S ribosomal 
protein S14, 60S ribosomal protein L23a, 
60S ribosomal protein L11, 60S acidic 
ribosomal protein P1, Elongation factor 1-
delta, Elongation factor 1-alpha 2, 
Eukaryotic translation initiation factor 
5A-1, Elongation factor 1-alpha 1 
 
40S ribosomal protein S15a, 60S 
ribosomal protein L23a, 40S ribosomal 
protein S7,  40S ribosomal protein S25, 
60S ribosomal protein L13, 40S ribosomal 
protein S14, 40S ribosomal protein S12, 
Elongation factor 1-alpha 2, 60S acidic 
ribosomal protein P1, 60S ribosomal 
protein L11, 60S ribosomal protein L18, 
60S acidic ribosomal protein P2, 
Elongation factor 2, Ubiquitin-60S 
ribosomal protein L40, Eukaryotic 
translation initiation factor 4B 
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Supplementary Table 2-5. Profile of the histone, cytoskeletal and ribosomal proteins 
within the glucagon interactome. α-TC1-6 cells were cultured in media containing 
25 mM glucose and treated with GABA (Table S5-A), insulin (Table S5-B) and 
GABA+ insulin (Table S5-C). Proteins were identified using LC-MS/MS. 
Table-S5-A 
GABA + 25 mM glucose 
Histone H2A type 1, Histone H2A type 1-F, Histone H2A type 1-F, Histone H2A type 
1-H, Histone H2A type 1-K, Histone H2A type 2-A, Histone H2A type 2-B, Histone 
H2A type 2-C, Histone H2A type 3, Histone H2A.J, Histone H2AX, Histone H2B type 
1-B, Histone H2B type 1-C/E/G, Histone H2B type 1-F/J/L, Histone H2B type 1-H, 
Histone H2B type 1-K, Histone H2B type 1-M, Histone H2B type 1-P, Histone H2B 
type 2-B, Histone H2B type 2-E, Histone H2B type 3-A, Histone H2B type 3-B, 
Histone H4 
 
Actin cytoplasmic 1, Actin cytoplasmic 2, Anionic trypsin-2, Tubulin alpha-1A chain, 
Tubulin alpha-1B chain, Tubulin alpha-1C chain, Tubulin beta-2A chain, Tubulin beta-
2B chain, Tubulin beta-3 chain, Tubulin beta-4A chain, Tubulin beta-4B chain, 
Tubulin beta-5 chain 
 
60S acidic ribosomal protein P1, 60S ribosomal protein L11, Elongation factor 1-alpha 
1, Eukaryotic translation initiation factor 4E 
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S5-B 
Insulin + 25 mM glucose 
Histone H1.5, Histone H1t, Histone H2A type 1, Histone H2A type 1-F, Histone H2A 
type 1-F, Histone H2A type 1-H, Histone H2A type 1-K, Histone H2A type 2-A, 
Histone H2A type 2-B, Histone H2A type 2-C, Histone H2A type 3, Histone H2A.J, 
Histone H2AX, Histone H2B type 1-B, Histone H2B type 1-C/E/G, Histone H2B type 
1-F/J/L, Histone H2B type 1-H, Histone H2B type 1-K, Histone H2B type 1-M, 
Histone H2B type 1-P, Histone H2B type 2-B, Histone H2B type 2-E, Histone H2B 
type 3-A, Histone H2B type 3-B, Histone H4 
 
Actin alpha cardiac muscle 1, Actin alpha skeletal muscle,  Actin aortic smooth 
muscle, Actin cytoplasmic 1, Actin cytoplasmic 2, Actin gamma-enteric smooth 
muscle, Tubulin alpha-1A chain, Tubulin alpha-1B chain, Tubulin alpha-1C chain, 
Tubulin beta-2A chain, Tubulin beta-2B chain, Tubulin beta-3 chain, Tubulin beta-4A 
chain, Tubulin beta-4B chain, Tubulin beta-5 chain 
 
40S ribosomal protein S14, 60 kDa heat shock protein mitochondrial, 60S acidic 
ribosomal protein P1, 60S ribosomal protein L11, Elongation factor 1-alpha 1, 
Elongation factor 1-alpha 2, Eukaryotic translation initiation factor 5A-1 
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S5-C 
GABA+ insulin + 25 mM glucose 
Histone H2B type 1-B, Histone H2B type 1-B, Histone H2B type 1-C/E/G, Histone 
H2B type 1-F/J/L, Histone H2B type 1-H, Histone H2B type 1-K, Histone H2B type 1-
M, Histone H2B type 1-P, Histone H2B type 2-B, Histone H2B type 2-B, Histone H2B 
type 2-E, Histone H2B type 3-A, Histone H2B type 3-B 
 
Actin alpha cardiac muscle 1, Actin alpha skeletal muscle, Actin aortic smooth muscle, 
Actin cytoplasmic 1, Actin cytoplasmic 1, Actin gamma-enteric smooth muscle, 
Tubulin alpha-1A chain, Tubulin alpha-1A chain, Tubulin alpha-1B chain, Tubulin 
alpha-1C chain, Tubulin alpha-1C chain 
 
60S ribosomal protein L23a 
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Supplementary Table 2-6. Profile of the histone, cytoskeletal and ribosomal proteins 
within the glucagon interactome. α-TC1-6 cells were cultured in media containing 
5.5 mM glucose and treated with GABA (Table S6-A), insulin (Table S6-B) and 
GABA+insulin (Table S6-C). Proteins were identified using LC-MS/MS.     
Table S6-A 
GABA + 5.5 mM glucose 
Histone H1.3, Histone H1.5, Histone H2A type 1, Histone H2A type 1-F, Histone H2A 
type 1-H, Histone H2A type 1-K, Histone H2A type 2-A, Histone H2A type 2-C, 
Histone H2A type 3, Histone H2A.J, Histone H2B type 1-B, Histone H2B type 1-
C/E/G, Histone H2B type 1-F/J/L, Histone H2B type 1-H, Histone H2B type 1-K, 
Histone H2B type 1-P, Histone H2B type 2-B, Histone H2B type 2-E, Histone H2B 
type 3-A, Histone H2B type 3-B, Histone H3.1, Histone H3.3, Histone H3.3C, Histone 
H4, Histone H1.2, Histone H2B type 1-B, Histone H2B type 1-M, Histone H3.2 
Actin cytoplasmic 1, Actin cytoplasmic 2, Tubulin alpha-1A chain, Tubulin alpha-1B 
chain, Tubulin alpha-1C chain, Tubulin beta-3 chain, Tubulin beta-5 chain 
40S ribosomal protein S14, 40S ribosomal protein S15, 40S ribosomal protein S25, 
40S ribosomal protein S5, 40S ribosomal protein SA, 60S acidic ribosomal protein P1, 
60S acidic ribosomal protein P2, 60S ribosomal protein L11, 60S ribosomal protein 
L15, 60S ribosomal protein L18, 60S ribosomal protein L7a, 60S ribosomal protein 
L7a, Ubiquitin-60S ribosomal protein L40, Eukaryotic initiation factor 4A-I, 
Eukaryotic initiation factor 4A-II, Eukaryotic initiation factor 4A-III, Elongation factor 
1-alpha 1, Elongation factor 2 
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Table S6-B 
Insulin + 5.5 mM glucose 
Histone H1.1, Histone H1.2, Histone H1.3, Histone H1.4, Histone H1.5, Histone H1t, 
Histone H2A type 1, Histone H2A type 1-F, Histone H2A type 1-H, Histone H2A type 
1-K, Histone H2A type 2-A, Histone H2A type 2-C, Histone H2A type 3, Histone 
H2A.J, Histone H2B type 1-B, Histone H2B type 1-C/E/G, Histone H2B type 1-F/J/L, 
Histone H2B type 1-H, Histone H2B type 1-K, Histone H2B type 1-M, Histone H2B 
type 1-P, Histone H2B type 2-B, Histone H2B type 3-A, Histone H2B type 3-B, 
Histone H3.1, Histone H3.2, Histone H3.3, Histone H3.3C, Histone H4 
Actin alpha cardiac muscle 1, Actin alpha skeletal muscle, Actin aortic smooth muscle, 
Actin cytoplasmic 1, Actin cytoplasmic 2, Actin gamma-enteric smooth muscle, 
Tubulin alpha-1A chain, Tubulin alpha-1B chain, Tubulin alpha-3 chain, Tubulin 
alpha-4A chain, Tubulin beta-5 chain, Tubulin-specific chaperone A  
40S ribosomal protein S12, 40S ribosomal protein S14, 40S ribosomal protein S15a, 
40S ribosomal protein S18, 40S ribosomal protein S19, 40S ribosomal protein S20, 
40S ribosomal protein S25, 40S ribosomal protein S3, 40S ribosomal protein S3, 40S 
ribosomal protein S3a,  40S ribosomal protein S8, 40S ribosomal protein SA, 60 kDa 
heat shock protein mitochondrial,  60S acidic ribosomal protein P1, 60S acidic 
ribosomal protein P2,  60S ribosomal protein L11, 60S ribosomal protein L12, 60S 
ribosomal protein L13, 60S ribosomal protein L15,  60S ribosomal protein L18, 60S 
ribosomal protein L23a, 60S ribosomal protein L26, 60S ribosomal protein L27, 60S 
ribosomal protein L7, 60S ribosomal protein L7, 60S ribosomal protein L9, Elongation 
factor 1-alpha 1, Elongation factor 1-alpha 2, Elongation factor 1-beta, Elongation 
factor 1-delta, Elongation factor 2, Eukaryotic initiation factor 4A-I, Eukaryotic 
initiation factor 4A-II, Eukaryotic initiation factor 4A-III, Transcription elongation 
factor A protein-like 3, Transcription elongation factor A protein-like 3, Transcription 
elongation factor A protein-like 5, Transcription factor SOX-1,  
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Table S6-C 
GABA+ insulin + 5.5 mM glucose 
Histone H1.5, Histone H2A type 1, Histone H2A type 1-F, Histone H2A type 1-H, 
Histone H2A type 1-K, Histone H2A type 2-A, Histone H2A type 2-C, Histone H2A 
type 3, Histone H2A.J, Histone H2AX, Histone H2B type 1-B, Histone H2B type 1-
C/E/G, Histone H2B type 1-H, Histone H2B type 1-M, Histone H2B type 1-P, Histone 
H2B type 2-B, Histone H2B type 3-A, Histone H2B type 3-B, Histone H4, Histone 
H2A type 2-B, Histone H2B type 1-F/J/L  
Actin cytoplasmic 1, Tubulin alpha-1A chain, Tubulin alpha-1B chain, Tubulin alpha-
1C chain, Tubulin beta-2A chain, Tubulin beta-2B chain, Tubulin beta-3 chain, 
Tubulin beta-4A chain, Tubulin beta-4B chain, Tubulin beta-5 chain 
60S ribosomal protein L11, Elongation factor 1-alpha 1, Elongation factor 2 
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Supplementary Table 2-7.  Functional categories of the proteins within the glucagon 
interactome in the context of 25 mM glucose. Proteins were functionally categorized 
using Panther GO-Slim Molecular Function analysis. Values show protein hits as 
percentage of the total number of hits within each category when α-TC1-6 cells were 
cultured in media containing 25 mM glucose. 
 Control GABA Insulin GABA+ 
insulin 
Binding 47.4 46.1 48.5 51.4 
Structural 
molecule 
activity 
24.7 13.7 15.4 28.6 
Catalytic 
activity 
19.6 22.5 26.2 17.1 
Receptor 
activity 
1 5.9 2.3 - 
Translation 
regulator 
activity 
4.1 1 2.3 - 
Transporter 
activity 
3.1 6.9 4.6 2.9 
Signal 
transducer 
activity 
- 2.9 - - 
Antioxidant 
activity 
- 1 0.8 - 
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Supplementary Table 2-8. Functional categories of proteins within the glucagon 
interactome in the context of 5.5 mM glucose. Proteins were functionally categorized 
using Panther GO-Slim Molecular Function analysis. Each value shows protein hit 
as percentage of the total number of hits within each category when α-TC1-6 cells 
were cultured in media containing 5.5 mM glucose. 
 
 Control GABA Insulin GABA+ 
insulin 
Binding 48.4 43.8 43.5 50.6 
Structural 
molecule 
activity 
15 11.4 14.9 17.6 
Catalytic 
activity 
25.5 28.6 31 22.4 
Receptor 
activity 
2 1.6 1.2 1.2 
Translation 
regulator 
activity 
2.6 1.1 2 2.4 
Transporter 
activity 
3.9 4.9 4.3 4.7 
Antioxidant 
activity 
2 1.6 1.6 1.2 
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Channel 
regulator 
activity 
- 0.5 - - 
Signal 
transducer 
activity 
- 6.5 1.6 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
 
Chapter 3 
 
 
This chapter was reformatted from its original published paper in Frontiers in 
Endocrinology under the license of Creative Commons Attribution 4.0 International 
License (https://creativecommons.org/licenses/by/4.0/). 
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Asadi F, Dhanvantari S. (2020) Stathmin-2 Mediates Glucagon Secretion From 
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3.1 Abstract 
Inhibition of glucagon hypersecretion from pancreatic α-cells is an appealing strategy for 
the treatment of diabetes. Our hypothesis is that proteins that associate with glucagon 
within α-cell secretory granules will regulate glucagon secretion, and may provide 
druggable targets for controlling abnormal glucagon secretion in diabetes. Recently, we 
identified a dynamic glucagon interactome within the secretory granules of the α cell line, 
α-TC1-6, and showed that select proteins within the interactome could modulate 
glucagon secretion. In the present study, we show that one of these interactome proteins, 
the neuronal protein stathmin-2, is expressed in α-TC1-6 cells and in mouse pancreatic α-
cells, and is a novel regulator of glucagon secretion. The secretion of both glucagon and 
Stmn2 was significantly enhanced in response to 55 mM K+, and immunofluorescence 
confocal microscopy showed co-localization of stathmin-2 with glucagon and the 
secretory granule markers chromogranin A and VAMP-2 in α-TC1-6 cells. In mouse 
pancreatic islets, Stathmin-2 co-localized with glucagon, but not with insulin, and co-
localized with secretory pathway markers. To show a function for stathmin-2 in 
regulating glucagon secretion, we showed that siRNA—mediated depletion of stathmin-2 
in α-TC1-6 cells caused glucagon secretion to become constitutive without any effect on 
proglucagon mRNA levels, while overexpression of stathmin-2 completely abolished 
both basal and K+-stimulated glucagon secretion. Overexpression of stathmin-2 increased 
the localization of glucagon into the endosomal-lysosomal compartment, while depletion 
of stathmin-2 reduced the endosomal localization of glucagon. Therefore, we describe 
stathmin-2 as having a novel role as an α-cell secretory granule protein that modulates 
glucagon secretion via trafficking through the endosomal-lysosomal system. These 
findings describe a potential new pathway for the regulation of glucagon secretion, and 
may have implications for controlling glucagon hypersecretion in diabetes. 
 
Keywords: glucagon, α-cell, glucagon hypersecretion, glucagon interactome, stathmin-2   
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3.2 Introduction 
Hyperglucagonemia is a characteristic sign of diabetes, causing fasting hyperglycemia 
and glycemic volatility. Clinically, glycemic variability contributes to the development of 
diabetes complications (1). Persistent hyperglucagonemia may exacerbate abnormal 
glucose metabolism in patients with type 2 diabetes and lead to metabolic disturbances in 
obese and prediabetic individuals (2). Further complicating glucose homeostasis in 
diabetes is the direct effect of glucose on the α-cells; while glucagon secretion is 
maximally suppressed at plasma glucose concentrations of 5–10 mM, it increases at 
glucose levels above 10 mM, thus exacerbating hyperglycemia (3–6). Therefore, 
controlling excess glucagon secretion may be a potential therapeutic strategy for diabetes 
(7) so that glycemia and glucose metabolism may be better regulated. Such an approach 
has been suggested as a priority for the treatment of diabetes (1). 
Combating hyperglucagonemia could be theoretically achieved by (i) inhibition of 
glucagon action at target organs by blocking the glucagon receptor, or (ii) inhibition of 
glucagon secretion from the pancreatic α cells. While in the short-term the former could 
be an effective therapeutic strategy, it can lead to α cell hyperplasia and 
hyperglucagonemia over a long-term period (8), along with a risk of hypoglycemia (9) 
and disturbances in lipid metabolism (10). Therefore, inhibiting glucagon secretion, 
rather than blocking the glucagon receptor, may be a more appropriate therapeutic 
approach for the treatment of hyperglucagonemia of diabetes (11). 
It has been documented that suppression of glucagon secretion can be mediated at the 
systemic, paracrine or intrinsic level (12). As a systemic modulator, GLP-1 inhibits 
glucagon secretion; however, there are controversies as to whether GLP-1 directly 
inhibits glucagon secretion from α cells by signaling through the α-cell GLP-1R (13–15), 
or indirectly by increasing inter-islet somatostatin or insulin secretion (13, 16). Glucagon 
secretion is also suppressed by paracrine signaling through the insulin, somatostatin and 
GABAA receptors on the α cell (16–18) At an intrinsic level, glucose directly or 
indirectly inhibits glucagon secretion from the α cell (19–22) by altering downstream 
activities of Ca2+ channels, KATP channels (23), and trafficking of secretory granules (24). 
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We are pursuing the hypothesis that glucagon secretion can also be controlled by proteins 
within the secretory granule that associate with glucagon. By conducting secretory 
granule proteomics in α-TC1-6 cells, we have recently described a dynamic glucagon 
interactome, and shown that components of this interactome can play a role in 
modulating glucagon secretion (25). Of these components, a protein of particular interest 
is Stathmin-2 (Stmn2 or SCG10), a member of the stathmin family of Golgi proteins (26) 
that may play a role in the regulation of neuroendocrine secretion (27). In the human 
islet, Stmn2 expression may be unique to α-cells, as shown by genome-wide RNA-Seq 
analysis (28) and single cell transcriptomics (23), and α-cell Stmn2 mRNA expression is 
differentially regulated in type 2 diabetes (29). These studies, together with our 
proteomics findings, led us to hypothesize that Stmn2 may function in α cells to modulate 
glucagon secretion. In the present study, we show that Stmn2 is co-localized with 
glucagon in secretory granules of α-TC1-6 cells and controls glucagon secretion by 
trafficking through the endosomal/lysosomal system. 
3.3 Materials and methods 
3.3.1 Cell culture 
α-TC1-6 cells (a kind gift from C. Bruce Verchere, University of British Columbia, 
Vancouver, BC, Canada) were cultured in regular DMEM medium containing 5.6 mM 
glucose (Cat# 12320032, Thermo Fisher Scientific) supplemented with 15% horse serum 
(Cat# 26050088, Thermo Fisher Scientific), 2.5% FBS (Cat# 16000044, Thermo Fisher 
Scientific), L-glutamine and sodium pyruvate. For secretion experiments, cells were 
plated in 6 –well plates and for all experiments, a low passage number (up to P6) was 
used. Twenty-four hours prior to secretion experiments, media were removed and 
replaced with DMEM without supplements. To evaluate (25) the regulated secretion of 
glucagon, cells were washed twice with HBSS, pre-incubated for 2 h in DMEM without 
supplements, then incubated for 15 min with or without KCl (55 mM). These media were 
collected into tubes containing protease inhibitor (PMSF, 45 mM) and phosphatase 
inhibitors (sodium orthovanadate, 1 mM; and sodium fluoride 5 mM) while tubes were 
kept on ice. After collection, media were centrifuged at 13,000× g for 5 min at 4°C, and 
the supernatant was collected into new microfuge tubes and immediately kept at −80°C 
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until analysis. After media were removed, cells were washed using ice-cold PBS (pH 7.4) 
and lysed in RIPA buffer (Cat# 89900, Thermo Fisher Scientific) containing 
abovementioned protease and phosphatase inhibitors. The lysed cells were centrifuged at 
13,000× g for 5 min at 4°C and the supernatant was kept at −80°C for protein assays. 
3.3.2 Gene construct and plasmid preparation 
To generate the expression plasmid for Stmn2, the Kozak sequence (GCCACC), signal 
peptide sequence and coding sequence of mouse Stmn2 
(https://www.uniprot.org/uniprot/P55821) were ligated into the NheI and ApaI restriction 
sites of pcDNA3.1(+) MAr. The construct was synthesized by GENEART GmbH, Life 
Technologies (GeneArt project 2018AAEGRC, Thermo Fisher Scientific). Then, Max 
Efficiency DH5α competent cells (Thermo Fisher Scientific, Cat# 18258012) were 
transformed according to the manufacturer's protocol. Plasmids were then extracted and 
purified using the PureLink HiPure Plasmid Maxiprep Kit (Thermo Fisher Scientific, 
Cat# K210006) for downstream experiments. Correct assembly of the final construct was 
verified by gene sequencing at the London Regional Genomics Facility, Western 
University. For Stmn2 overexpression studies, α-TC1-6 cells were transiently transfected 
by pcDNA3.1 (+) MAr-stmn2 construct or empty vector (negative control). All 
transfections were done using Lipofectamine 2000 (Cat#11668-027, Invitrogen). To 
monitor normal cell growth and morphology, cells were checked daily by the EVOS cell 
imaging system (Thermo Fisher Scientific). The efficiency of transfection was 
determined  in a preliminary study at >70% through co-transfection with pEGFP. 
3.3.3 Gene silencing experiments 
siRNA-mediated depletion of stathmin-2 
Functional analysis of Stmn2 was done by gene silencing experiments. siRNAs targeting 
three regions within the Stmn2 mRNA (Cat# s73356, s73354, s73355) were chosen from 
pre-designed mouse siRNAs (Silencer siRNA, Thermo Fisher Scientific). The control 
group was treated with Mission siRNA Universal Negative Control # 1 (Cat# SIC001, 
Sigma-Aldrich). Gene silencing was done based on a previously published protocol (30) 
and as we have done previously with some modifications (25). Briefly, α-TC1-6 cells 
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were cultured in regular DMEM to 60% confluency. Media were removed and replaced 
with 2 mL Opti-MEM (Cat# 31985-070, Gibco) containing 50 nM pooled siRNAs with 
Lipofectamine 2000. After 8 h, media were changed to regular DMEM without sera (FBS 
and horse serum) and cultured for 72 h. Then, media were refreshed and cells were 
cultured for 15 min in the absence or presence of 55 mM KCl as described above. Gene 
silencing was confirmed by analyzing mRNA expression levels of Stmn2. After 
removing media, cells were washed by cold PBS (pH 7.4) and total RNA was extracted 
(RNeasy extraction kit; Cat # 74104, Qiagen). cDNA synthesis was performed using the 
SuperScript III First Strand Synthesis Supermix for qRT-PCR (Cat # 11752050, Thermo 
Fisher Scientific), according to the supplier's protocol. Real-time PCR was performed 
using Quant Studio Design and Analysis Real-Time PCR Detection System in 
conjunction with the Maxima SYBR Green qPCR Master Mix (Cat # K0221, Thermo 
Fisher Scientific) using specific primers for Stmn2: forward, 5′-
GCAATGGCCTACAAGGAAAA-3′; reverse, 5′-GGTGGCTTCAAGATCAGCTC-3′; 
and β-Actin; forward, 5′-AGCCATGTACGTAGCCATCC-3′; reverse, 5′-
CTCTCAGCTGTGGTGGTGAA-3′. Gene expression levels for stathmin-2 were 
normalized to that of β-Actin. The normalized level of transcripts in the depleted cells 
was shown relative to that of the non-targeting negative control. Relative expression 
levels were determined as percent of alterations compared to the control. Statistical 
analysis was performed using t-test at α = 0.05. 
Proglucagon gene expression levels following Stmn2 depletion 
After siRNA treatments, proglucagon gene expression levels were measured by real-time 
PCR as described above using proglucagon-specific primers (forward: 5′-
CAGAGGAGAACCCCAGATCA-3′, reverse: 5′-TGACGTTTGGCAATGTTGTT-3′). 
3.3.4 Immunoblotting 
 To test for effects of siRNA transfection on levels of Stmn2, α-TC1-6 cells were lysed 
using non-ionic lysis buffer (50 mM Tris pH 7.4, 150mM NaCl, 1% Triton X-100 plus 
cOmplete Mini Protease Inhibitor Cocktail and 5 μg/mL Aprotinin). Proteins were 
resolved by 4-12% NuPAGE gel (Cat # NP0335Box, Invitrogen), transferred to a PVDF 
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membrane (Cat # IB401001, Invitrogen) and probed with primary antibodies (Stmn2, 
Cat# 720178, Thermo Fisher Scientific; 1:1000; beta actin, Cat# ab8227, Abcam, 1:1000) 
overnight. Immunoreactive bands were visualized using HRP-conjugated goat anti-rabbit 
secondary antibody (Cat# 31460, Invitrogen; 1:1000) and Clarity Western ECL substrate 
(Cat# 170-5061, Bio-Rad). Images were acquired on a BioRad ChemiDoc Imaging 
System. Total cell extracts from control cells were used as positive control. 
3.3.5 Immunofluorescence confocal microscopy  
α-TC1-6 cells 
To determine if Stmn2 and glucagon could be co-localized to the same intracellular 
compartments, we used immunofluorescence confocal microscopy. Wild type α-TC1-6 
cells were seeded on collagen (type I)-coated coverslips and grown in regular DMEM, 
then incubated in non-supplemented DMEM for 24 h. At the end of incubation, cells 
were washed once with PBS, fixed in 2% paraformaldehyde (in PBS) for 30 min, 
permeabilized with 0.25% Triton X-100 (in PBS) for 5 min and washed with PBS. After 
1 h incubation with blocking buffer (10% goat serum in 1% BSA/PBS), coverslips were 
incubated with primary antibodies against glucagon (mouse anti- glucagon antibody, Cat 
# ab10988, Abcam; 1:1000), Stathmin-2 (goat anti-SCG10 antibody, Cat # ab115513, 
Abcam; 1:1000), secretory granule marker, chromogranin A (mouse anti-ChgA antibody, 
Cat# MAB319, Sigma; 1:1000), secretory granule marker, VAMP2 (rabbit anti-VAMP2, 
Cat# ab215721, Abcam; 1:1000), early endosome marker, EEA1 (rabbit antiEEA1, Cat # 
ab 2900, Abcam; 1:500) or the lysosomal marker, Lamp2A (rabbit anti-Lamp2A, Cat# 
ab18528, Abcam; 1:500) overnight. After washing with PBS, coverslips were incubated 
with the following secondary antibodies as appropriate: goat anti-mouse IgG Alexa Fluor 
488 (Cat# A-11001, Molecular Probes; 1:500), goat anti-rabbit IgG Alexa Fluor 594 
(Cat# A11037, Invitrogen; 1:500) or donkey anti-goat IgG Alexa Fluor 555 (Cat# 
ab150130, Abcam; 1:500) Invitrogen) for 2 h in the dark at room temperature. Then, 
coverslips were washed with PBS and mounted on glass slides using DAPI containing 
ProLong antifade mountant (Cat # P36935, Molecular Probes) for image analysis by 
confocal immunofluorescence microscopy (Nikon A1R, Mississauga, Canada). Coverslip 
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preparation was done at least four different times with freshly thawed cells. Each thawed 
batch of the cell was cultured and passaged three times.  
Mouse pancreatic islets 
All mice were treated in accordance with the guidelines set out by the Animal Use 
Subcommittee of the Canadian Council on Animal Care at Western University based on 
the approved Animal Use Protocol AUP 2012-020. Six to eight-week old male C57BL/6 
mice (n = 7) were sacrificed by cervical dislocation under anesthesia with inhalant 
isoflurane. Pancreata were collected and fixed in 10% buffered formalin for 3 days and 
treated with 70% ethanol for 1 day before paraffin embedding at the Molecular Pathology 
Core Facility, Robarts Research Institute, Western University. The paraffin-embedded 
blocks were longitudinally sectioned in 5 μm slices and fixed onto glass microscope 
slides. The samples were de-paraffinized by graded washes using xylene, ethanol and 
PBS. Background Sniper (Cat# BS966H, Biocare Medical) was used to reduce non-
specific background staining. Samples were incubated with primary antibodies against 
glucagon (1:500), Stmn2 (1:250), insulin (Cat# ab7842, Abcam; 1:250) and TGN46 
(Cat# ab16059, Abcam; 1:200) and followed by secondary antibodies of goat anti-mouse 
IgG Alexa Fluor 488 (1:500), donkey anti-goat IgG Alexa Fluor 555 (1:500), and goat 
anti-guinea pig IgG Alexa Fluor 647 (Cat# A21450, Invitrogen; 1:500). Nuclei were 
stained with DAPI (1:1000), and tissues were mounted in Prolong Antifade mountant 
(Cat# P36982, Thermo Fisher Scientific). As a background control for Stmn2, islet 
staining for Stmn2 was done using only the secondary antibody.  
Image acquisition 
High-resolution images were acquired through a Nikon A1R Confocal microscope with a 
×60 NA plan-Apochromat oil differential interference contrast objective and NIS-
Elements software (Nikon, Mississauga, Canada) using a pinhole of 1 Airy unit. Images 
were sampled according to Nyquist criteria, and images of the Nyquist-cropped areas 
were captured at 1,024 × 1,024 pixel resolution, and deconvoluted by the 2D- 
deconvolution algorithm of the NIS-Elements software, thereby optimizing images for 
accurate co-localization of fluorescent signals. 
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Image Analysis 
For cell image analysis, we prepared three coverslips for each group. Image analysis was 
performed by NIS-Elements software (Nikon, Mississauga, Canada), using the co-
localization option and Pearson's correlation coefficient (PCC). Regions of interest (ROI) 
were manually drawn around distinct single or multicellular bodies, and merged values of 
glucagon and Stmn2 were taken for analysis. Colocalization of the pixels from each 
pseudo-colored image was used to calculate Pearson's correlation coefficient, as we 
described previously (25, 31). 
For mouse pancreatic islets, images were captured using four channels of green 
(glucagon), red (Stmn2), purple (insulin) and blue (nucleus; DAPI). To calculate the 
extent of co-localization between glucagon and stathmin-2 (glucagon+, Stmn2+), images 
of 15 islets per pancreas were captured and analyzed by Pearson's correlation coefficient 
(PCC). To this end, we manually drew ROIs around each islet and then defined PCC 
values for colocalization between Stmn2 and glucagon or insulin using the colocalization 
option of the NIS-Elements software. To predict expression levels of Stmn2 in α or β- 
cells of the pancreatic islets we have performed binary analysis using M-Thresholding 
algorithm of NIS-Elements software, followed by regression analysis of Stmn2 vs. 
glucagon or insulin using GraphPad Prism 7. 
3.3.6 Immunoelectron microscopy 
Double immunogold transmission electron microscopy was done based on the protocol 
by Aida et al. (32) with some modifications. Briefly, pieces of mouse pancreata were cut 
and immediately placed into McDowell Trump's fixative (Cat# 18030-10; Electron 
Microscopy Sciences) for 1h. Then, after washing with PBS, samples were dehydrated in 
increasing concentrations of ethanol (10, 20, 30, 50, 70, 90, 100, and 100%) at 30 min per 
concentration. We followed the following protocol for LR White embedding and 
incubation: Incubation in ethanol-LR White mixture (3:1, v/v; 2 h), ethanol-LR White 
(1:1, v/v; 8 h), ethanol-LR White mixture (1:3, v/v; 12 h), pure LR White mixture (12 h), 
pure LR White (12 h) and pure LR White (12 h). The sample was then placed into a beem 
capsule, filled with pure LR White and incubated at 50°C for 24 h. Semi-thin sections 
132 
 
(500 nm) were cut from the embedded sample for Toluidin blue staining (1% Toluidin 
blue for 2 min). By defining the position of the islets, ultra-thin sections (70 nm) were 
prepared using a diamond microtome. The sections were mounted on formvar-carbon 
coated nickel grid (300 meshes) (Cat# FCF300-NI, Electron Microscopy Sciences). Then, 
slices were washed with Tris-buffered saline (Tris 1M, NaCl 5M pH 8) containing 0.05% 
Tween 20 (TBS-T) and incubated in blocking buffer (2% BSA in PBS plus 0.05% Tween 
20) for 30 min at room temperature. Slices were incubated with primary antibodies (1:10 
in blocking buffer) against glucagon (Cat# ab92517; Abcam) and Stmn2 (Cat# ab115513; 
Abcam) at 4°C overnight. After washing with TBS-T, slices were incubated with gold 
conjugated secondary antibodies (1:50 in blocking buffer) of donkey anti-goat IgG (18 
nm; cat# ab105270, Abcam) and goat anti-rabbit IgG (10 nm; Cat# ab27244; Abcam) for 
2 h at room temperature. After washing with TBS-T and staining with Uranyless (Cat# 
22409, Electron Microscopy Sciences), transmission electron microscopy was conducted 
at the Biotron Experimental Research Center, Western University, London, ON, Canada. 
3.3.7 Primary islet culture  
Islet preparation and culture 
Islet preparation and culture was done according to the Li et al. (33) protocol with some 
modifications. Male C57BL/6 mice (n = 5–6) were euthanized by CO2. The abdominal 
cavity was opened and 3 mL of 1.87 mg/mL collagenase V (Cat# C9263, Sigma;) in 
Hanks' Balanced Salt Solution was injected into the common bile duct. The pancreas was 
then removed, placed into a Falcon tube containing 2 mL of the ice-cold collagenase V 
solution and incubated for 12 min at 37°C with occasional shaking. Digestion was 
stopped by adding 1mM CaCl2 and the cell suspension was washed twice in the CaCl2 
solution. Islets were collected into a sterile petri dish using a 70 μm cell strainer with 
RPMI1640 containing 11 mM glucose plus 20 mM glutamine, 10% FBS and penicillin 
(110 U/mL) and streptomycin (100 μg/mL). 180 islets were handpicked into the medium 
under a stereomicroscope and incubated for 2 h in the cell culture incubator. The medium 
was then changed to RPMI1640 containing 11 mM glucose plus 10% FBS and penicillin 
(110 U/mL) and streptomycin (100 μg/mL) and cultured overnight at 37°C. 
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Islet glucagon secretion experiments 
Glucagon secretion from islets was measured based on the protocol by Suckow et al. 
(34). Briefly, islets were washed three times using Krebs-Ringer bicarbonate (KRB) 
buffer (135 mM NaCl, 3.6 mM KCl, 5 mM NaHCO3, 0.5 mM NaH2PO4, 0.5 mM MgCl2, 
1.5 mM CaCl2, 10 mM HEPES; pH 7.4) containing 11 mM glucose, and then pre-
incubated in this buffer for 1 h. Glucagon secretion was tested by incubating islets in 
KRB containing 1 mM glucose in the presence or absence of arginine (25 mM) for 20 
min. Media were collected into microcentrifuge tubes containing enzyme inhibitors 
(PMSF, 45 mM; Aprotinin, 5 μg/mL and sodium orthovanadate, 1 mM). Samples were 
centrifuged at 14,000 × g for 5 min at 4°C and the supernatant was collected and kept at 
−80°C until analysis. 
Measurement of glucagon and stathmin-2  
Glucagon levels in the media were determined by ELISA (Cat # EHGCG, Thermo Fisher 
Scientific) according to the manufacturer's instructions. Stmn2 levels in the media were 
measured using mouse stathmin-2 ELISA kit (Cat# MBS7223765, MyBioSource) 
according to the manufacturer's instruction. For each measurement, the values were 
compared between groups by t-test and among groups by 1-Way ANOVA and 
Bonferroni post-hoc test (α = 0.05). Cell protein levels were determined using BCA assay 
and used for normalization of the glucagon or Stmn2 levels. 
3.3.8 Statistical analysis 
Values were compared among treatment groups by one-way ANOVA or between groups 
by unpaired t-test using Sigma Stat 3.5 software (α = 0.05). For image analysis, co-
localization of channels in the merged images was calculated by Pearson's correlation 
coefficient (PCC) using NIS-Elements software (Nikon, Canada). 
3.4 Results 
Immunostaining of glucagon and Stmn2 in α-TC1-6 cells revealed significant co-
localization, as shown in Figure 3-1A and by a positive Pearson's correlation coefficient 
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(0.74 ± 0.05) between endogenously expressed glucagon and Stmn2. Linear regression of 
binary intensities showed a sensitive and significant relationship between colocalization 
of glucagon and Stmn2 (Figure 3- 1B). The secretion of both glucagon and Stmn2 was 
significantly enhanced in response to 55 mM K+ (Figure 3- 1C), with corresponding 
decreases in cell contents (Figure 3- 1D). To further confirm the presence of stathmin-2 
in secretory granules, α-TC1-6 cells were immunostained for stathmin-2 and the 
secretory granule markers chromogranin A (Figure 3- 1E) and VAMP2 (Figure 3-1F). 
There was moderate colocalization (35) between Stmn2 and chromogranin A (PCC 0.58 
± 0.07) or VAMP2 (PCC 0.56 ± 0.09) (Figure 3-1G), indicating that Stmn2 is partially 
localized to the secretory granule compartment in α-TC1-6 cells. 
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3.4.1 Stathmin-2 localizes to the α-cell secretory pathway in 
mouse pancreatic islets  
Immunostaining of mouse pancreatic islets showed a pattern of Stmn2 
immunofluorescence similar to that of glucagon, and not insulin (Figure 3- 2A). Analysis 
by Pearson correlation showed a strong colocalization between glucagon and Stmn2 in 
the islets (PCC = 0.77 ± 0.02), but not between insulin and Stmn2 (Figure 3-2B). Linear 
regression analysis of the binary intensities revealed a very strong and significant 
relationship between Stmn2 and glucagon immunofluorescence (Figure 3- 2C), while 
there was no significant relationship between Stmn2 and insulin (Figure 3- 2D). There 
was also a strong relationship between Stmn2 and the trans Golgi marker, TGN46 (PCC 
= 0.72 ± 0.09) in both islet clusters (Figure 3- 2E) and mature islets (Figure 3- 2F). 
Figure 3-1. Stathmin-2 localizes to secretory granules in α-TC1-6 cells.  α-TC1-6 
cells were immunostained using primary antibodies against glucagon (GCG, 
green) and stathmin-2 (Stmn2, red). DAPI (blue) indicates the nucleus in the 
merged image. Resolution of the images was extended by applying Nyquist XY 
scan and then 2D- Deconvolution in NIS Elements image analysis software.  
Images are representative of four biological replicates with 3 technical replicates 
each. (A) Areas of yellow in the merged image show colocalization of glucagon 
and Stmn2. (B) Linear regression analysis of binary intensities of glucagon and 
Stmn2 predicts a significant (p<0.001) correlation. Each value represents mean 
intensities of 5-7 cells. The secretion of both glucagon and Stmn2 (C) was 
significantly increased after KCl stimulation (KCl Stim)for 15 min. Cell Stmn2 
and glucagon levels show reduction following KCl stimulation (KCl Stim) (D). 
Values are expressed as mean ± SEM (n=5). *p<0.05. Stmn2 colocalizes with the 
secretory granule proteins ChgA (E) and VAMP2 (F), as indicated by yellow 
punctate staining. (G) The extent of colocalization was analyzed by Pearson 
correlation coefficient for Stmn2 with ChgA or with VAMP2. Dots represent all 
biological and technical replicates. 
 
Figure 3-2. Pro osed pathways by which stathmin-2 modulates glucagon 
secretion from α-TC1-6 cells. The model denotes status of glucagon secretion 
from α-TC1-6 cells in normal physiology or in the event of Stmn2- depletion or 
overexpression. Blue arrows indicate the normal trafficking of glucagon, together 
with Stmn2, to secretory granules, where they are stored until their release is 
triggered by a stimulus.  Stmn2 overexpression (red arrows) reduces the amount 
of glucagon available for secretion by diverting secretory granules to lysosomes. 
Stmn2 depletion (black arrows) reduces the trafficking of glucagon into secretory 
granules and promotes the constitutive release of glucagon.Figure 3-3. Stathmin-2 
localizes to secretory granules in α-TC1-6 cells.  α-TC1-6 cells were 
immunostained using primary antibodies against glucagon (GCG, green) and 
stathmin-2 (Stmn2, red). DAPI (blue) indicates the nucleus in the merged image. 
Resolution of the images was extended by applying Nyquist XY scan and then 2D- 
Deconvolution in NIS Elements image analysis software.  Images are 
representative of four biological replicates with 3 technical replicates each. (A) 
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In addition, double immunogold-labeling TEM revealed the presence of both glucagon 
and Stmn2 within secretory granules of pancreatic α-cells. The co-localization of 
glucagon (10 nm particles; white arrows) and Stmn2 (18 nm particles; black arrows) was 
mostly within the core area of the secretory granules (Figure 3- 3A). Finally, 25 mM Arg 
significantly enhanced the secretion of both glucagon and Stmn2 from isolated islets 
(Figure 3- 3B). These results indicate that Stmn2 is localized to the secretory pathway of  
α cells in mouse pancreatic islets. Our approach was based on qualitatively showing the 
presence of Stmn2 within the secretory granules. 
 
 
 
 
Figure 3-4. Stathmin-2 is present in α-cells, but not β-cells, in murine pancreatic 
islets. Pancreata of C57BL/6 mice (n=7; 5µm sections) were immunostained for 
against glucagon (GCG), stathmin-2 (Stmn2) and insulin (INS). Images were 
acquired and analysed for co-localization as described in Figure 1. (A) Both 
glucagon and Stmn2 localize to the mantle of the islets, and areas of yellow in the 
merged image demonstrate dual positive α-cells (glucagon+ and Stmn2+). (B) 
Pearson’s correlation coefficient for colocalization of Stmn2 and glucagon or 
insulin. (C) Linear regression analysis predicts a strong positive correlation 
between the binary intensities of glucagon and Stmn2 (p<0.001). (D) There is no 
correlation between the binary intensities of insulin and Stmn2. (E, F) 
Colocalization of Stmn2 and the trans-Golgi marker TGN46 in murine pancreatic 
islets. Areas of white (arrows in the magnified panel) indicate co-localization of 
glucagon, Stmn2 and TGN46 in islet clusters (E) and a single islet (F). 
 
Figure 3-5. Stathmin-2 localizes to secretory granules in α-TC1-6 cells.  α-TC1-6 
cells were i munostained using primary antibodies ag inst glucagon (GCG, 
green) a d stathmin-2 (Stmn2, red). DAPI (blue) indicates the nucleus in the 
merged image. Resolution of the images w s extended by applying Nyquist XY 
scan and then 2D- Deconvolution in NIS Elements image analysis software.  
Images are representative of four biological replicates with 3 technical replicates 
each. (A) Areas of yellow in the merged image show colocalization of glucagon and 
Stmn2. (B) Linear regression analysis of binary intensities of glucagon and Stmn2 
predicts a significant (p<0.001) correlation. Each value represents mean intensities 
of 5-7 cells. The secretion of both glucagon and Stmn2 (C) was significantly 
increased after KCl stimulation (KCl Stim)for 15 min. Cell Stmn2 and glucagon 
levels show reduction following KCl stimulation (KCl Stim) (D). Values are 
expressed as mean ± SEM (n=5). *p<0.05. Stmn2 colocalizes with the secretory 
granule proteins ChgA (E) and VAMP2 (F), as indicated by yellow punctate 
staining. (G) The extent of colocalization was analyzed by Pearson correlation 
coefficient for Stmn2 with ChgA or with VAMP2.Figure 3-6. Stathmin-2 is present 
in α-cells, but not β-cells, in murine pancreatic islets. Pancreata of C57BL/6 mice 
(n=7; 5µm sections) were immunostained for against glucagon (GCG), stathmin-2 
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3.4.2 Effects of depletion and overexpression of Stmn2 on 
glucagon secretion 
In order to determine if Stmn2 had any functional effects in α-cells, we manipulated 
levels of Stmn2 and measured K+-stimulated glucagon secretion. Following siRNA-
mediated knockdown of Stmn2 in α-TC1-6 cells, basal secretion of glucagon was 
increased ~4.5-fold, and was not significantly different from K+-stimulated secretion 
(Figure 3- 4A), indicating increased constitutive secretion. Efficacy of siRNA-mediated 
depletion of Stmn2 was shown by a significant reduction (p < 0.01) in Stmn2 mRNA 
levels (Figure 3- 4B) and the Stmn2 immunoreactive band by western blot (Figure 3- 
4C). As well, silencing of Stmn2 did not affect proglucagon gene expression levels 
(Figure 3- 4D), indicating that the effects of Stmn2 depletion were on glucagon secretion 
alone. Conversely, overexpression of Stmn2 dramatically reduced both basal and 
stimulated glucagon secretion compared to the corresponding control groups (Figure 3-
4E; p < 0.001). These findings suggest that Stmn2 levels may control the regulated 
secretion of glucagon from α-TC1-6 cells. 
 
 
Figure 3-7. Glucagon and Stmn2 are present within secretory granules of 
pancreatic α-cells. (A) Immunogold labels for both glucagon (10 nm; white 
arrows) and Stmn2 (18 nm; black arrows) are localized within secretory 
granules. The low magnification image  (25000×, scale bar = 1 μm) shows the 
ultrastructure of one α-cell. N (nucleus); M (mitochondria); ER (endoplasmic 
reticulum); SG (secretory granule). The magnified image (41000×, scale bar 
= 0.6 μm) highlights the presence of immunogold labels within a single 
secretory granule. (B) Isolated mouse islets were incubated in the presence or 
absence of 25 mM Arg for 20 min. Both glucagon and Stmn2 secretion from 
murine islets is stimulated by arginine. Values were normalized to the non-
stimulated condition and expressed as mean ± SEM (n=5-6). *p<0.01. 
 
Figure 3-8. Stathmin-2 is present in α-cells, but not β-cells, in murine 
pancreatic islets. Pancreata of C57BL/6 mice (n=7; 5µm sections) were 
immunostained for against glucagon (GCG), stathmin-2 (Stmn2) and insulin 
(INS). Images were acquired and analysed for co-localization as described in 
Figure 1. (A) Both glucagon and Stmn2 localize to the mantle of the islets, 
and areas of yellow in the merged image demonstrate dual positive α-cells 
(glucagon+ and Stmn2+). (B) Pearson’s correlation coefficient for 
colocalization of Stmn2 and glucagon or insulin. (C) Linear regression 
analysis predicts a strong positive correlation between the binary intensities 
of glucagon and Stmn2 (p<0.001). (D) There is no correlation between the 
binary intensities of insulin and Stmn2. (E, F) Colocalization of Stmn2 and 
the trans-Golgi marker TGN46 in murine pancreatic islets. Areas of white 
(arrows in the magnified panel) indicate co-localization of glucagon, Stmn2 
and TGN46 in islet clusters (E) and a single islet (F).Figure 3-9. Glucagon 
and Stmn2 are present within secretory granules of pancreatic α-cells. (A) 
Immunogold labels for both glucagon (10 nm; white arrows) and Stmn2 (18 
nm; black arrows) are localized within secretory granules. The low 
magnification image  (25000×, scale bar = 1 μm) shows the ultrastructure of 
one α-cell. N (nucleus); M (mitochondria); ER (endoplasmic reticulum); SG 
(secretory granule). The magnified image (41000×, scale bar = 0.6 μm) 
highlights the presence of immunogold labels within a single secretory 
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3.4.3 Stmn2 directs glucagon into early endosomes 
 In wild type α-TC1-6 cells, there was weak co-localization between glucagon and the 
early endosome marker EEA1 (Figure 3- 5A) (PCC = 0.15 ± 0.02). When Stmn2 was 
overexpressed (Figure 3- 5B), the extent of colocalization between glucagon and EEA1 
increased markedly (PCC = 0.53±0.08). Depletion of Stmn2 (Figure 3- 5C) drastically 
reduced the extent of colocalization (PCC = 0.05) between glucagon and EEA1. 
Pearson's correlation coefficient of co-localization between glucagon and Stmn2 showed 
a significant increase when Stmn2 was overexpressed (p < 0.001) and a significant 
reduction when Stmn2 was knocked down (p < 0.05) compared to the control (Figure 3- 
Figure 3-10. Silencing Stathmin-2 increased glucagon secretion and 
overexpression of stathmin-2 suppressed glucagon secretion in α-TC1-6 cells.  
Wild type (wt; control) and stathmin-2 depleted (Stmn2-KD)  α-TC1-6 cells 
were preincubated 2h in serum- free medium and then incubated with or 
without KCl (55 mM) for 15 min. (A) Glucagon secretion is significantly 
stimulated by KCl in wt cells, while in Stmn2-KD cells, basal glucagon 
secretion is increased and does not respond to KCl. * p<0.01 compared to basal 
secretion in wt cells. (B) Stmn2 mRNA levels are decreased by about 70% after 
siRNA-mediated depletion in α-TC1-6 cells. Values are means ± SEM (n=5), * 
p<0.01.  (C) siRNA-mediated silencing of Stmn2, shutdown expression of 
Stmn2.Western blot (WB) shows a faint band for Stmn2 after siRNA-mediated 
depletion of Stmn2 in α-TC1-6 cells. (D) Proglucagon mRNA levels are not 
affected by siRNA- mediated depletion of stathmin-2. (E) Glucagon secretion is 
inhibited by overexpression of Stmn2. α-TC1-6 cells were transfected with 
pcDNA3.1 (+) MAr-stmn2 construct or empty vector (control). Both basal 
(p<0.001) and K+-stimulated (p<0.001) (KCl stimulation; KCl Stim) glucagon 
secretion were inhibited by overexpression of Stmn2. Values are means ± SEM 
(n=4).  
 
Figure 3-11. Glucagon and Stmn2 are present within secretory granules of 
pancreatic α-cells. (A) Immunogold labels for both glucagon (10 nm; white 
arrows) and Stmn2 (18 nm; black arrows) are localized within secretory 
granules. The low magnification image  (25000×, scale bar = 1 μm) shows the 
ultrastructure of one α-cell. N (nucleus); M (mitochondria); ER (endoplasmic 
reticulum); SG (secretory granule). The magnified image (41000×, scale bar = 
0.6 μm) highlights the presence of immunogold labels within a single secretory 
granule. (B) Isolated mouse islets were incubated in the presence or absence of 
25 mM Arg for 20 min. Both glucagon and Stmn2 secretion from murine islets 
is stimulated by arginine. Values were normalized to the non-stimulated 
condition and expressed as mean ± SEM (n=5-6). *p<0.01.Figure 3-12. 
Silencing Stathmin-2 increased glucagon secretion and overexpression of 
stathmin-2 suppressed glucagon secretion in α-TC1-6 cells.  Wild type (wt; 
control) and stathmin-2 depleted (Stmn2-KD)  α-TC1-6 cells were 
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5D). These findings suggest that Stmn2 plays a role in directing glucagon toward early 
endosomes. 
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3.4.4 Stmn2 overexpression increases glucagon presence in the 
late endosome/lysosome compartment  
Similar to our findings in early endosomes, there was a weak correlation between 
glucagon and the late endosome-lysosome marker, Lamp2A (PCC = 0.2 ± 0.02) in wild 
type α-TC1-6 cells (Figures 3- 6A,D). Following overexpression of Stmn2, the levels of 
colocalization between glucagon and Lamp2A were significantly increased (PCC = 0.89 
± 0.05, p < 0.001) (Figures 3- 6B,D). Depletion of Stmn2 significantly reduced the extent 
of colocalization between glucagon and Lamp2A compared to wild type cells (PCC = 
0.001, p < 0.01) (Figures 3- 6C,D). Interestingly, the signal intensity of the endo-
lysosomal marker, Lamp2A, was significantly increased (p < 0.01) upon overexpression 
of Stmn2, but did not change upon depletion of Stmn2 (Figure 3- 6E). 
 
 
Figure 3-13. Stathmin-2 modulates glucagon trafficking through early 
endosomes. After transfection with either empty vector (A), vector encoding 
Stmn2 (B) or siRNAs against Stmn2 (C), α-TC1-6 cells were immunostained 
using primary antibodies against glucagon and the early endosome marker 
EEA1. Images were acquired and analysed for co-localization as described in 
Figure 1. Colocalization of glucagon and EEA1 (yellow puncta) are indicated 
by arrows in wt cells (A) or arrowheads in cells overexpressing Stmn2 (B). (D) 
Level of colocalization between glucagon and EEA1 was determined by 
Pearson’s correlation coefficient in wt cells, cells in which Stmn2 was 
overexpressed (OE) and in which Stmn2 was knocked down by siRNA (KD). 
Values were expressed as mean ± SEM (n=5) and compared by 1-Way 
ANOVA. *p<0.05; **<0.001 compared to wt. 
 
Figure 3-14. Silencing Stathmin-2 increased glucagon secretion and 
overexpression of stathmin-2 suppressed glucagon secretion in α-TC1-6 cells.  
Wild type (wt; control) and stathmin-2 depleted (Stmn2-KD)  α-TC1-6 cells 
were preincubated 2h in serum- free medium and then incubated with or 
without KCl (55 mM) for 15 min. (A) Glucagon secretion is significantly 
stimulated by KCl in wt cells, while in Stmn2-KD cells, basal glucagon 
secretion is increased and does not respond to KCl. * p<0.01 compared to basal 
secretion in wt cells. (B) Stmn2 mRNA levels are decreased by about 70% after 
siRNA-mediated depletion in α-TC1-6 cells. Values are means ± SEM (n=5), * 
p<0.01.  (C) siRNA-mediated silencing of Stmn2, shutdown expression of 
Stmn2.Western blot (WB) shows a faint band for Stmn2 after siRNA-mediated 
depletion of Stmn2 in α-TC1-6 cells. (D) Proglucagon mRNA levels are not 
affected by siRNA- mediated depletion of stathmin-2. (E) Glucagon secretion is 
inhibited by overexpression of Stmn2. α-TC1-6 cells were transfected with 
pcDNA3.1 (+) MAr-stmn2 construct or empty vector (control). Both basal 
(p<0.001) and K+-stimulated (p<0.001) (KCl stimulation; KCl Stim) glucagon 
secretion were inhibited by overexpression of Stmn2. Values are means ± SEM 
(n=4). Figure 3-15. Stathmin-2 modulates glucagon trafficking through early 
endosomes. After transfection with either empty vector (A), vector encoding 
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3.5 Discussion 
 
Glucagon secretion is governed by systemic, paracrine and intrinsic factors. Our work has 
focused on the regulation of glucagon secretion by proteins that associate with glucagon 
within α-cell secretory granules. To this end, we have shown that a neuronal protein, 
Stmn2, which we have previously identified as part of the glucagon interactome (25), can 
be localized to the secretory granules of α-TC1-6 cells. We validated this association in 
mouse pancreatic islets, and through silencing and overexpression experiments, we 
showed that Stmn2 can play a role in glucagon secretion by trafficking through the 
endosomal-lysosomal pathway. 
We have previously identified Stmn2 as part of a network of proteins that associate with 
glucagon within the secretory granules of α-TC1-6 cells (25). Data in the current study 
show that Stmn2 is localized to the secretory granule and Golgi compartments in α-TC1-
6 cells and mouse pancreatic α-cells, respectively. Stathmin-2 is part of a family of 
Figure 3-16. Overexpression of Stathmin-2 increases the presence of glucagon in 
late endosomes. After transfection with either empty vector (A), vector encoding 
Stmn2 (B) or siRNAs against Stmn2 (C), α-TC1-6 cells were immunostained 
using primary antibodies against glucagon and the late endosome-lysosome 
marker LAMP2A. Images were acquired and analysed for co-localization as 
described in Figure 1. (A) In wt cells, glucagon and LAMP2 show some co-
localization at the plasma membrane (arrowheads). (B) In cells overexpressing 
Stmn2, there is colocalization of glucagon and LAMP2A in the cell body 
(arrowheads) and at the plasma membrane (arrows). (C) In cells in which 
Stmn2 levels are depleted, there is almost no detectable co-localization of 
glucagon and LAMP2A. (D) Level of colocalization between glucagon and 
LAMP2A was determined by Pearson’s correlation coefficient in wt cells, cells 
in which Stmn2 was overexpressed (OE) and in which Stmn2 was knocked down 
by siRNA (KD). (E) Fluorescence intensity of Lamp2A in wt cells, and following 
overexpression (Stmn2-OE) or knockdown (Stmn2-KD) of Stmn2.  Values are 
expressed as mean ± SD and compared by 1-Way ANOVA. *p<0.01; **<0.001 
compared to wt. 
 
Figure 3-17. Stathmin-2 modulates glucagon t afficking thr ugh early
e dosomes. After tr sf ction w th either empty vector (A), vect r enc ding 
Stmn2 (B) or siRNAs against Stmn2 (C), α-TC1-6 ce ls were mmun stained 
using primary antibodies against glucagon and the ear y endosome marker 
EEA1. Images were acquired and analysed f r co-localization as described in 
Figure 1. Colocalization of glucagon and EEA1 (yellow puncta) a e indicated by 
arrows in wt cel s (A) or arrowheads in cells overexpressing Stmn2 (B). (D) 
Level of colocalization between glucagon and EEA1 was determined by 
Pearson’s correlation coefficient in wt cells, cells in which Stmn2 was 
overexpressed (OE) and in which Stmn2 was knocked down by siRNA (KD). 
Values were expressed as mean ± SEM (n=5) and compared by 1-Way ANOVA. 
*p<0.05; **<0.001 compared to wt.Figure 3-18. Overexpression of Stathmin-2 
increases the presence of glucagon in late endosomes. After transfection with 
either empty vector (A), vector encoding Stmn2 (B) or siRNAs against Stmn2 
(C), α-TC1-6 cells were immunostained using primary antibodies against 
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neuronal phosphoproteins that associates with intracellular membranes, notably the Golgi 
and vesicle transporters, in neurons (36). Although Stmn2 has been identified as a 
neuron-specific protein that functions in differentiation and development, its presence in 
pancreatic α-cells is not surprising, as several types of neuronal proteins, such as SNARE 
proteins, neurotransmitters and granins, are also expressed in endocrine cells (37–39). 
The expression of neuronal proteins such as Stmn2 in α-cells may be due to the absence 
of the transcriptional repressor RE-1 silencing transcription factor (REST) in mature 
endocrine cells (40, 41). The absence of Stmn2 in mouse pancreatic β-cells suggests that 
transcriptional silencing programs may operate in a cell-specific manner. 
Our results indicate that Stmn2 is localized largely to punctate structures within α-TC1-6 
cells, notably at the plasma membrane. Its colocalization with glucagon, ChgA and 
VAMP2 at the plasma membrane suggests that it is efficiently sorted from the Golgi to 
plasma membrane-associated secretory granules. Double immunogold labeling TEM 
confirmed the presence of glucagon and Stmn2 within secretory granules of α-cells in 
mouse pancreatic islets. The presence of Stmn2 within the dense core of the granule 
suggests that it is part of the soluble granule cargo along with glucagon. These results are 
consistent with our secretory granule proteomics, which predicted the presence of both 
glucagon and Stmn2 in secretory granules of α-TC1-6 cells (25). Our model also 
predicted that the complement of proteins within α-cell secretory granules differs in 
response to microenvironmental inputs, so it possible that Stmn2 is present only in a 
subpopulation of secretory granules. The trafficking of Stmn2 to secretory granules in α-
TC1-6 cells may occur through specific molecular domains within its sequence. The 
subcellular trafficking pattern of Stmn2 in neurons and neuroendocrine cells is 
determined by its N-terminal extension, which contains a Golgi localization domain and a 
membrane anchoring domain that contains two conserved Cys residues as sites for 
palmitoylation (36). This lipid modification occurs in the Golgi (42) and is sufficient and 
necessary for the association of Stmn2 with Golgi membranes, and its sorting to post-
Golgi vesicles (42, 43). While we have not directly shown that palmitoylation of these 
Cys residues is required for localization in secretory granules in α-TC1-6 cells, it is likely 
that this is a conserved sorting mechanism in neuroendocrine cells. 
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Consistent with its localization within secretory granules, the secretion of both glucagon 
and Stmn2 was significantly enhanced in response to 55 mM K+. Although there was a 
statistically significant response to KCl, α-TC1-6 cells as a rule do not show robust 
secretory responses to KCl, glucose or other secretagogues. In general, α-TC1-6 cells 
differ in their complement of transcriptional and epigenetic factors from mouse primary 
α-cells, which may explain the relatively blunted secretory response seen in this cell line 
(44). The reduced response to glucose in particular could be due to a low efficiency in 
coupling between the glycolytic and TCA pathways, as has been shown in pancreatic 
islets (45). We have not shown alterations in glucagon secretion in response to 
physiological secretagogues such as glucose, which could be a limitation for our current 
study. Nonetheless, we were able to show similar secretory behavior of glucagon and 
Stmn2 in isolated mouse islets, thus confirming their localization within the releasable 
pool of secretory granules in pancreatic α-cells. While Stmn2 is a membrane–bound 
protein, it is also present in normal human blood as determined by serum ELISA (46) and 
plasma proteomics (47) and therefore can be also secreted. There is some evidence of a 
lower molecular weight form of Stmn2 that may correspond to a cleaved, soluble form 
(43, 48). In our model, it may be that a portion of Stmn2 becomes cleaved within the 
secretory granule, thus becoming part of the soluble cargo that is released. 
By manipulating the expression of Stmn2, we were able to demonstrate a role in the 
control of glucagon secretion. There is precedence for a role for Stmn2 in the regulation 
of neuroendocrine secretion that has some interesting parallels with our results. While we 
showed that silencing of Stmn2 increased the constitutive secretion of glucagon, one 
study showed that silencing Stmn2 in PC12 cells decreased both basal and stimulated 
secretion of chromogranin A (27). In that study, it was shown that Stmn2 interacted 
directly with ChgA and its depletion reduced the buoyant density of chromaffin granules, 
suggesting that Stmn2 may participate in secretory granule formation, perhaps in 
partnership with ChgA (42) and thus promote regulated secretion. Although we could not 
demonstrate a direct interaction between Stmn2 and glucagon (data not shown), our 
results align with the idea that Stmn2 may be a sorting partner for glucagon, perhaps 
indirectly by interacting with other granule proteins such as ChgA or carboxypeptidase E 
(31), in the regulated secretory pathway of α-cells. 
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Overexpression of Stmn2 resulted in an almost complete shutdown of glucagon secretion 
and an increase in the localization of glucagon in early endosomes and lysosomes. These 
results may suggest induction of ER stress. However, overexpression of Stmn2 in 
Neuro2A cells, another cell line commonly used to examine regulated secretion, had the 
opposite effect and enhanced trafficking of post-Golgi carriers to the plasma membrane 
(49). There are only a few reports on how ER stress in α-cells is manifest; in one report, 
palmitate-induced ER stress in isolated rat α-cells resulted in an increase in glucagon 
secretion, not inhibition, even though the traditional markers of ER stress [DNA damage-
inducible transcript 3 protein (Ddit3; Chop), X-box-binding protein (1Xbp1s), 
Endoplasmic reticulum chaperone BiP (Hspa5; BiP)] were elevated (50). Another study 
showed that in vivo depletion of Xbp1, which plays a crucial role in the unfolded protein 
response, induced dysfunctional glucagon secretion that was not fully suppressed by 
insulin (51). Therefore, the suppression of glucagon secretion by Stmn2 overexpression is 
not consistent with the phenotype of ER stress in the α-cell. Instead, these results, 
together with the increased the presence of glucagon in the lysosomal compartment, 
suggest that Stmn2 overexpression causes alterations in glucagon trafficking independent 
of ER stress. 
We believe that the overexpression experiments suggest a mechanism whereby an 
increase in Stmn2 in the α-cell inhibits glucagon secretion by targeting glucagon 
secretory granules for degradation in the endosome-lysosome pathway, perhaps in a 
manner similar to that of insulin secretory granules in Type 2 diabetes (52). Very 
recently, it has been shown that insulin secretion can be inhibited by the targeting of 
proinsulin for lysosomal degradation by Rab7-interacting lysosomal protein (RILP) (53). 
The proposed mechanism of action was through interactions between RILP and an insulin 
secretory granule membrane protein, Rab26. It is tempting to speculate that Stmn2 could 
have a similar mechanism of action in α-cells. The increase in LAMP2A fluorescence 
intensity upon Stmn2 overexpression further suggests a role for Stmn2 in modulating 
glucagon secretion through increased lysosome function or biogenesis. We are currently 
investigating this mechanism of control of glucagon secretion in mouse islets. 
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In conclusion, we propose that Stmn2, a protein that is associated with glucagon in 
secretory granules, modulates glucagon secretion in α-cells by playing a role in its 
intracellular trafficking. Under conditions that decrease Stmn2 levels, constitutive 
secretion of glucagon is increased; and under conditions that increase levels of Stmn2, 
glucagon is targeted to the endolysosomal system, presumably for degradation (Figure 3-
7). Our findings, which are mainly based on the clonal α-cell line α-TC1-6, represent a 
potentially novel intracellular pathway for the control of glucagon secretion, and may 
lead to new mechanistic insights in the dysregulation of glucagon secretion in diabetes. 
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Figure 3-19. Proposed pathways by which stathmin-2 modulates glucagon 
secretion from α-TC1-6 cells. The model denotes status of glucagon secretion 
from α-TC1-6 cells in normal physiology or in the event of Stmn2- depletion 
or overexpression. Blue arrows indicate the normal trafficking of glucagon, 
together with Stmn2, to secretory granules, where they are stored until their 
release is triggered by a stimulus.  Stmn2 overexpression (red arrows) reduces 
the amount of glucagon available for secretion by diverting secretory granules 
to lysosomes. Stmn2 depletion (black arrows) reduces the trafficking of 
glucagon into secretory granules and promotes the constitutive release of 
glucagon.   
 
Figure 3-20. Glucagon is not localized in recycling endosome of α-cells. (A) 
Islets from non-diabetic mice (n=7) were immunostained with antibodies 
against glucagon (GCG), insulin (INS) and the recycling endosome marker, 
Rab11A. (B) Colocalization of glucagon and Rab11A. The Rab11A image was 
pseudocoloured red for visualization of colocalization in the merged image 
and inset. (C) Colocalization of insulin and Rab11A. The Rab11A image was 
pseudocoloured green for visualization of colocalization in the merged image 
and inset. (D) Islets from diabetic mice (n=7) were immunostained for 
glucagon, insulin and Rab11A. (E) Colocalization of glucagon and Rab11A. 
The Rab11A image was pseudocoloured red for visualization of colocalization 
i  the merged image a d inset. (F) Colocalization of insulin and Rab11A. The 
Rab11A image was pseudocoloured green for visualization of colocalization in 
the merged image and inset. (G)  Islets from non-diabetic mice were 
immunostained for glucagon, insulin and Rab11B. (H) Colocalization of 
glucagon and Rab11B. The Rab11B image was pseudocoloured red for 
visualization of colocalization in the merged image and inset. (I) 
Colocalization of insulin and Rab11B. The Rab11B image was pseudocoloured 
green for visualization of colocalization in the merged image and inset. (J) 
Islets from diabetic mice were immunostained for glucagon, insulin and 
Rab11B. (K) Colocalization of glucagon and Rab11B. The Rab11B image was 
pseudocoloured red for visualization of colocalization in the merged image 
and inset. (L) Colocalization of insulin and Rab11B. The Rab11B image was 
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4.1 Abstract 
Glucagon hypersecretion from the pancreatic α-cell is a characteristic sign of diabetes, 
which exacerbates fasting hyperglycemia. Thus, targeting glucagon secretion from α-cells 
may be a promising approach for combating hyperglucagonemia.  We have recently 
shown that stathmin-2 (Stmn2), a protein that associates with glucagon in secretory 
granules, can regulate glucagon secretion by directing glucagon towards the 
endolysosomal system in α-cells. Here, we examined how Stmn2-mediated glucagon 
trafficking is affected in diabetes, and if such a mechanism could explain the 
hyperglucagonemia of diabetes. To this end, C57BL/6 mice were rendered diabetic by 
streptozotocin (STZ; 30 mg/kg i.p. for 5 days). Using confocal immunofluorescence 
microscopy, we showed strong colocalization between Stmn2 and glucagon in intact 
islets of both non-diabetic (PCC 0.77±0.02) and diabetic mice (PCC 0.83±0.06). 
Immunogold labeling transmission electron microscopy showed the presence of both 
glucagon and Stmn2 in the dense core portion of secretory granules in both control and 
diabetic mice. The secretion of both glucagon and Stmn2 from either normal or diabetic 
islets was significantly enhanced by arginine. In contrast, cell glucagon content was 
significantly increased in diabetic islets, (p<0.001), but Stmn2 levels were reduced 
(p<0.01).  In islets from diabetic mice, there was an increase (p<0.001) in glucagon 
immunofluorescence that was concomitant with a decrease (p<0.01) in Stmn2 
immunofluorescence, and expression of Gcg mRNA increased ~4.5 times, while Stmn2 
mRNA levels did not change. We then followed changes in glucagon and Stmn2 
trafficking in diabetes. In islets from control mice, both glucagon and Stmn2 showed a 
moderate level of colocalization with the lysosomal marker, Lamp2A; however, this 
colocalization was dramatically reduced (p<0.001) in islets from diabetic mice. 
Interestingly, the co-localization of Stmn2 with the late endosome marker, Rab7, 
significantly (p<0.01) increased in islets from diabetic mice, while the co-localization 
between glucagon and Rab7 did not change. As well, there was a significant increase in 
the intensity of Rab7 in diabetic α-cells compared to control. Retrograde shuttling of 
glucagon towards early endosome or recycling endosome was not prominent in α-cells.  
Thus, we propose that the hyperglucagonemia of diabetes may be partially explained by a 
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decrease in the lysosomal trafficking of glucagon and Stmn2 associated with a relative 
decrease in cellular Stmn2 and re-routing of Stmn2 to late endosomes.  
 
Keywords: diabetes, hyperglucagonemia, glucagon secretion, stathmin-2, lysosome, 
endosome 
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4.2 Introduction 
In diabetes, glucagon secretion from the pancreatic α-cell becomes abnormally up-
regulated, resulting in hyperglucagonemia. This paradoxical glucagon hypersecretion 
from α-cells then causes exacerbation of hyperglycemia (1–3). It has been suggested that, 
in order to fully control hyperglycemia in diabetes, glucagon secretion should be 
suppressed. Therefore, the mechanisms and pathways that underlie the abnormal 
secretion of glucagon must be elucidated, so that potential targets for suppressive therapy 
can be identified. 
Studies have shown that glucagon secretion can be controlled by targeting mediators of 
intracellular signaling and exocytosis within the α-cell.  Agonists of the glucagon-like 
peptide receptor (GLP-1R)  inhibit glucagon secretion by directly acting on α-cells, or 
indirectly through releasing insulin, Zn2+, and GABA from β-cells, or by releasing 
somatostatin from δ-cells (4). GABA receptor agonists also directly inhibit glucagon 
secretion through binding with GABAA receptor on α-cells, increasing  Cl
- influx, and 
hyperpolarization of plasma membrane (5,6). Antagonists of the glucose-dependent 
insulinotropic peptide receptor (GIP-R) directly suppress the glucagonotropic effect of 
GIP on α-cells (7). Insulin itself suppresses glucagon secretion through binding its 
receptor on α-cells (8,9) or indirectly by increasing secretion of somatostatin from δ-cells  
(10). Amylin inhibits  amino acid-dependent exaggerated glucagon secretion in patients 
with diabetes (11,12). Blockers of KATP channels inactivate ion channels, and reduce α-
cell electrical activity, which result in suppression of glucagon secretion (13–15). n 
addition to blocking the effects of glucagon on hepatic glucose mobilization, anti- 
glucagon receptor antibodies may also block  the autocrine effect of glucagon on 
glucagon secretion from α-cells (16,17).  
All of the above mechanisms eventually converge on the α-cell secretory pathway by 
which glucagon is stored in and secreted from secretory granules. We hypothesize that 
elucidating the intracellular mechanisms of glucagon trafficking through the α-cell 
secretory pathway could also yield clues on possible mechanisms of the regulation of 
glucagon secretion. Using α-TC1-6 cells, we have shown that components of the 
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regulated secretory pathway are up-regulated after chronic exposure to high levels of 
glucose (18) and proposed that proteins that associated with glucagon within secretory 
granules (glucagon interactome) play a role in the regulation of glucagon secretion (19). 
We showed that the interactome was responsive to glucose, GABA and insulin, known 
modulators of glucagon secretion. In particular, treatment with insulin, which is a potent 
inhibitor of glucagon secretion at euglycemic and hypoglycemic conditions (8), appeared 
to recruit stathmin-2 (Stmn2 or SCG10) to the interactome, thus potentially identifying 
another inhibitor of glucagon secretion. In a subsequent study, we showed that Stmn2 is 
co-secreted in a regulated manner with glucagon, and when over-expressed, suppressed 
glucagon secretion by increasing its trafficking through the endolysosomal pathway in α-
TC1-6-cells(20). 
There is one report on the reuptake of glucagon by α-cells after secretion and  trafficking 
to the endolysosomal system for degradation (21). Our previous study was the first to 
show that the endolysosomal system may figure prominently in the intracellular 
trafficking of glucagon as it is directed through the regulated secretory pathway(20). 
Interestingly, parallel findings in β-cells showed that there is a shuttling of insulin from 
secretory pathway towards the endolysosomal system for degradation, which may be an 
underlying mechanism for β-cell failure in  type 2 diabetes (22). Therefore, the 
endolysosomal trafficking pathway may be a novel pathway for the dysregulation of both 
insulin and glucagon secretion in diabetes. We hypothesize that a disruption in the 
Stmn2-mediated trafficking of glucagon through the endolysosomal pathway might be a 
possible mechanism by which glucagon secretion becomes dysregulated in diabetes, 
resulting in glucagon hypersecretion and hyperglucagonemia.  
In the present study, we show that there is a discordance in the levels of glucagon and 
Stmn2 in diabetic mouse islets. This discordance is associated with increased glucagon 
secretion, cell content and mRNA levels, and an inhibition of the trafficking of both 
glucagon and Stmn2 to the lysosome. There appears to be re-routing of Stmn2 to late 
endosomes which accompanies the increased secretion of glucagon.  Therefore, we 
propose that the loss of the α-cell lysosomal trafficking pathway in diabetes could 
contribute to glucagon hypersecretion and hyperglucagonemia. 
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4.3 Materials and methods 
4.3.1 Animals 
 C57BL/6 male mice (8 weeks old) were purchased from the Jackson Laboratory (Bar 
Harbor, Maine, United States). Mice were kept at 12h light/12h dark cycle and had free 
access to water and regular chow diet. All mice were treated and euthanized in 
accordance with the guidelines set out by the Animal Use Subcommittee of the Canadian 
Council on Animal Care at Western University based on the approved Animal Use 
Protocol AUP 2012-020. Mice were fasted 5h before blood collection or euthanasia.  
Induction of diabetes: Streptozotocin (STZ; Cat# S0130, Sigma) was dissolved in 
freshly prepared 0.1 M sodium citrate buffer, pH 4.5, and immediately used. Mice (n=18) 
were intraperitoneally injected with 30 mg/kg STZ for 5 consecutive days and used for 
microscopic (total n=7; 7 out of 7 for immunofluorescent microscopy; 4 out of 7 for 
transmission electron microscopy), islet secretion (n=7) and gene expression (n=4) 
studies. Three days after the last STZ injection, blood was sampled by tail vein lancing 
and glucose levels were determined with the OneTouch Ultra glucometer. Values above 
14 mmol/L were considered an indicator of diabetes onset (https://www.jax.org). Control 
mice (n=18) were injected with citrate buffer alone at the same regimen. Animals were 
euthanized 14 days after the last STZ injection by cervical dislocation under deep 
isoflurane anesthesia. 
Blood collection: Prior to cervical dislocation and under isoflurane induced anesthesia, 
blood (1 mL) was collected by cardiac puncture into microcentrifuge tubes containing 15 
µL of anticoagulant (15% Na2-EDTA) and 15 µL of freshly prepared enzyme inhibitor 
cocktail (Cat# 4693159001 Millipore Sigma). Samples were kept on ice and then 
centrifuged at 1500 g for 15 min at 4°C. Plasma was collected and kept at -80°C until 
analysis.  
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4.3.2 Preparation of pancreas tissue sections for confocal 
immunofluorescence  
Microscopy: Immediately after euthanasia, pancreata of STZ-treated (n=7) and vehicle-
treated (n=7) mice were excised, fixed in 10% buffered formalin for 3 days and treated 
with 70% ethanol for one day before paraffin embedding. Paraffin-embedded tissue 
blocks were longitudinally sectioned in 5 µm slices and fixed on glass microscope slides. 
The tissue samples were de-paraffinized by graded washes using xylene, ethanol and 
PBS. Antigen retrieval was conducted in sodium citrate buffer (10 mM sodium citrate, 
0.05% Tween 20, pH 6) with 20 min steam heating of slides in a steam cooker. After 
permeabilization with 0.1% Triton X-100 in PBS, Background Sniper (Cat# BS966H, 
Biocare Medical) was used to block non-specific background staining. Samples were 
incubated with primary antibodies against glucagon (Cat # ab10988 or Cat# ab92517, 
Abcam; 1:1000), Stmn2 (Cat # ab115513, Abcam; 1:250 or Cat# 720178, Thermo Fisher 
Scientific; 1:500), insulin (Cat# ab7842, Abcam; 1:500  or Cat# I2018, Sigma; 1:1000), 
late endosome marker, Rab7 (Cat# ab126712, Abcam; 1:500), lysosomal marker, 
Lamp2A (Cat# ab18528, Abcam; 1:1000), or recycling endosome markers Rab11A (Cat# 
ab180778, Abcam; 1:100) and Rab11B (Cat# ab 228954, Abcam;1:100). The 
corresponding secondary antibodies used were goat anti-mouse IgG Alexa Fluor 488 
(Cat# A-11001, Molecular Probes; 1:500), donkey anti-goat IgG Alexa Fluor 555 (Cat# 
ab150130, Abcam; 1:500), goat anti-guinea pig IgG Alexa Fluor 647 (Cat# A21450, 
Invitrogen; 1:500), donkey anti-rabbit 488 (Cat#ab150073, Abcam; 1:500), donkey anti-
mouse 555 (Cat# A-31570, Molecular Probes; 1:500) and goat anti-rabbit IgG Alexa 
Fluor 594 (Cat# A 11037, Invitrogen; 1:500). Nucleus counter-staining was done by 
DAPI and coverslips were mounted using Prolong Antifade mountant (Cat# P36982, 
Thermo Fisher Scientific). As a background control for Stmn2, islet staining for Stmn2 
was done using only the secondary antibody.  
Image acquisition: Images were acquired through Nikon A1R Confocal microscope with 
a ×60 NA plan-Apochromat oil differential interference contrast objective and NIS-
Elements software (Nikon, Mississauga, Canada). Acquisition of high-resolution images 
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was done by selecting Nyquist XY scan area, 1024×1024-pixel size scanning of the 
selected area and 2D- Deconvolution of the captured images.  
Image Analysis: Three adjacent longitudinal slices of pancreas were placed on each 
glass slide. In total, 10 slides were prepared from each pancreas. Image analysis was 
performed by NIS-Elements software (Nikon, Mississauga, Canada). To calculate 
colocalization values of endosomal and lysosomal markers with glucagon or Stmn2 
within the same islet, channels were pseudocolored for Lamp2A, Rab7, Rab11A or 
Rab11B. Colocalization of pixels from each pseudocolored image was used to calculate 
Pearson’s correlation coefficient (PCC), as we have done previously (23)(19). Regions of 
interest (ROIs) were manually drawn around each islet and then defined PCC values for 
colocalization between Stmn2 and target markers (glucagon, insulin, Lamp2A, Rab7, 
Rab11A, Rab11B) were calculated using the colocalization algorithm of NIS-Elements 
software. To show the relationships between expression levels of Stmn2 and the target 
markers (glucagon, insulin, Lamp2A, Rab7, Rab11A, Rab11B) in α or β- cells of the 
pancreatic islets, binary images were generated using M-Threshold algorithm of NIS-
Elements software. ROIs were manually drawn around each binary arranged image of the 
islet and the fluorescence intensity of each marker was calculated. Levels of fluorescence 
intensities were normalized by dividing by the intensity of DAPI within each ROI. These 
values were used for linear regression analysis between Stmn2 and the target markers.  
4.3.3 Double immunogold labeling transmission electron 
microscopy 
 Double immunogold labeling TEM was done based on the protocol of Aida et al (2014) 
with some modifications (24) as we have recently used (20). Briefly, in both non-diabetic 
(n=4) and diabetic (n=4) mice, pancreas was dissected, and a piece of pancreas in its long 
axis was cut, and immediately placed into McDowell Trump’s fixative (Cat# 18030-10, 
Electron Microscopy Sciences) for 1h. Then, after washing with PBS, samples were cut 
into smaller pieces, and dehydrated in the increasing concentrations of ethanol (10%, 
20%, 30%, 50%, 70%, 90%, 100% and 100%) at 30 min per concentration. Samples were 
sequentially embedded in LR White Resin (Cat# 14381, Electron Microscopy Sciences) 
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as follows: ethanol-LR White mixture A (3:1, v/v; 2h), ethanol-LR White mixture B (1:1, 
v/v; 8h), ethanol-LR White mixture C (1:3, v/v; 12h), and 3 × 12h in pure LR White. 
Samples were then placed into a beem capsule, filled with pure LR White and incubated 
at 50°C for 24h. Semi-thin sections (500 nm) were cut from embedded samples for 
Toluidin blue staining (1% Toluidin blue for 2 min). After defining the position of the 
islets within the pancreatic tissue, ultra-thin section slices (70 nm) were prepared using a 
diamond microtome. The sections were mounted on formvar-carbon coated nickel grid 
(300 meshes; Cat# FCF300-NI, Electron Microscopy Sciences). Afterwards, slices were 
washed with Tris-buffered saline, 0.1% Tween 20 (TBS-T) and incubated in blocking 
buffer (2% BSA in PBS plus 0.05% Tween 20) for 30 min at room temperature. Slices 
were incubated with primary antibodies (1:10 in blocking buffer) against glucagon (Cat# 
ab10988; Abcam) and Stmn2 (Cat# ab115513; Abcam) at 4°C overnight. After washing 
with TBS-T, slices were incubated with gold-conjugated secondary antibodies of donkey 
anti-goat (18 nm; cat# ab105270, Abcam; 1:50) and donkey anti-mouse (10nm; cat# 
ab39593, Abcam; 1:50) for 2h at room temperature. After washing with TBS-T and 
staining with Uranyless (Cat# 22409, Electron Microscopy Sciences), TEM was 
conducted at the Biotron Experimental Research Center, Western University, London, 
ON, Canada.  
4.3.4 Proglucagon and stathmin-2 gene expression  
Handpicked islets (~180) from control (n=4) and diabetic (n=4) mice were placed into 1 
mL Trizol (Cat# 15596018, Ambion) and processed for RNA extraction, as described 
previously (25,26) . Islets were homogenized by being passed 10 times through a 25-
gauge needle, and again through a 27-gauge needle. After centrifugation at 10000×g for 5 
min at 4°C, the supernatant was mixed with chloroform, vortexed for 30 seconds and 
placed on ice for 2 min. After centrifugation at 12000×g for 15 min at 4°C, the aqueous 
layer was collected and mixed with 0.5 volumes of high salt solution (0.8 M Na-citrate 
containing 1.2 M NaCl).  Isopropanol (0.5 volumes) was added, and the samples were 
mixed, incubated for 10 min at room temperature and centrifuged at 12000×g for 30 min 
at 4°C. The pellet was dissolved in 70% ethanol and RNA was purified by RNeasy kit 
(Cat # 74104, Qiagen) according to the supplier’s protocol. cDNA synthesis was 
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performed using the SuperScript III First Strand Synthesis Supermix for qRT-PCR (Cat # 
11752050, Thermo Fisher Scientific), according to the manufacturer’s protocol. Real-
time PCR was performed using Quant Studio Design and Analysis Real-Time PCR 
Detection System in conjunction with the Maxima SYBR Green qPCR Master Mix (Cat 
# K0221, Thermo Fisher Scientific) using specific primers for Stmn2: forward, 5'-
GCAATGGCCTACAAGGAAAA-3'; reverse, 5'-GGTGGCTTCAAGATCAGCTC-3'; 
Gcg: forward, 5'-AACAACATTGCCAAACGTCA-3'; reverse, 5'-
TGGTGCTCATCTCGTCAGAG-3' and 18S rRNA: forward, 5'-
ACGATGCCGACTGGCGATGC-3'; reverse, 5'-CCCACTCCTGGTGGTGCCCT-3'. 
Gene expression levels were normalized to that of 18S rRNA. Gene expression in the 
diabetic condition was normalized to the corresponding control group and expressed as 
percent of matched control. Statistical analysis was performed using t-test at α = 0.05. 
4.3.5 Primary islet culture 
 Islets were isolated and cultured as we have done previously (20) using a modified 
protocol from Li et al. (27). Non-diabetic (n=7) or diabetic mice (n=7) were euthanized. 
The abdominal cavity was opened and 3 mL of 1.87 mg/mL collagenase V (Cat# C9263, 
Sigma;) in Hanks' Balanced Salt Solution was injected into the common bile duct. The 
pancreas was then removed, placed into a Falcon tube containing 2 mL of the ice-cold 
collagenase V solution and incubated for 12 min at 37°C with occasional shaking. 
Digestion was stopped by adding 1mM CaCl2 and the cell suspension was washed twice in 
the CaCl2 solution. Islets were collected into a sterile petri dish using a 70 µm cell strainer 
with RPMI1640 containing 11 mM glucose plus 20 mM glutamine, 10% FBS and 
penicillin (110U/mL) and streptomycin (100 µg/mL). A total of 180 islets were handpicked 
under a stereomicroscope and incubated for 2h at 37°C. The medium was then changed to 
RPMI1640 containing 11 mM glucose plus 10% FBS and penicillin (110U/mL) and 
streptomycin (100 µg/mL) and islets were cultured overnight at 37°C. 
Glucagon secretion experiments: Glucagon secretion from islets was measured based on 
the protocol by Suckow et al (2014). Briefly, islets were washed three times using Krebs-
Ringer bicarbonate (KRB) buffer (135 mM NaCl, 3.6 mM KCl, 5 mM NaHCO3, 0.5 mM 
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NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 mM HEPES; pH 7.4) containing 11 mM 
glucose, and then pre-incubated in this KRB for 1h. Islets were then incubated in KRB 
containing 1mM glucose in the presence or absence of arginine (25 mM) for 20 min. Media 
were collected into microcentrifuge tubes containing enzyme inhibitors (PMSF, 45 mM; 
Aprotinin, 5 µg/mL and sodium orthovanadate, 1mM). Samples were centrifuged at 14000 
× g for 5 min at 4°C and the supernatant was collected and kept at -80°C until analysis. 
Islets were lysed in lysis buffer (0.1 M citric acid, 1% Triton X-100 plus enzyme inhibitors) 
and homogenized by passing 10 times through a 25-gauge needle, and again through a 27-
gauge needle. The extracts were centrifuged at 14000×g for 15 min at 4°C and the 
supernatant was collected and kept at -80°C until analysis (28).    
Measurement of glucagon and stathmin-2: Glucagon levels in the media and islet 
extracts were determined by ELISA (Cat # EHGCG, Thermo Fisher Scientific) according 
to the manufacturer’s instructions. Stmn2 levels in the media and islet extracts were 
measured using stathmin-2 ELISA kit (Cat# MBS7223765, MyBioSource) according to 
the supplier’s instruction. For each measurement, the values were compared between 
groups by t-test and among groups by one-way ANOVA (α = 0.05). Total cellular protein 
was determined using BCA assay and used to normalize cellular glucagon or Stmn2 per 
mg of cell protein. Then, alterations in values were expressed as percent changes 
compared to the baseline control. To this end, the Arg-stimulated secretion of glucagon 
or Stmn2 was normalized to the baseline level of glucagon and Stmn2, respectively, and 
expressed as relative fold changes.  
Statistical analyses: Comparison of values among groups was done by one-way 
ANOVA (Bonferroni post-hoc test), and between groups by t-test using Sigma Stat 3.5 
software at α=0.05. For colocalization analysis of images, Pearson correlation coefficient 
values were extracted using NIS-Elements software and then values were compared 
between groups by t-test (α=0.05). 
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4.4 Results 
4.4.1 Induction of diabetes in C57BL/6 mice 
Measuring blood glucose levels following STZ injection showed fasting hyperglycemia 
(>14 mmol/L), indicating onset of diabetes (Figure 4- 1A). Plasma levels of glucagon 
were significantly (p<0.001) higher and plasma levels of insulin were significantly 
reduced (p<0.001) in STZ-treated mice compared to the control group (Figure 4- 1B, C), 
and there was a significantly (p<0.001) higher glucagon: insulin ratio in STZ-treated 
mice compared to the control (Figure 4- 1D). These findings indicate development of a 
diabetic metabolic and hormonal profile following STZ administration. 
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4.4.2 Glucagon and Stmn2 co-localize in islets of diabetic and 
non-diabetic mice   
Confocal immunofluorescence microscopy studies on islets of non-diabetic mice (Figure 
4- 2A) showed colocalization between glucagon and Stmn2 (Figure 4- 2B) but not 
between insulin and Stmn2 (Figure 4- 2C). This pattern of co-localization was conserved 
in islets from diabetic mice (Figures 4- 2D-F). Quantification and analysis (Figure 4- 2G) 
revealed strong colocalization between glucagon and Stmn2 in α-cells of both control 
(PCC  0.77± 0.02) and STZ-induced diabetic mice (PCC 0.83 ± 0.06). In contrast, there 
was almost no colocalization between insulin and Stmn2 in both control (PCC 0.04±0.03) 
and STZ-induced diabetic mice (PCC  0.03±0.06).  
 
 
 
 
 
 
Figure 4-1. Streptozotocin (STZ) induced diabetes in C57BL/6 mice. (A) 
Plasma glucose, (B) plasma insulin, (C) plasma glucagon, and (D) 
glucagon: insulin ratio per µm2 of islet in STZ-induced diabetic mice. 
Values (mean± SD) were compared between diabetic (n=7) and control 
(n=7) mice by t-test. *p<0.001. 
 
Figure 4-2. Predicted proteins in the first shell of interacting proteins 
with glucagon within the glucagon interactome. α-TC1-6 cells were 
cultured (A) in  25 mM glucose containing medium (HGM); or 
supplemented with GABA, insulin (INS) or GABA+INS.  (B) α-TC1-6 
cells were cultured (A) in 5.5 mM glucose containing medium (LGM); or 
supplemented with GABA, insulin (INS) or GABA+INS.Figure 4-3. 
Streptozotocin (STZ) induced diabetes in C57BL/6 mice. (A) Plasma 
glucose, (B) plasma insulin, (C) plasma glucagon, and (D) glucagon: 
insulin ratio per µm2 of islet in STZ-induced diabetic mice. Values 
(mean± SD) were compared between diabetic (n=7) and control (n=7) 
mice by t-test. *p<0.001. 
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4.4.3 STZ-induced diabetes increases glucagon levels and 
reduces Stmn2 levels in α-cells  
Analysis of fluorescence intensities revealed increased cellular levels of glucagon 
(p<0.001) and reduced levels of Stmn2 (p<0.01) in islets of STZ-induced diabetic mice 
(Figure 4- 3A). As a consequence, the ratio of glucagon: Stmn2 in α-cells of STZ-
induced diabetic mice significantly increased (p<0.01) compared to the non-diabetic 
controls (Figure 4- 3B). Linear regression analysis of  binary sum intensities showed a 
strong positive correlation between expression of Stmn2 and glucagon in α-cells of non-
diabetic mice (R2 = 0.9, p<0.001) that was disrupted in STZ-induced diabetic mice (R2 = 
0.07, p >0.05) (Figure 4- 3C).  
 
 
Figure 4-4. Stathmin-2 colocalizes with glucagon but not insulin in both non-
diabetic and STZ-induced diabetic mice.  (A) Islets of non-diabetic  mice (n=7) 
were immunostained for glucagon (GCG), insulin (INS) and stathmin-2 
(Stmn2); (B) after removing INS channel, colocalization was determined 
between GCG and Stmn2; (C) after removing GCG channel, and 
pseudocoloring of INS channel to green,  colocalization was determined 
between Stmn2 and INS. (D) Islets of diabetic mice (n=7) were immunostained 
for  GCG, INS and Stmn2; (E) after removing INS channel, colocalization was 
determined between GCG and Stmn2; (F) after removing GCG channel and 
pseudocoloring of INS channel to green, colocalization was determined between 
Stmn2 and INS.  In each panel, marked area by square was magnified to show 
a typical individual cell. (G) Correlation between GCG and Stmn2 or INS and 
Stmn2 was determined by Pearson’s correlation coefficient (PCC) using NIS-
Elements software. Images were acquired by Nikon A1R confocal microscope. 
 
Figure 4-5. Streptozotocin (STZ) induced diabetes in C57BL/6 mice. (A) 
Plasma glucose, (B) plasma insulin, (C) plasma glucagon, and (D) glucagon: 
insulin ratio per µm2 of islet in STZ-induced diabetic mice. Values (mean± SD) 
were compared between diabetic (n=7) and control (n=7) mice by t-test. 
*p<0.001.Figure 4-6. Stathmin-2 colocalizes with glucagon but not insulin in 
both non-diabetic and STZ-induced diabetic mice.  (A) Islets of non-diabetic  
mice (n=7) were immunostained for glucagon (GCG), insulin (INS) and 
stathmin-2 (Stmn2); (B) after removing INS channel, colocalization was 
determined between GCG and Stmn2; (C) after removing GCG channel, and 
pseudocoloring of INS channel to green,  colocalization was determined 
between Stmn2 and INS. (D) Islets of diabetic mice (n=7) were immunostained 
for  GCG, INS and Stmn2; (E) after removing INS channel, colocalization was 
determined between GCG and Stmn2; (F) after removing GCG channel and 
pseudocoloring of INS channel to green, colocalization was determined between 
Stmn2 and INS.  In each panel, marked area by square was magnified to show 
a typical individual cell. (G) Correlation between GCG and Stmn2 or INS and 
Stmn2 was determined by Pearson’s correlation coefficient (PCC) using NIS-
Elements software. Images were acquired by Nikon A1R confocal microscope. 
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This increase in cellular glucagon was paralleled by a ~ 4.5 times increase in the levels of 
Gcg mRNA, while there was no effect on Stmn2 mRNA levels (Figure 4- 4). 
 
 
 
 
 
 
 
 
 
 
Figure 4-7. Imbalanced ratios of stathmin-2 and glucagon in islets of STZ-
induced diabetic mice. Islets were immunostained for stathmin-2 (Stmn2) and 
glucagon and images were acquired by A1R confocal microscope. (A) 
Expression of glucagon and Stmn2 were determined in islets of non-diabetic 
and diabetic mice by  immunofluorescence intensity analysis . (B) Ratios of 
glucagon: Stmn2 levels were calculated per µm2 of islets in non-diabetic and 
diabetic mice. (C) Linear regression analysis on binary image intensities of the 
Stmn2 and glucagon. Filled circles and open squares demonstrate values in 
non-diabetic and diabetic islets, respectively. 
 
Figure 4-8. Stathmin-2 colocalizes with glucagon but not insulin in both non-
diabetic and STZ-induced diabetic mice.  (A) Islets of non-diabetic  mice (n=7) 
were immunostained for glucagon (GCG), insulin (INS) and stathmin-2 
(Stmn2); (B) after removing INS channel, colocalization was determined 
between GCG and Stmn2; (C) after removing GCG channel, and 
pseudocoloring of INS channel to green,  colocalization was determined 
between Stmn2 and INS. (D) Islets of diabetic mice (n=7) were immunostained 
for  GCG, INS and Stmn2; (E) after removing INS channel, colocalization was 
determined between GCG and Stmn2; (F) after removing GCG channel and 
pseudocoloring of INS channel to green, colocalization was determined between 
Stmn2 and INS.  In each panel, marked area by square was magnified to show 
a typical individual cell. (G) Correlation between GCG and Stmn2 or INS and 
Stmn2 was determined by Pearson’s correlation coefficient (PCC) using NIS-
Elements software. Images were acquired by Nikon A1R confocal 
microscope.Figure 4-9. Imbalanced ratios of stathmin-2 and glucagon in islets 
of STZ-induced diabetic mice. Islets were immunostained for stathmin-2 
(Stmn2) and glucagon and images were acquired by A1R confocal microscope. 
(A) Expression of glucagon and Stmn2 were determined in islets of non-diabetic 
and diabetic mice by  immunofluorescence intensity analysis . (B) Ratios of 
glucagon: Stmn2 levels were calculated per µm2 of islets in non-diabetic and 
diabetic mice. (C) Linear regression analysis on binary image intensities of the 
Stmn2 and glucagon. Filled circles and open squares demonstrate values in 
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4.4.4 Both glucagon and Stmn2 are localized within secretory 
granules of α-cells 
 Double immunogold-labeling transmission electron microscopy revealed co-localization 
of glucagon and Stmn2 within the secretory granules of mouse islet α-cells. Glucagon (10 
nm particles; white arrows) and Stmn2 (18 nm particles; black arrows) were co-localized 
within the dense core of secretory granules in both non-diabetic (Figure 4- 5A) and 
diabetic (Figure 4- 5B) mice.  
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Figure 4-10. Expression of Stmn2 and Gcg mRNA levels were determined in 
islets of non-diabetic (n=4) and diabetic (n=4) mice by RT-qPCR. Gene 
expression levels were normalized to that of 18S rRNA. For each gene 
alterations in diabetic condition was normalized by the corresponding 
control group and expressed as matched control percent. Comparison 
between control and diabetic ones was done by t-test, α=0.05. 
 
Figure 4-11. Imbalanced ratios of stathmin-2 and glucagon in islets of STZ-
induced diabetic mice. Islets were immunostained for stathmin-2 (Stmn2) 
and glucag n and images were acquir d by A1R c nf cal microscope. (A) 
Expression of glucagon and Stmn2 were det rmined in i l s of non-diabetic 
and diabetic mice by  immunofluorescence intensity an lysis . (B) Ratios of 
glucagon: Stmn2 lev ls were c lc lated per µm2 of islets in non-diabetic and 
diabetic mice. (C  Lin ar regression analysis on binary image intensities of 
the Stmn2 and glucagon. Filled circles and open squares demonstrate values 
in non-diabetic and diabetic islets, respectively.Figure 4-12. Expression of 
Stmn2 and Gcg mRNA levels were determined in islets of non-diabetic (n=4) 
and diabetic (n=4) mice by RT-qPCR. Gene expression levels were 
normalized to that of 18S rRNA. For each gene alterations in diabetic 
condition was normalized by the corresponding control group and expressed 
as matched control percent. Comparison between control and diabetic ones 
was done by t-test, α=0.05. 
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Figure 4-13. The presence of stathmin-2 and glucagon within secretory 
granules of α-cells. (A) Double immunogold labelling transmission electron 
microscopy of islets in non-diabetic and (B) STZ-induced diabetic mice  was 
done by antibody against glucagon (10 nm gold, white arrows in the magnified 
section) and stathmin-2 (18 nm gold, black arrows in the magnified section). 
The low magnification images (19000×, scale bar = 1 μm) show the 
ultrastructure of one α-cell. N (nucleus); ER (endoplasmic reticulum); SG 
(secretory granule); PM (plasma membrane). The magnified images (21000×, 
scale bar = 0.6 μm) highlight the presence of immunogold labels within a single 
secretory granule. 
 
Figure 4-14. Expression of Stmn2 and Gcg mRNA levels were determined in 
islets of non-diabetic (n=4) and diabetic (n=4) mice by RT-qPCR. Gene 
expression levels were normalized to that of 18S rRNA. For each gene 
alterations in diabetic condition was normalized by the corresponding control 
group and expressed as matched control percent. Comparison between control 
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4.4.5 Arginine stimulates parallel increases in glucagon and 
Stmn2 secretion  
In line with our recent findings (20),  there was an increase in the secretion of both 
glucagon  (~2.9 times) and Stmn2 (~2.3 times) from isolated islets in response to 25 mM 
Arg. In islets from diabetic mice, the glucagon secretory response was exaggerated, with 
increased basal and Arg-stimulated secretion (Figure 4- 6A). There was also a small but 
significant increase in basal Stmn2 secretion and a significant increase in response to Arg 
in diabetic islets (Figure 4- 6B). There was a concomitant reduction in cell glucagon 
content of non-diabetic islets in response to Arg (Figure 4- 6A). In contrast, cell glucagon 
content of diabetic islets was elevated in the absence of Arg, and remained elevated after 
Arg stimulation (Figure 4- 6A), consistent with the diabetic phenotype of glucagon 
production. In parallel with the pattern of cell glucagon content in non-diabetic islets, cell 
Stmn2 content also decreased in response to Arg (Figure 4- 6B). Interestingly, cell Stmn2 
content was reduced in islets of diabetic mice, and further reduced after Arg stimulation 
(Figure 4- 6B), thereby showing a different profile from that of glucagon in diabetes.    
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4.4.6 Trafficking of glucagon and Stmn2 to the lysosome is 
inhibited in islets from STZ-induced diabetic mice:  
Based on our recent study that indicated a role for Stmn2 in regulating glucagon secretion 
by trafficking through the endolysosomal compartment in α-TC1-6 cells [187], we were 
interested to determine if the diabetes-induced alterations in the levels of Stmn2 and 
glucagon in mouse islets were due to changes in the pattern of intracellular trafficking 
through the endolysosomal system. We therefore determined the presence of glucagon 
and Stmn2 in all four compartments of the endolysosomal pathway (the recycling 
endosome, early endosome, late endosome and lysosome) in normal and diabetic mouse 
islets.  
Using confocal immunofluorescence microscopy (Figure 4- 7A), we identified individual 
α-cells in which Lamp2A colocalized with either glucagon (Figure 4- 7B) or Stmn2 
Figure 4-16. Parallel alterations in secretion of glucagon and Stmn2 from α-
cells in both non-diabetic and diabetic mice.  (A) Secretion of glucagon and 
islet glucagon content in isolated islets of non-diabetic (C; n=7) and diabetic 
mice (STZ; n=7) at the presence or absence of Arginine (25 mM, 20 min). 
Secretion values were normalized by baseline control secretion and expressed 
as fold changes. Glucagon contents were normalized by baseline control and 
expressed as percent changes. (B) Secretion of Stmn2 and islet Stmn2 content 
in isolated islets of non-diabetic (C; n=7) and diabetic mice (STZ; n=7) at the 
presence or absence of Arginine (25 mM, 20 min). Secretion values were 
normalized by baseline secretion in control and expressed as fold changes. 
Glucagon contents were normalized by baseline content in control and 
expressed as percent changes.  Values were expressed as mean ± SEM and 
compared among groups by 1-Way ANOVA at α=0.05. *p<0.05; **p<0.01; 
***p<0.001. 
 
Figure 4-17. The presence of stathmin-2 and glucagon within secretory 
granules of α-cells. (A) Double immunogold labelling transmission electron 
microscopy of islets in non-diabetic and (B) STZ-induced diabetic mice  was 
done by antibody against glucagon (10 nm gold, white arrows in the magnified 
section) and stathmin-2 (18 nm gold, black arrows in the magnified section). 
The low magnification images (25000×, scale bar = 1 μm) show the 
ultrastructure of one α-cell. N (nucleus); ER (endoplasmic reticulum); SG 
(secretory granule); PM (plasma membrane). The magnified images (41000×, 
scale bar = 0.6 μm) highlight the presence of immunogold labels within a single 
secretory granule.Figure 4-18. Parallel alterations in secretion of glucagon and 
Stmn2 from α-cells in both non-diabetic and diabetic mice.  (A) Secretion of 
lucagon and islet glucago  ontent in isolated islets of non-diabetic (C; n=7) 
and diabetic ice (STZ; n=7) at the presence or absence of Arginine (25 mM, 
20 min). Secretion values were normalized by baseline control secretion and 
expressed as fold changes. Glucagon contents were normalized by baseline 
control and expressed as percent changes. (B) Secretion of Stmn2 and islet 
Stmn2 content in isolated islets of non-diabetic (C; n=7) and diabetic mice 
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(Figure 4- 7C) in normal mouse islets. In contrast, Lamp2A did not colocalize with either 
glucagon or Stmn2 in individual α-cells in islets of STZ-induced diabetic mice (Figures  
4- 7D-F). Quantification and analysis of colocalization showed a moderate level of 
colocalization between Lamp2A and glucagon (PCC  0.48±0.08) and between Lamp2A 
and Stmn2 (PCC  0.52±0.09) in the control group (Figure 4- 7G). In contrast, STZ -
induced diabetes significantly reduced levels of colocalization between glucagon and 
Lamp2A (PCC  0.14±0.03; p<0.01) and also between Stmn2 and Lamp2A (PCC  
0.15±0.03; p<0.01) (Figure 4- 7G).    
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4.4.7 STZ-induced diabetes increased the localization of Stmn2 in 
late endosomes  
The late endosome marker, Rab7, colocalized with glucagon (Figure 4- 8B), but did not 
appear to colocalize with Stmn2 (Figure 4- 8C). However, following induction of 
diabetes, Rab7 did appear to colocalize with Stmn2 (Figure 4- 8F) and maintained 
Figure 4-19. The localization of Stmn2 and glucagon in lysosomes of α-cells is 
inhibited in diabetes. (A) Islets from non-diabetic mice (n=7) were 
immunostained with antibodies against glucagon (GCG), stathmin-2 (Stmn2) 
and the lysosomal marker, Lamp2A. Representative images are shown. (B) 
Colocalization of glucagon and Lamp2A.  The Lamp2A image was 
pseudocoloured red for visualization of co-localization in the merged image and 
inset. (C) Colocalization of Stmn2 and Lamp2A. The Lamp2A image was 
pseudocoloured green for visualization of co-localization in the merged image 
and inset. (D) Islets of diabetic mice (n=7) were immunostained for glucagon, 
Stmn2 and Lamp2A. (E) Colocalization of glucagon and Lamp2A.  The 
Lamp2A image was pseudocoloured red for visualization of co-localization in 
the merged image and inset. (F) Colocalization of Stmn2 and Lamp2A. The 
Lamp2A image was pseudocoloured green for visualization of co-localization in 
the merged image and inset. All images were acquired and post-processed as 
described in Methods.  In each merged panel, selected areas (white square) 
were magnified to show individual cells within islets. (G) Analysis of 
colocalization of glucagon and LAMP2A, and Stmm2 and LAMP2A in normal 
and diabetic (STZ) islets. Pearson’s correlation coefficient (PCC) values are 
shown as means ± SEM. Each dot represents a mean of 9-15 images per mouse. 
 
Figure 4-20. Parall l alterations in secretion of glucagon and Stmn2 fro  α-
cells in both non-diabetic and diabetic mice.  (A) Secretion of glucagon and islet 
glucagon content in isolated islets of non-diabetic (C; n=7) and diabetic mice 
(STZ; n=7) at the presence or absence of Arginine (25 mM, 20 min). Secretion 
values were normalized by baseline control secretion and expressed as fold 
changes. Glucagon contents were normalized by baseline control and expressed 
as percent changes. (B) Secretion of Stmn2 and islet Stmn2 content in isolated 
islets of non-diabetic (C; n=7) and diabetic mice (STZ; n=7) at the presence or 
absence of Arginine (25 mM, 20 min). Secretion values were normalized by 
baseline secretion in control and expressed as fold changes. Glucagon contents 
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colocalization with glucagon (Figure 4- 8E). Quantification and analysis showed a 
moderate level of colocalization between glucagon and Rab7 in both control (PCC  
0.42±0.1) and STZ-induced diabetic (PCC  0.48±0.1) mice (Figure 4- 8G). Colocalization 
between Stmn2 and Rab7 in the control group was weak (PCC  0.29±0.12), but 
significantly increased (PCC  0.48±0.09, p<0.01) in islets from STZ-induced diabetic 
mice. In addition, the fluorescence intensity of Rab7 itself increased in α cells from islets 
of diabetic mice (Figures 4- 8H, I), and quantification demonstrated that this increase was 
significant (p<0.001) (Figure 4- 8J). Importantly, quantification and analysis 
demonstrated (Figure 4- 8J) similar levels of Rab7 fluorescence intensity in α and β-cells 
of control mice. However, following induction of diabetes, Rab7 intensity significantly 
increased (p < 0.001) in α-cells, but not in β-cells.  
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Figure 4-22. Diabetes enhanced colocalization of Stmn2 with late endosome in 
α-cells. (A) Islets from non-diabetic mice (n=7) were immunostained with 
antibodies against glucagon (GCG), stathmin-2 (Stmn2) and the late 
endosome marker, Rab7. Representative images are shown. (B) Colocalization 
of glucagon and Rab7. The Rab7 image was pseudocoloured red for 
visualization of colocalization in the merged image and inset. (C) 
Colocalization of Stmn2 and Rab7. The Rab7 image was pseudocoloured 
green for visualization of colocalization in the merged image and inset. (D) 
Islets from diabetic mice (n=7) were immunostained for glucagon, Stmn2 and 
Rab7; (E) Colocalization of glucagon and Rab7. The Rab7 image was 
pseudocoloured red for visualization of colocalization in the merged image 
and inset. (F) Colocalization of Stmn2 and Rab7. The Rab7 image was 
pseudocoloured green for visualization of colocalization in the merged image 
and inset.   All images were acquired and post-processed as described in 
Methods.  In each merged panel, selected areas (white square) were magnified 
to show individual cells within islets. (G) Analysis of colocalization of glucagon 
and Rab7, and Stmm2 and Rab7 in normal and diabetic (STZ) islets. 
Pearson’s correlation coefficient (PCC) values are shown as means ± SEM. 
Each dot represents a mean of 15 images per mouse. (H) Fluorescent 
intensities of glucagon, insulin (INS) and Rab7 were shown in islets from non-
diabetic and (I) diabetic mice. (J) Analysis of fluorescent intensities of Rab7 in 
α and β-cells. Intensities of DAPI- stained nuclei were used to normalize Rab7 
intensities. 
 
Figure 4-23. The localization of Stmn2 and glucagon in lysosomes of α-cells is 
inhibited in diabetes. (A) Islets from non-diabetic mice (n=7) were 
immunostained with antibodies against glucagon (GCG), stathmin-2 (Stmn2) 
and the lysosomal marker, Lamp2A. Representative images are shown. (B) 
Colocalization of glucagon and Lamp2A.  The Lamp2A image was 
pseudocoloured red for visualization of co-localization in the merged image 
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4.4.8 Glucagon and Stmn2 do not localize within the early 
endosome  
The early endosome marker, EEA1, appeared to be localized strongly to the core of the 
islet (Figure 4- 9A). As shown by the magnified images, EEA1 did not colocalize with 
either glucagon (Figure 4- 9B) or Stmn2 (Figure 4- 9C). These patterns of colocalization 
remained unchanged in diabetes (Figures 4- 9D-F). Quantification and analysis showed a 
very weak colocalization of EEA1 with glucagon (PCC  0.07±0.05) or Stmn2 (PCC  
0.07±0.04) in the control group. Following induction of diabetes, colocalization of EEA1 
with glucagon (PCC  0.03±0.07) or Stmn2 (PCC  0.04±0.07) still remained very weak. 
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4.4.9 Glucagon is not present in recycling endosome  
The immunofluorescence signal of the recycling endosome marker, Rab11A, also 
appeared to be quite strong in the core of the islet (Figure 4- 10A), and did not colocalize 
with glucagon (Figure 4- 10B), but colocalized with insulin (Figure 4- 10C). As well, 
STZ-induced diabetes did not alter the pattern of distribution between Rab11A and 
glucagon (Figure 4- 10D), but did decrease the colocalization between insulin and 
Rab11A (Figures 4- 10D-F). In addition, another recycling endosome marker, Rab11B, 
showed a similar distribution within the islet (Figure 4- 10 G); it also did not colocalize 
with glucagon (Figure 4- 10H) but colocalized with insulin (Figure 4- 10I); this pattern 
remained unchanged in diabetes (Figures 4- 10K, L). Quantification and analysis (Figure 
Figure 4-25. Glucagon and stathmin-2 are not localized in early endosomes in 
α-cells.  (A) Islets from non-diabetic mice (n=7) were immunostained with 
antibodies against glucagon (GCG), stathmin-2 (Stmn2) and the early 
endosome marker, EEA1. Representative images are shown.  (B) Colocalization 
of glucagon and EEA1. The EEA1 image was pseudocoloured red for 
visualization of colocalization in the merged image and inset. (C) Colocalization 
of Stmn2 and EEA1. The EEA1 image was pseudocoloured green for 
visualization of colocalization in the merged image and inset. (D) Islets from 
diabetic mice (n=7) were immunostained for glucagon, Stmn2 and EEA1. (E) 
Colocalization of glucagon and EEA1. The EEA1 image was pseudocoloured 
red for visualization of colocalization in the merged image and inset. (F) 
Colocalization of Stmn2 and EEA1. The EEA1 image was pseudocoloured 
green for visualization of colocalization in the merged image and inset. All 
images were acquired and post-processed as described in Methods.  In each 
merged panel, selected areas (white square) were magnified to show individual 
cells within islets. (G) Analysis of colocalization of glucagon and EEA1, and 
Stmm2 and EEA1 in normal and diabetic (STZ) islets. Pearson’s correlation 
coefficient (PCC) values are shown as means ± SEM. Each dot represents a 
mean of 9-15 images per mouse. 
 
Figure 4-26. Diabete  e hanced colocalization of Stmn2 with l te endosome in 
α-cells. (A) Isl t  from on-diabetic mice (n=7) w re immunostained with 
antibodies against glucagon (GCG), stathmin-2 (Stmn2) and the late endosome 
marker, R 7. Representative im g s are shown. (B) Colocalization of glucagon 
nd Rab7. The Rab7 image was pseudocoloured red for visualizatio of 
colocalization in the merge  image and inset. (C) Colocalization of Stmn2 and
Rab7. The Rab7 image as pseudocoloured green for v sualization of 
coloc lization in the merged image and inset. (D) Islets from diabetic mice (n=7) 
were immunostained for glucagon, Stmn2 and Rab7; (E) Colocaliz tion of 
glucagon and Rab7. The Rab7 image was pseudocoloured red for visualization 
of colocalization in the merged image and inset. (F) Colocalization of Stmn2 
and Rab7. The Rab7 image was pseudocoloured green for visualization of 
colocalization in the merged image and inset.   All images were acquired and 
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4- 10M) confirmed the weak colocalization between glucagon and Rab11A (PCC  
0.13±0.05) or Rab11B (PCC  0.13±0.04) in non-diabetic mice, and in diabetic mice 
(colocalization of glucagon with Rab11A, PCC 0.13±0.04 or Rab11B, PCC 0.13±0.03). 
In contrast, insulin showed a strong colocalization with Rab11A (PCC 0.63±0.09) or 
Rab11B (PCC 0.61±0.06), which significantly decreased (p<0.001) following induction 
of diabetes (colocalization of insulin with Rab11A, PCC 0.35±0.5) or Rab11B, PCC 
0.38±0.07). 
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Figure 4-28. Glucagon is not localized in recycling endosome of α-cells. (A) Islets 
from non-diabetic mice (n=7) were immunostained with antibodies against 
glucagon (GCG), insulin (INS) and the recycling endosome marker, Rab11A. (B) 
Colocalization of glucagon and Rab11A. The Rab11A image was pseudocoloured 
red for visualization of colocalization in the merged image and inset. (C) 
Colocalization of insulin and Rab11A. The Rab11A image was pseudocoloured 
green for visualization of colocalization in the merged image and inset. (D) Islets 
from diabetic mice (n=7) were immunostained for glucagon, insulin and Rab11A. 
(E) Colocalization of glucagon and Rab11A. The Rab11A image was 
pseudocoloured red for visualization of colocalization in the merged image and 
inset. (F) Colocalization of insulin and Rab11A. The Rab11A image was 
pseudocoloured green for visualization of colocalization in the merged image and 
inset. (G)  Islets from non-diabetic mice were immunostained for glucagon, 
insulin and Rab11B. (H) Colocalization of glucagon and Rab11B. The Rab11B 
image was pseudocoloured red for visualization of colocalization in the merged 
image and inset. (I) Colocalization of insulin and Rab11B. The Rab11B image 
was pseudocoloured green for visualization of colocalization in the merged image 
and inset. (J) Islets from diabetic mice were immunostained for glucagon, insulin 
and Rab11B. (K) Colocalization of glucagon and Rab11B. The Rab11B image 
was pseudocoloured red for visualization of colocalization in the merged image 
and inset. (L) Colocalization of insulin and Rab11B. The Rab11B image was 
pseudocoloured green for visualization of colocalization in the merged image and 
inset. All images were acquired and post-processed as described in Methods.  In 
each merged panel, selected areas (white square) were magnified to show 
individual cells within islets. (M) Analysis of colocalization of glucagon and 
Rab11A or Rab11B, and Stmm2 and Rab11A or Rab11B in normal and diabetic 
(STZ) islets. Pearson’s correlation coefficient (PCC) values are shown as means ± 
SEM. Each dot represents a mean of 9-15 images per mouse. 
 
Figure 4-29. Glucagon and stathmin-2 are not localized in early endosomes in α-
cells.  (A) Islets from non-diabetic mice (n=7) were immunostained with 
antibodies against glucagon (GCG), stathmin-2 (Stmn2) and the early endosome 
marker, EEA1. Representative images are shown.  (B) Colocalization of glucagon 
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4.5 Discussion 
Diabetes is always accompanied by a degree of hyperglucagonemia, which reflects 
dysregulated glucagon secretion from α-cells. We have recently proposed that protein 
components of glucagon interactome within secretory granules of α-cells may regulate 
glucagon secretion (19) and one of these proteins, Stmn2, may mediate glucagon 
secretion through the endolysosomal system in α-TC1-6 cells and islets from non-diabetic 
mice (20). In the present study, we show that in diabetes,  there is a disruption in the ratio 
of glucagon:Stmn2 together with hyperglucagonemia. These phenomena were 
accompanied by a sharp reduction in the trafficking of both glucagon and Stmn2 into the 
lysosome, and increased localization of Stmn2 within the late endosome, but not in the 
early or recycling endosomal compartment. We propose that, in diabetic α-cells, 
glucagon hypersecretion may result from a loss of Stmn2-mediated trafficking of 
glucagon to the lysosomal pathway.  
In non-diabetic α-cells, glucagon secretion is regulated by several factors (29) mainly 
nutritional elements, such as glucose, amino acids and free fatty acids (2,12,30–33), 
neuronal effectors, such as norepinephrine and acetylcholine (12,34), and hormonal 
stimuli, particularly through paracrine regulation by insulin and somatostatin, and 
autocrine regulation by glucagon itself) (12,35–39). Diabetes disrupts this fine regulation, 
resulting in glucagon hypersecretion and aggravation of hyperglycemia. Most notably, 
alterations in the paracrine control of glucagon secretion by insulin results in an abnormal 
α-cell response to high glucose concentrations, either through insulin deficiency (40,41) 
or α cell  insulin resistance(41,42).  Additionally, impairments in hepatic amino acid 
turnover increases glucagon secretion from α-cells through the  liver-α-cell axis (43,44). 
As well, higher secreted glucagon and concomitantly co-secreted glutamate from diabetic 
α-cells exacerbate glucagon hypersecretion in an autocrine manner (45). 
The search for novel regulators of glucagon secretion has revealed that proteins 
associated with the α-cell secretory pathway may also comprise mechanisms that underlie 
hyperglucagonemia. Exposure of α-TC1-6 cells to chronically high glucose 
concentrations resulted in an up-regulation of several secretory granule proteins, 
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including processing enzymes, chromogranins and exocytotic proteins (18), indicating 
that many components of the α-cell secretory pathway play a role in glucagon 
hypersecretion in diabetes. Secretory granule proteomics in α-TC1-6 cells revealed 
several proteins predicted to associate with glucagon as possible mediators of glucagon 
secretion (19), and our recent work has shown that Stmn2 may be one such novel 
regulator (20). Knockdown of Stmn2 enhanced glucagon secretion from α-TC1-6 cells, 
indicating that Stmn2 could be a negative regulator of glucagon secretion. Our present 
results demonstrating a reduction in Stmn2 cell content in diabetes concomitantly with 
glucagon hypersecretion are consistent with these results.  A similar database search has 
shown that another granule protein,  brefeldin A-inhibited guanine nucleotide exchange 
protein 3 or BIG3, also regulated glucagon secretion from  mouse pancreatic islets, and 
its depletion in vivo resulted in glucagon hypersecretion (46), possibly through promoting 
secretory granule biogenesis or maturation. Therefore, proteins within the α-cell secretory 
pathway are emerging as prominent regulators of glucagon secretion by mediating the 
intracellular trafficking of glucagon, and may explain dysregulated glucagon 
hypersecretion in diabetes. 
In the present study, we observed that the relationship between glucagon and Stmn2 was 
disrupted, indicated by increased glucagon and decreased Stmn2 cell content. 
Proglucagon gene transcription, glucagon synthesis and secretion are all highly 
responsive to prevailing glucose concentrations (18,47–49), reflecting the 
hyperglucagonemic state of diabetes. However, it appears that Stmn2 mRNA and protein 
levels show a different profile. A BLAST search of the promoter region of the Stmn2 
gene (GeneBank: AH000817 ; mouse Stmn2 complete cds) against sequence of the 
glucose response element in the mouse glucagon receptor gene  (50) (GeneBank: 
AF229079.1; mouse Gcgr complete cds), did not reveal any sequence homology.  Thus, 
the enhanced secretion of Stmn2 in diabetes may reflect its localization in secretory 
granules, which may be elevated in number and exocytotic activity in hyperglucagonemia 
(48), or an increase in α-cell mass(5,51). 
The altered balance between glucagon and Stmn2 has also been found in islets from 
patients with diabetes. By means of α-cell RNA sequencing analysis, Lawlor et al (2017) 
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showed a higher Gcg: Stmn2 gene expression ratio in islets of people with type 2 diabetes 
compared to healthy controls (52). Since there are many other metabolic disturbances in 
diabetes as described above, those results, along with ours, suggest that Stmn2 gene and 
protein expression levels within α-cells do not show parallel behavior with glucagon over 
chronic disruptions in metabolism.  
Since Stmn2 within the α-cell appears to persist within secretory granules in diabetes, and 
does not show the same dynamics as glucagon in diabetes, we reasoned that changes in 
its intracellular trafficking may be a mechanism of glucagon hypersecretion. In our 
previous study, we showed that overexpression of Stmn2 in α-TC1-6 cells suppressed 
glucagon secretion by increasing its trafficking through the endolysosomal pathway (20). 
Conversely, knockdown of Stmn2 increased glucagon secretion and decreased its 
localization in endosomes and lysosomes. In the present study, we explored the dynamics 
of glucagon and Stmn2 trafficking in the endolysosomal pathway as a possible 
mechanism of glucagon hypersecretion in diabetes. 
The endolysosomal system is comprised of lysosomes, late endosomes, early endosomes 
and recycling endosomes (53). In the context of dynamic movements of cargos within the 
endolysosomal system, late endosome cargos can be transported to the lysosome 
(anterograde) or the plasma membrane (retrograde). Retrograde transport can occur in 
two ways: 1) to the early endosome, recycling endosome and then the plasma membrane, 
or 2) to the Golgi apparatus and through the secretory pathway (54,55). The dramatic 
decrease in localization of glucagon and Stmn2 in lysosomes and increased localization 
of Stmn2 in the late endosomal compartment, together with Rab7, in diabetes suggest that 
glucagon and Stmn2 are re-routed from anterograde transport to the lysosome to 
retrograde transport to the late endosome and the secretory pathway.  This pathway is 
further confirmed by the lack of glucagon and Stmn2 localization in early endosomes and 
recycling endosomes, suggesting that retrograde transport from the late endosome 
towards the early endosome-recycling endosome is not prominent in α-cells. Therefore, 
increased retrograde trafficking of glucagon from the late endosome to the secretory 
pathway may be a potential new pathway of glucagon hypersecretion in diabetes. 
Although a mechanism has not been investigated in this study, it is possible that Rab7, a 
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member of the Rab family of GTPase endosomal trafficking proteins, interacts with the 
retromer complex in this retrograde transport in α-cells (56–58). Retrograde transport of 
proteins from endosomes to the TGN has been documented for some proteins such as the 
acid hydrolase cathespsin D and its sorting receptor, mannose-6-phosphate receptor 
(M6PR), transmembrane enzymes and SNAREs (59,60). It has been suggested that Rab7 
may act as a master regulator of multiple endosomal processes, functioning in retrograde 
transport throughout the process of endosome maturation(61) Our findings showing 
higher fluorescence intensity of Rab7 together with increased co-localization with Stmn2 
in diabetic α-cells suggests increased recruitment of Stmn2 a potential sorting protein, 
into the late endosome to facilitate movement of glucagon towards TGN and secretory 
pathway for glucagon hypersecretion.  
It is well documented that Rab proteins can impact the regulated secretory pathway 
through direct effects on secretory granules. The early endosomal protein Rab5 regulates 
homotypic fusion of mast cell secretory granules prior to compound exocytosis (62) and 
transports CD63 from early endosomes to secretory granules to promote granule 
maturation (63). A more recent study has shown that trafficking proteins from early 
endosomes are required for secretory granule maturation in Drosophila larval salivary 
gland cells (64). However, our study did not reveal a role for early endosomes in 
diabetes-induced glucagon hypersecretion; rather, we suggest that there is a possible role 
for late endosomes in the transport of glucagon to the secretory pathway. Interestingly, it 
has been found that, in pancreatic β-cells, there is an increase in insulin trafficking to the 
lysosome in  diabetic ob/ob mice (22), and a very recent study has determined a role for 
the Rab7-interacting lysosomal protein RILP in the transport of insulin from secretory 
granules to late endosomes and lysosomes for degradation in diabetes (65). Therefore, it 
is tempting to speculate that, in diabetes, insulin is directed to lysosomes from granules 
for degradation and glucagon is transported from late endosomes to granules for 
enhanced secretion via the action of endosomal trafficking proteins.  
In conclusion, our findings suggest that Stmn2 as an α-cell protein plays a potential role 
in the abnormal intracellular glucagon trafficking in diabetes. We propose that there is a 
switch from anterograde transport of glucagon and Stmn2 from endosomes to lysosomes, 
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to retrograde transport of glucagon from late endosomes to the secretory pathway. These 
findings suggest a potentially novel pathway that could account for the 
hyperglucagonemia of diabetes. 
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Chapter 5 
 
5. Discussion and Future Directions 
5.1 Glucagon interactome in secretory granules of α-cells 
and its plasticity 
It is well known that under normal physiological conditions, glucagon secretion is 
suppressed by high glucose, GABA and insulin (1–5). However, chronic hyperglycemia 
disrupts this fine regulation and results in elevated glucagon secretion (6–10). In Chapter 
2, my results confirmed that chronic exposure of α-TC1-6 cells to high glucose increases 
both glucagon production and secretion. My proteomics findings, together with related 
functional studies, reflect a relationship between components of the glucagon interactome 
and glucagon secretion from α-cells. Changes in the microenvironmental conditions of α-
cells alters the protein components of the glucagon interactome, which results in altered 
glucagon secretion.  Proteomic analysis also revealed that the glucagon interactome 
contains two clusters of proteins: a histone core of proteins, previously unknown in α- 
cell granules, and a cytoplasmic cluster of proteins.  
The protein components of the cytoplasmic cluster were altered in response to the 
paracrine inhibitors of glucagon secretion, GABA and insulin, and also to ambient 
glucose levels. These alterations were accompanied by changes in glucagon secretion. 
We propose that effects of either insulin or GABA, alone or in combination, on the α-cell 
secretory phenotype could be governed through their effects on the glucagon interactome 
within secretory granules.  
Regarding the plasticity of cytoplasmic proteins within the glucagon interactome in 
response to intrinsic or paracrine effectors, our proposed mechanism expands our lab’s 
model for sorting proglucagon into the secretory granule via sorting signals (11) and 
sorting receptors. To this end, several proteins were projected to have interactions with 
glucagon and among them some proteins are predicted to directly interact with glucagon 
in response to ambient glucose levels (5.5 mM or 25 mM) and presence of paracrine 
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effectors (GABA, INS or GABA+INS)  (Figures 5- 1A-B). The formation of the 
glucagon interactome may begin within the immature secretory granule, and based on the 
“sorting by retention” theory, immature secretory granules transform into mature 
secretory granules. The maturation process is accompanied by protein condensation in the 
dense core portions of secretory granules, localization of integral proteins within the 
membrane of secretory granule, acidification of granule contents, and removal of some of 
their protein contents (12,13). This process could be accompanied by i) forming different 
types of secretory granules, which bring about plasticity in secretory granules, and ii) 
trafficking some proteins towards degradation machinery or exocytosis pathway. 
Currently, there is no published document to show α-cell granule subtypes or glucagon 
interactome in islets of animal models or humans to be able to make a matched 
comparison. However, in a parallel comparison with secretory granules of β-cells (14), 
some proteins of the glucagon interactome are well-known secretory granule proteins 
such as carboxypeptidase E, PC2, chromogranin A, secretogranin family, GTP-binding 
proteins, VAMP family, and Ras-related proteins of Rab family. 
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Figure 5-1. Predicted proteins in the first shell of interacting proteins with 
glucagon within the glucagon interactome. α-TC1-6 cells were cultured (A) in  
25 mM glucose containing medium (HGM); or supplemented with GABA, 
insulin (INS) or GABA+INS.  (B) α-TC1-6 cells were cultured (A) in 5.5 mM 
glucose containing medium (LGM); or supplemented with GABA, insulin 
(INS) or GABA+INS.   
 
Figure 5-2. Schematic structure of Stmn2 in comparison with other members 
of the stathmin family. Both stathmin-1 (Stmn1) and stathmin-2 (Stmn2) 
contain a “stathmin-like domain” (SLD). This domain includes the following 
subdomains: tubulin binding repeats (TBR1 and TBR2), “Proline rich 
domain” (PRD), and N-terminal region of SLD (SLDN). Stmn2 contains an 
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Treatment with insulin showed recruitment of ChgA into the first shell of the glucagon 
interactome (Figure 5- 1B). This finding supports sorting receptor role of ChgA towards 
secretory granule biogenesis in α-cells. Actually,  special characteristics of ChgA in 
terms of its aggregation in low pH, and high Ca2+microenvironment and also in response 
to catecholamine makes it a good sorting receptor candidate(15). ChgA is the main 
component of the secretory granules in neuroendocrine cells, and pancreatic α and β-cells 
(16,17). Depletion of ChgA in neuroendocrine cell line PC12 suppressed secretory 
granule biogenesis. In contrast, overexpression of ChgA in neuroendocrine cell line of 
6T3 cells and in fibroblastic cell line of CV-1 cells, induced secretory granule biogenesis 
(18). It was shown that ablation of ChgA in the mouse model reduced granule size and 
number in the chromaffin cells of adrenal medulla (19). Anti-sense vector against ChgA 
in the mouse model, reduced secretory granule numbers in the chromaffin cell (20). Our 
lab already proposed that chromogranin A plays a potential sorting receptor for glucagon 
in both α-TC1-6 cells and PC12 cells (11). Thus, finding potential interaction between 
ChgA and Stmn2 could provide a novel protein network as a sorting receptor for granule 
biogenesis.  
My findings showed that GRP78 (Hspa5) is present in the interactome regardless of 
glucose concentrations or presence of paracrine inhibitors, and co-localizes with and 
interacts directly with glucagon. Interestingly, its depletion suppressed cell glucagon 
content with no effect on glucagon secretion. This pattern reflects two potential roles for 
GRP78; i) enhancing glucagon synthesis, and ii) reducing glucagon degradation. 
Recently, it was shown that GRP78 is a component of the secretory granule in β-cells 
(21), which provides further evidence on presence of  GRP78 within secretory granules, 
and its potential role in the secretory granule biogenesis, and trafficking. In terms of 
interaction between GRP78 and ChgA, it was shown that GRP78 interacted with a ChgA- 
derived peptide (pancreastatin) , which resulted in suppression of GRP78’s ATPase 
activity. It was proposed that this interaction results in dysglycemia through increasing 
hepatic glycogenolysis (22). However, underlying mechanism of interaction between 
GRP78 and ChgA within the secretory granule of α-cells, and its physiological effect or 
pathological consequences remain to be elucidated.   
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My findings propose that plasticity in secretory granules of α-cells determine which 
granules can dock and fuse with the plasma membrane. It was already discussed that 
protein components of secretory granules play a vital role in the fusion and exocytosis of 
secretory granules (23). To this end, it was shown that some select proteins of secretory 
granules could be accelerator (such as Rabphilin3A) or inhibitor  (such as Rab3A) for 
docking machinery of secretory granules and exocytosis (24,25). In the context of the 
pancreatic islet, it is well-known that all secretory granules are not functionally 
equivalent. About 10% of the total granule population will dock to the plasma membrane, 
and about 10% of those are in readily releasable pool (26,27). Granule properties are 
likely governed by other parameters, such as homotypic fusion (28), membrane 
composition (29) and composition of cargo proteins within the secretory granule. Since I 
found that the granule cargo is remodeled in response to glucose and paracrine effectors, 
it’s likely that the membrane components can also be remodeled to govern exocytosis.  
The proteomics analysis has also revealed a cluster of histone proteins within the 
glucagon interactome. Unlike the plasticity exhibited by the cytoplasmic core, the protein 
components of the histone cluster appeared to have small changes in treatment groups. 
The discovery of the histone cluster within α-cell secretory granules is novel, and 
supported by the finding that the cytosolic fraction in pooled islets from multiple human 
donors with 5 mM  blood glucose had abundant amounts of the histone H2A (30). In this 
respect, we showed the histone H2 as the most abundant histone in secretory granules 
regardless of the prevailing glucose levels. We propose that the histone cluster within 
secretory granules in α-cells is a conserved part of the glucagon proteome in which small 
changes result in a significant effect on the α-cell response to different stimuli. As I have 
already discussed, the presence of histone proteins within secretory granules could be an 
adaptive mechanism in α-cells for responding to unfavorable microenvironmental 
conditions (31–34).  
One limitation of the study in Chapter 2 was the use of the murine pancreatic islet cell 
line, α-TC1-6, for proteomics and glucagon secretion studies. Importantly, this well-
differentiated cell line keeps normal endocrine properties of α-cells. It was shown that α-
TC1 derived cell lines (α-TC1, α-TC1-6, α-TC1-9) correctly process proglucagon 
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towards production of matured glucagon and properly respond to stimuli especially in 
high glucose condition (35). This cell line has been extensively used by our lab 
(11,36,37) and others (38,39) for glucagon secretion studies and uncovering related 
molecular aspects. As well, proteomic analysis of this cell line has been used to uncover 
druggable targets in α-cells for clinical application (40) and its integrated proteomics-
genomics has been well demonstrated (41). On the other hand, preparing sufficient 
amount of purified primary α-cells is a challenging subject, in a way that has been an 
obstacle for doing research on α-cells. Thus, this cell line has afforded advantages to 
perform molecular studies on several aspects of glucagon in a well-differentiated α-cell 
model. However, I acknowledge that using mouse primary islets or human primary islets 
would provide conditions closer to normal physiological conditions.  
5.2 Stmn2 modulates glucagon secretion through the 
endolysosomal system in non-diabetic α-cells 
Stathmin-2 is a neuronal protein that possesses a stathmin-like domain (SLD) and an N-
terminal extension (Figure 5- 2) (42). The former contains four conserved sites for 
phosphorylation and the latter has three subdomains as follows; Golgi-specifying sub-
domain (n), membrane anchoring subdomain (m) and a variable subdomain (c). Membrane 
anchoring is mediated by palmitoylation of two cysteine residues within “m” subdomain. 
SLD is a conserved domain, which has four phosphorylation sites and two tubule binding 
repeats. As a membrane-associated phosphoprotein it has been mostly found in cell 
membranes of Golgi and some vesicles (such as endosomes) in neuronal cells (43–45); a 
fact that has been recapitulated in current findings by showing localization of Stmn2 in the 
cell membrane and cytoplasmic organelles, Golgi and secretory granules. In terms of 
function, it has been shown that Stmn2 has a role in regulation of signal transduction, 
microtubule dynamics, and protein transport and secretion (46,47). 
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For the first time, my findings show the presence of Stmn2 within the α-cell secretory 
granule and its regulatory role in glucagon secretion. Co-presence of glucagon and Stmn2 
within the secretory granule and their increased secretion in response to stimulation 
suggests  α-cells use co-secreted secretory granule proteins as a strategy for regulation of 
glucagon secretion from α-cells. In this respect, co-storage and co-secretion of glucagon 
and glutamate have been shown in α-TC1-6 cells, rat isolated islets and mouse islets 
(23,48,49). It was shown that when α-cells are exposed to low glucose conditions, co-
secreted glutamate plays an autocrine role in increasing glucagon secretion from α-cells 
(23). In addition, co-storage and co-secretion of glucagon with acetylcholine and a number 
of proglucagon-derived factors (such as un-processed proglucagon, proglucagon 1-61 and 
miniglucagon) have been reported (50–52).  
Overexpression of Stmn2 in α-TC1-6 cells suppressed glucagon secretion and its depletion 
brought about an increase in glucagon secretion, suggesting that Stmn2 may be a tonic 
inhibitor of glucagon secretion. In a parallel study on β-cells, the concept of hormone-
protein co-storage and co-secretion has been already documented for insulin. To this end, 
the regulatory role of insulin-interacting proteins [such as transmembrane protein 24 
Figure 5-4. Schematic structure of Stmn2 in comparison with other members 
of the stathmin family. Both stathmin-1 (Stmn1) and stathmin-2 (Stmn2) 
contain a “stathmin-like domain” (SLD). This domain includes the following 
subdomains: tubulin binding repeats (TBR1 and TBR2), “Proline rich 
domain” (PRD), and N-terminal region of SLD (SLDN). Stmn2 contains an 
extra domain of N-terminal extension. This domain includes conserved Golgi-
specifying subdomain “n”, conserved membrane anchoring subdomain “m”, 
and poorly conserved subdomain “c”. 
 
Figure 5-5. Rab7 mediates late endosomal cargos towards lysosome (for 
degradation) or plasma membrane (for secretion). The Figure was extracted 
from reference 48 according to the Creative Commons Attribution License 
(http://creativecommons.org/Licenses/by/4.0/).Figure 5-6. Schematic structure 
of Stmn2 in comparison with other members of the stathmin family. Both 
stathmin-1 (Stmn1) and stathmin-2 (Stmn2) contain a “stathmin-like 
domain” (SLD). This domain includes the following subdomains: tubulin 
binding repeats (TBR1 and TBR2), “Proline rich domain” (PRD), and N-
terminal region of SLD (SLDN). Stmn2 contains an extra domain of N-
terminal extension. This domain includes conserved Golgi-specifying 
subdomain “n”, conserved membrane anchoring subdomain “m”, and poorly 
conserved subdomain “c”. 
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(TMEM24) carboxypeptidase E or chromogranin A] on insulin secretion has been shown 
in INS-1E cells, MIN6 cells and mouse pancreatic β cells (53–55). Furthermore, it was 
shown that co-secretion of the co-stored proteins with insulin (53,56)could be a mechanism 
to locally regulate insulin secretion from β-cells. For instance, ChgA or its cleaved product, 
betagranin,  could inhibit glucose stimulated insulin secretion through binding KATP 
channel and keeping it in an opened state, which prevents β-cell depolarization and insulin 
secretion (56,57). I acknowledge that I used an immunostaining approach on fixed islets to 
study the subcellular status of Stmn2. To this end, making a knock-in of fluorescent 
reporter gene for Stmn2 in the mouse islet and its tracking using immunofluorescence 
confocal microscopy would uncover more details about role of Stmn2 in glucagon 
secretion in both normal and pathological condition. 
5.3 Stmn2 plays a role in glucagon hypersecretion 
through intracellular glucagon trafficking towards 
endolysosomal system in diabetic α-cells 
By tracking Stmn2 and glucagon, I have shown degradation of glucagon within the α-cell 
and disturbance of this pathway in the diabetic condition. My findings proposed that under 
normal physiological conditions, Stmn2 directs glucagon into the endolysosomal system 
for degradation; however, in case of diabetes it takes a role in glucagon hypersecretion 
from α-cells. To this end my findings propose that  1) there is a basal level of degradation 
for glucagon within the endolysosomal system when there are coordinated levels of 
glucagon and Stmn2; 2) this basal level of glucagon degradation will be compromised in 
diabetes due to discordance between glucagon and Stmn2 levels; 3) the relatively lower 
Stmn2 levels reduce trafficking of glucagon and Stmn2 towards lysosome; 4) As a 
consequence, the levels of glucagon and Stmn2 within the late endosome will be increased; 
5) in addition, there is an increased colocalization of Stmn2 and Rab7 within the late 
endosome, and 6) these phenomena direct glucagon towards secretory pathway, which 
results in higher glucagon secretion in diabetic α-cells. Thus, it can be proposed that Stmn2 
could have a dual role in both the degradation and secretion of glucagon. In this context, 
Rab7 may interact with Stmn2 in directing glucagon towards the secretory pathway. Of 
note, such a dual role has been already proposed for Rab7 in β-cells (58). It has recently 
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Figure 5-7. Rab7 mediates late endosomal cargos towards lysosome (for 
degradation) or plasma membrane (for secretion). The Figure was 
extracted from reference 60 according to the Creative Commons 
Attribution License (http://creativecommons.org/Licenses/by/4.0/). 
 
Figure 5-8. Late endosomal re-routing of glucagon and Stmn2 from 
lysosome towards secretory pathway in diabetic α-cells. Lysosomal 
degradation of glucagon and Stmn2 were suppressed. There is an 
enhanced Rab7 levels within the late endosome of diabetic α-
cells.Figure 5-9. Rab7 mediates late endosomal cargos towards lysosome 
(for degradation) or plasma membrane (for secretion). The Figure was 
extracted from reference 48 according to the Creative Commons 
Attribution License (http://creativecommons.org/Licenses/by/4.0/). 
been shown that insulin is degraded within  the endolysosomal system of β-cells, which is 
mediated by interaction of Rab7 with Rab7 interacting lysosomal protein (RILP) (58). In 
fact, this finding highlights a previously proposed model for Rab7-mediated late endosome 
trafficking, in which Rab7 directs late endosome cargos towards perinuclear lysosomes for 
degradation or the plasma membrane for secretion (59,60)(Figure 5- 3).  
 
                   Late endosome or 
 
 
 
 
 
 
 
 
 
 
5.4 Summary 
My overall findings indicate that th re is a gluca on interactome within the secretory 
granule that regulates glucagon secre ion from α-cells. This glucagon interactome shows 
dynamic lterations in response to in rinsic and paracrine factors and m y be a defense 
tactic for α-cells to cope with stressful conditions such as tes. In this context, 
recruitment of Stmn2 within the n ractome could be α-cells’ adaptive re ponse to 
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variability in blood glucose levels. Recruitment of Stmn2 within the interactome occurred 
in the presence of glucagon secretion inhibitor, insulin, which was accompanied by 
reduced fractional glucagon secretion and cell glucagon content. It seems that Stmn2 
should be considered as a  regulator of glucagon secretion with  bimodality roles, in a 
way that 1) directing glucagon towards endolysosomal system for degradation in normal 
physiological condition when there is a balanced glucagon: Stmn2 ratio, and 2) mediating 
glucagon hypersecretion in diabetic condition when the glucagon:Stmn2 ratio becomes 
imbalanced. In this respect, I suggest that coordination of Stmn2 and Rab7 plays a role in 
late endosomal re-routing of glucagon from lysosomal degradation towards secretory 
pathway (Figure 5- 4). My findings reflect that reduction in Stmn2: glucagon ratio 
increases glucagon secretion and an increase in this ratio suppresses glucagon secretion. 
In fact, it seems that α-cell contains limiting amounts of Stmn2 in the diabetic condition 
due to 1) lack of response in Stmn2 gene expression and Stmn2 synthesis to prevailing 
glucose levels and 2) increased secretion of Stmn2 in diabetic condition. Thus, diabetic 
hyperglucagonemia may occur through increased trafficking of glucagon to the secretory 
pathway and decreased degradation through the lysosomal pathway mediated through an 
association between Stmn2 and Rab7 within the late endosome.  
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5.5 Future Directions 
In my thesis, I revealed a mediating role for Stmn2 in glucagon degradation through the 
endolysosomal system and its impairment in the diabetic condition. To further uncover 
role of Stmn2 in glucagon hypersecretion from diabetic α-cells the following future 
directions will be taken. By generating a transgenic mouse model  with  knock-out of 
Stmn2 in α-cells (for instance, through tissue specific Cre/lox system), and following 
glucagon secretion and intracellular glucagon trafficking in α-cells, it would  complement 
our findings on knock down of Stmn2 in α-TC1-6 cells. In this context, by generating 
transgenic mouse model with knock-out of Rab7 in α-cells it would complement our 
findings on potential role of Rab7 in glucagon secretion. In addition, by knock- in of a 
fluorescent reporter gene for glucagon and inducing diabetes (through STZ injection) in 
the abovementioned models it would be an approach to dynamically study role of Stmn2 
and Rab7 in glucagon hypersecretion. In all of the abovementioned animal models, 
performing glucose tolerance tests would provide more clinically related findings. As 
well, generating Stmn2 knock-out in a type 2 diabetic model animal and following 
glucagon intracellular tracking, glucagon secretion, and glucose tolerance tests would 
extend our knowledge on role of Stmn2 in type 2 diabetes- related glucagon 
hypersecretion. In addition, applying these approaches for testing potential role of other 
uncovered proteins in my study (ChgA or GRP78; proteins in the first shell of interaction 
with glucagon) could potentially introduce more candidate regulators for secretion of 
glucagon. As well, one option for all of abovementioned models would be studying 
related cell signaling pathways to Stmn2 through electrophysiological studies (patch 
clamp studies) on single primary α-cells. This approach would be helpful to find a key 
signaling pathway for Stmn2 and targeting its related elements for treatment of diabetes. 
Figure 5-10. Late endosomal re-routing of glucagon and Stmn2 from lysosome 
towards secretory pathway in diabetic α-cells. Lysosomal degradation of 
glucagon and Stmn2 were suppressed. There is an enhanced Rab7 levels 
within the late endosome of diabetic α-cells. 
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By confirming current findings through these approaches, designing a pharmacological 
agonist for Stmn2 would be a long-term goal to effectively reduce glucagon 
hypersecretion in α-cells as a potential treatment for hyperglucagonemia of diabetes.  
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